# EDGAR Filing Document

**Accession Number:** 0001160420
**File Stem:** 0001683168-25-008925
**Filing Date:** 2025-12
**Character Count:** 585986
**Document Hash:** 53987487a9488353cd17a10b0921a238
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001683168-25-008925.hdr.sgml**: 20251205

**ACCESSION NUMBER**: 0001683168-25-008925

**CONFORMED SUBMISSION TYPE**: 10-12G

**PUBLIC DOCUMENT COUNT**: 25

**FILED AS OF DATE**: 20251205

**DATE AS OF CHANGE**: 20251205

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Adia Nutrition, Inc.
- **CENTRAL INDEX KEY:** 0001160420
- **STANDARD INDUSTRIAL CLASSIFICATION:** MEDICINAL CHEMICALS & BOTANICAL PRODUCTS [2833]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 870675769
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 10-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 000-33265
- **FILM NUMBER:** 251552149

**BUSINESS ADDRESS:**
- **STREET 1:** 4421 GABRIELLA LANE
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792
- **BUSINESS PHONE:** 321-231-2843

**MAIL ADDRESS:**
- **STREET 1:** 4421 GABRIELLA LANE
- **CITY:** WINTER PARK
- **STATE:** FL
- **ZIP:** 32792

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PivX Solutions, Inc.
- **DATE OF NAME CHANGE:** 20040518

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** DRILLING INC
- **DATE OF NAME CHANGE:** 20011003

[**Table of Contents**](#a_012)

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

------

**FORM 10**

------

**GENERAL FORM FOR REGISTRATION OF SECURITIES**

**Pursuant to Section 12(b) or (g) of The Securities Exchange Act of 1934**

**ADIA NUTRITION, INC.**

*(Exact name of registrant as specified in its charter)*

---

| | |
|:---|:---|
| **<u>Nevada</u>**<br> *(State or other jurisdiction of*<br> *incorporation or organization)*<br>| **<u>35-2829671</u>**<br> *(I.R.S. Employer*<br> *Identification No.)* |
| **1561 West Fairbanks Avenue, Suite 205**<br> **<u>Winter Park, FL</u>** <br> *(Address of principal executive offices)* | <br> **<u>32789</u>**<br> *(Zip Code)* |

---

*Registrant's telephone number, including area code:* (321) 788-0850

Securities to be registered pursuant to Section 12(b) of the Act: **None**

Securities to be registered pursuant to Section 12(g) of the Act:

**<u>Common A Stock, par value $0.001 per share</u>**

**Title of Class**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

[**Table of Contents**](#a_012)

**TABLE OF CONTENTS**

---

| | |
|:---|:---|
|  | **<u>Page</u>** |
| **[CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS](#a_013)** | **1** |
| **[Item 1. Business.](#a_014)** | **1** |
| **[Item 1A. Risk Factors.](#a_015)** | **7** |
| **[Item 2. Financial Information.](#a_016)** | **17** |
| **[Item 3. Properties.](#a_017)** | **27** |
| **[Item 4. Security Ownership of Certain Beneficial Owners and Management.](#a_018)** | **27** |
| **[Item 5. Directors and Executive Officers.](#a_019)** | **29** |
| **[Item 6. Executive Compensation.](#a_020)** | **30** |
| **[Item 7. Certain Relationships and Related Transactions, and Director Independence.](#a_021)** | **30** |
| **[Item 8. Legal Proceedings.](#a_022)** | **32** |
| **[Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.](#a_023)** | **32** |
| **[Item 10. Recent Sales of Unregistered Securities.](#a_024)** | **33** |
| **[Item 11. Description of Registrant's Securities to be Registered.](#a_025)** | **34** |
| **[Item 12. Indemnification of Directors and Officers.](#a_026)** | **38** |
| **[Item 13. Financial Statements and Supplementary Data.](#a_027)** | **39** |
| **[Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.](#a_028)** | **39** |
| **[Item 15. Financial Statements and Exhibits.](#a_029)** | **F-1** |

---

i

[**Table of Contents**](#a_012)

**CAUTIONARY STATEMENT CONCERNING FORWARD-LOOKING STATEMENTS**

Some of the statements contained in this registration statement on Form 10 (this "Registration Statement") of ADIA Nutrition, Inc. (the "Company", "we", "our" or "ADIA Nutrition") discuss future expectations, contain projections of our plan of operation or financial condition or state other forward-looking information. In this registration statement, forward-looking statements are generally identified by the words such as "anticipate", "plan", "believe", "expect", "estimate", and the like. Forward-looking statements involve future risks and uncertainties, there are factors that could cause actual results or plans to differ materially from those expressed or implied. These statements are subject to known and unknown risks, uncertainties, and other factors that could cause the actual results or plans to differ materially from those contemplated by the statements. The forward-looking information is based on various factors and is derived using numerous assumptions. A reader, whether investing in the Company's securities or not, should not place undue reliance on these forward-looking statements, which apply only as of the date of this Registration Statement. Important factors that may cause actual results to differ from projections include, for example:

· the success or failure of management's efforts to implement the Company's business plan;

· the ability of the Company to fund its operating expenses;

· the ability of the Company to compete with other companies that have a similar business plan;

· the effect of changing economic conditions impacting our plan of operation; and

· the ability of the Company to meet the other risks as may be described in future filings with the Securities and Exchange Commission.

Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. We believe the information contained in this Registration Statement to be accurate as of the date hereof. Changes may occur after that date. We will not update that information except as required by law in the normal course of our public disclosure practices.

**Item 1. Business.**

**Corporate History**

ADIA Nutrition Inc. (the "Corporation"), a corporation incorporated under the laws of the State of Nevada on April 24, 1975, as Domi Associates, Inc. Subsequently, the Company amended its articles of incorporation in March 2001, changing its name to Drilling, Inc., and again changed its name to PIVX Solutions, Inc in April 2004. The Company amended its articles of incorporation in 2012 to change its name to the current name of ADIA Nutrition, Inc.

**Custodianship**

The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2013 to 2022 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In March 2022, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company in June 2022. The Company's Nevada charter was reinstated on June 27, 2022, and all required reports were filed with the State of Nevada soon thereafter.

[**Table of Contents**](#a_012)

On March 14, 2022, UMA LLC, a shareholder of the Company, made a demand to the Company, at the last address of record, to comply with the Nevada Secretary of State statutes N.R.S. 78.710 and N.R.S. 78.150. UMA, LLC, made several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked. On, May 6, 2022, UMA, LLC filed a petition against the Company in the District Court of Clark County, Nevada, entitled "In the Matter of ADIA Nutrition Inc., a Nevada corporation", case number A-22-852241-C, along with an Application for Appointment of Custodian.

On June 17, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the "Order"), as Custodian of the Company. Pursuant to the Order, the UMA LLC (the "Custodian") has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit pursuant to, including, but not limited to, issuing shares of stock, and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On June 17, 2022, the Custodian appointed Nikki Lee as the Company's sole officer and director. The Custodian designated one share of preferred stock as Special 2022 Series A Preferred Stock at par value $0.001. The Special 2022 Series A Preferred stock has 60% voting rights over all classes of stock and is convertible into sixty million shares of the Company's common stock. On June 17, 2022, the Custodian granted to itself, one share of Special Series A Preferred Stock.

**Receivership** 

On June 27, 2022, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company's charter and appointed a new Resident Agent in Nevada.

On August 5, 2022, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with Nairobi Anderson, to sell the Special 2022 Series A Preferred stock, and upon closing, Nairobi Anderson acquired 60% voting control of the Company.

On February 27, 2023, Nairobi Anderson entered into an SPA with The Leonard and Elizabeth Greene Family Trust to sell its share of Special 2022 Series A Preferred stock.

On January 22, 2024, The Leonard and Elizabeth Greene Family Trust sold its Special 2022 Series A Preferred share to Legends Investments Properties, LLC, 100% owned by Larry Powalisz. Leonard Greene resigned as Director and Larry Powalisz was appointed Chief Executive Officer and Director, and Rebecca Miller was appointed as Chief Financial Officer.

**Change in Shell Status to a Non-Shell Company**

On January 22, 2024, the Company engaged in a change of control and merged the operation of ADIA Nutrition, Inc. with the operations of the public entity. During the course of the year ended December 31, 2024, the Company began executing upon its business model and acquired operations, assets and inventory. On June 30, 2024, the Company acquired Biolete LLC. Directly prior to the acquisition of Biolete, the Company was a Shell Company. Immediately following the acquisition, the Company was no longer a Shell Company as defined in Rule 12b-2 under the Securities Exchange Act of 1934 as amended (the "Exchange Act"). The effective date of the change in Shell Company status was June 30, 2024.

The Company is no longer a Shell Company since through the acquisition, executing upon its business model, and the acquisition of inventory, the Company now has substantial assets and operations. In addition, as of January 1, 2025, the Company has opened additional medical clinics as wholly owned subsidiaries, and has been seeing patients and generating revenues. It is for the aforementioned reasons that the Company is no longer a Shell Company as defined by Rule 12b-2 under the Exchange Act.

[**Table of Contents**](#a_012)

**Current Business**

In connection with the change in control on January 22, 2024, the Company integrated the operations of ADIA Nutrition, Inc.

ADIA is dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT). ADIA has opened Adia Med of Winter Park, LLC as the clinic to perform treatments, and Adia Labs, LLC which will procure and sell the products relating to these procedures. ADIA Nutrition, Inc. operates under SIC 2836 – *"Biologic Products, Except Diagnostic Substances."*

The Company's medical and supplement divisions aim to boost health and vitality through innovation and expansion. Adia Med leads with a nationwide rollout of satellite locations offering Umbilical Cord Stem Cell (UCB-SC) treatments using AdiaVita from Adia Labs LLC, providing even greater access to the benefits of regenerative medicine. Our UCB-SC contain at least 100 million stem cells and 3 trillion exosomes per unit, and are registered with the FDA under section 361 of the Public Health Service Act (PHSA), which provides for the registration of human cells, tissues and cellular and tissue-based products (HCT/Ps) to be registered pursuant to compliance with FDA 21 CFR part 1271.

Our products and the deployment of the therapies utilizing our products address various orthopedic issues, pain management, and wound repair. With dramatic changes in the regulatory environment during 2024 and 2025 coupled with consumers' better understanding, acceptance of and proactive search for stem cell therapies, the opportunities for stem cell treatment and therapies is increasing rapidly.

Partnerships with top medical entities help expand access to regenerative medicine. Full clinics with apheresis machines will also offer AHSCT for conditions like Multiple Sclerosis (MS) and Therapeutic Plasma Exchange (TPE) for diseases like Alzheimer's. ADIA's revenue comes from services, product sales, while pushing for standardized stem cell protocols with FDA-approved labs.

ADIA is also committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality. The mission is to empower individuals worldwide to prioritize their health and well-being by providing access to premium supplements crafted exclusively from organic ingredients. ADIA has, during 2024, taken an 18% equity position in Cement Factory, LLC. In addition, while we originally acquired Biolete, LLC, we subsequently sold it to Cement factory so they can focus on growth in the supplements market, allowing the Company to focus its primary efforts on the deployment of stem cells and the beneficial therapies associated with stem cells.

ADIA strives to cultivate a portfolio of brands that exemplify excellence, transparency, and sustainability, ensuring that every product that it offers contributes to the enhancement of consumers' lives.

**Market Overview**

The stem cell therapy sector is a rapidly expanding segment of biotechnology and regenerative medicine, projected to reach $28.89 billion globally by 2030 according to Grand View Research. As of late 2025, numerous publicly traded companies are actively developing stem cell-based therapies for conditions like cancer, diabetes, neurodegenerative diseases, and cardiovascular disorders. These firms focus on areas such as allogeneic and autologous stem cells, induced pluripotent stem cells, and gene-edited cellular therapies.

*<u>The Autologous Hematopoietic Stem Cell Transplantation Market Summary</u>*

Autologous Hematopoietic Stem Cell Transplantation (AHSCT) is a procedure where a patient's own stem cells are harvested, stored, and reinfused after high-dose chemotherapy or radiation to treat conditions like multiple myeloma, lymphoma, and certain autoimmune diseases. It represents the dominant segment within the broader Hematopoietic Stem Cell Transplantation (HSCT) market, accounting for approximately 55-58% of total procedures due to its lower risk of graft-versus-host disease and faster recovery compared to allogeneic transplants. The AHSCT market benefits from rising incidences of hematological malignancies, aging populations, and advancements in cell processing and cryopreservation technologies.

[**Table of Contents**](#a_012)

The global HSCT market, with AHSCT as its largest component, is experiencing robust expansion driven by increasing cancer prevalence and improved accessibility. As of 2025, the overall HSCT market is valued at around USD 3.74 billion, projected to reach USD 6.25 billion by 2030 at a compound annual growth rate (CAGR) of 10.79%. Longer-term forecasts indicate even stronger growth, with the market surpassing USD 10.16 billion by 2037 – a CAGR of 9.7% from 2024. AHSCT specifically is expected to grow at a similar or slightly higher rate, fueled by its preference for non-malignant and solid tumor applications. <sup>1</sup>

*<u>The Umbilical Cord Stem Cell Market Summary</u>*

The umbilical cord stem cell market, often encompassed within the broader stem cell banking and umbilical cord blood banking sectors, focuses on the collection, processing, storage, and therapeutic use of hematopoietic and mesenchymal stem cells derived from umbilical cord blood and tissue. These cells are valued for their regenerative potential in treating conditions like leukemia, lymphoma, immune disorders, and emerging applications in regenerative medicine. As of November 2025, the market is experiencing robust growth driven by rising awareness of personalized medicine, advancements in cryopreservation technology, and increasing clinical trials for chronic diseases.

Market data varies due to differences in scope (e.g., banking services vs. therapeutic applications), but consensus points to a global valuation around USD 7-8 billion in 2025, with strong expansion projected through 2032 and beyond.

**Sales and Marketing Strategy**

*<u>Biologic Products</u>*

Our Adia Med operation administers our biologic products using trained medical professionals to treat conditions or ailments whose negative affects can be mitigated by the administration of our biologic. Our sales strategy employs: (1) word of mouth, (2) advertising, (3) seminar sales and, (4) repeat customers. The business model of Adia Med is also replicable with other Adia Med facilities (owned and operated by ADIA) in the future, and the same business model is capable of being applied by other regenerative healthcare facilities throughout the United States. Adia Labs provides its biologic products to Adia Med, and also sells the ADIA biologic products directly to other regenerative healthcare facilities through the United States that are capable of administering the products to their patients by trained medical professionals and practitioners.

 

*<u>Supplement Products</u>*

We cater directly to consumers that can benefit from the utilization of our supplements. We sell our supplements on a direct-to-consumer basis (i.e., www.cementfactory.co) as well as through other direct to consumer channels/portals.

**Brand Names, Trademarks and Intellectual Property**

Our success depends in part upon our ability to protect our intellectual property. To establish and protect our proprietary rights, we will rely on a combination of know-how, trade secrets, license agreements, confidentiality procedures, non-disclosure agreements, non-circumvent agreements, non-solicitation agreements and other contractual agreements and rights.

________________

<sup>1</sup> Sources: Aggregated from Mordor Intelligence, Research Nester, and Market Research Future reports.

[**Table of Contents**](#a_012)

We generally wish to brand and trademark all of our products, and will file patents on products and processes as needed to protect our intellectual property. We have filed for one provisional patent during 2025. To date we have branded or trademarked two of our products:

&nbsp;&nbsp;&nbsp;&nbsp;· **AdiaVita (trademarked):** A private-label product featuring umbilical cord stem cells. Each unit of AdiaVita guarantees a minimum
of 100 million viable cells and 3 trillion exosomes, designed to support advanced medical research and therapeutic applications. This
product has undergone rigorous third-party verification to ensure unparalleled quality, purity, and potency.

· **AdiaLink (branded):** A product offering exosomes with a guaranteed count of 3.5 trillion per unit. It's specifically crafted
for exclusive use in clinical studies, trials, and research by doctors and clinics, aiming to push the boundaries of medical science.

**Product Descriptions, Testing and Quality Standards** 

Donor qualification is performed under FDA CFR 1271. Donor qualification is certified following the review of the mother's medical history, social history, physical examination, and raw product recovery information. All donors are screened for 13 communicable infectious diseases.

Raw amniotic fluid and cords are collected by FDA-approved and AABB accredited cord-blood banks within the United States. All manufacturing is performed by qualiﬁed, trained scientists under cGMP laboratory with an ISO7 clean room. Release criteria including sterility is performed by and certified by independent third-party labs.

**AdiaVita**

&nbsp;&nbsp;&nbsp;&nbsp;· Umbilical Cord Blood Plasma combined with Mononuclear Cells (UCB-PM)

&nbsp;&nbsp;&nbsp;&nbsp;· UCB-PM is an allogeneic, minimally manipulated product derived from allogenic umbilical cord blood collected
from normal healthy planned cesarean section donors. We have completed extensive characterization of the final UCB-PM product to analyze
its biological components for research purposes.

&nbsp;&nbsp;&nbsp;&nbsp;· The manufacturing methodology is designed to preserve the naturally-occurring soluble proteins and nanoparticles
including exosomes present in full-term cord blood UCB-PM. These components have been characterized for their biological properties in
research settings.

&nbsp;&nbsp;&nbsp;&nbsp;· All umbilical cords are sourced from prequalified donors.

**AdiaLink**

&nbsp;&nbsp;&nbsp;&nbsp;· Derived from human amniotic fluid donated from consenting adults during routine, full-term planned cesarean
sections under IRB approved donor screening.

&nbsp;&nbsp;&nbsp;&nbsp;· At this stage of fetal development, amniotic fluid consists of water, salts to maintain proper osmolarity,
proteins and enzymes to aid in fetal growth.

&nbsp;&nbsp;&nbsp;&nbsp;· To address the protein composition of our product, we performed arrayscan analysis to detect up to 80
different cytokines all having functions relating to tissue repair and remodeling.

&nbsp;&nbsp;&nbsp;&nbsp;· Our product is unadulterated. Following procurement, the amniotic fluid is not mixed or diluted with any
additional components. We have evaluated the composition and characteristics of the final product in reference to original unprocessed
amniotic fluid.

**Government Regulations**

The foundation of the Company is its rigorous science-based approach to product development. We seek to educate the medical community to the benefits of perinatal tissue, which is naturally endowed with the capabilities to support immune modulation and tissue and cell regeneration.

We are subject to extensive and ongoing regulation by the FDA under Section 361 of the PHSA and FDA's implementing regulations, as well as other federal and state regulatory bodies in the United States. These laws and regulations govern, among other things, product design and development, pre-clinical and clinical testing, manufacturing, processing, packaging, labeling, storage, record keeping and reporting, marketing, distribution, promotion, import and export, and post-marketing surveillance.

[**Table of Contents**](#a_012)

Unless an exemption applies, each establishment that manufactures HCT/P under Section 361 of the PHSA ("Section 361 HCT/P") must register with the FDA and list all HCT/Ps with the FDA. The development, manufacturing, and marketing of HCT/Ps can be resource intensive, expensive, and lengthy, as well as require payment of significant fees, unless an exemption is available.

We do not currently sell any cellular and tissue-based products considered to be drugs, devices, and/or biological products subject to licensure under Section 351 of the Public Health Service Act or approval or clearance under the Federal Food, Drug, and Cosmetic Act and related regulations. HCT/Ps that are not solely Section 361 HCT/Ps are regulated as biological products, drugs, and/or devices, and, in order to be lawfully marketed in the United States, require FDA pre-market licensure, approval, or clearance.

As discussed above, the products in our portfolio are currently regulated as Section 361 HCT/Ps. However, we may in the future decide to offer new products that would constitute, or qualify as, medical devices, drugs, and/or biologics, which would require compliance with more stringent FDA regulatory requirements, including a Biologics License Application, New Drug Application, or medical device Premarket Approval or 510(k) clearance.

The AATB is a nationwide organization that establishes standards relating to tissue banking and associated products. AATB standards include specific requirements for recovery, screening, testing, labeling, processing, and storing of birth tissue. Generally, AATB accreditation is voluntary. However, some state regulatory bodies and managed care organizations use AATB accreditation as a credentialing or licensing standard. Our lab has obtained AATB accreditation, has undergone a corporate survey, and undergoes continuous audits by the AATB to maintain our accreditation. Our lab is accredited by the AATB, is registered with the FDA as a licensed tissue establishment as required by 21 CFR 1271 and adheres to applicable FDA standards, including the submission by us of a list of each HCT/P that we manufacture at our labs to the FDA as required by 21 CFR 1271.

As mentioned above, we are required to have our products registered with the FDA and our laboratory is also registered with the FDA. All of our products are processed and distributed in compliance with the FDA regulations 21 CFR 1271 Section 361 and AATB standards with end-user safety as our principal focus. At the state level, the regulatory environment varies. In Florida for instance, where we primarily operate, the regulatory environment has eased significantly during the second half of 2024 and throughout 2025. We anticipate that other states will follow suit and, as such we will be able to expand our efforts as the regulatory environment allows us to effectively operate in other markets in the same manner as in which we operate in Florida.

**Competition**

The market for providing regenerative tissue products is moderately fragmented with approximately 30 to 50 competitors providing either amniotic based or umbilical cord based regenerative tissue products. Various competitors are not adequately funded, and as such there is either a natural degree of financial-related attrition within the market, and to a lesser extent, some consolidation within the small group of competitors that exists. While companies like ADIA identify applications within the regenerative medicine market specifically, they do not face competition from the overall pharmaceutical industry.

Unlike companies participating in regenerative medicine products, the pharmaceutical industry concentrates on providing "cures" to medical conditions. As a result, the pharmaceutical industry does not (yet) play a roll in the regenerative market segment, however, it is anticipated that at some point in the future, the pharmaceutical industry will see an opportunity in regenerative care, and will more than likely enter this space through acquisition – once the regenerative market begins to consolidate, similarly to most other markets in the medical space.

[**Table of Contents**](#a_012)

**Smaller Reporting Company Status**

We qualify as a "smaller reporting company" under Rule 12b-2 of the Exchange Act, which is defined as a company with a public equity float of less than $250 million or it has less than $100 million in annual revenues and no public float or public float of less than $700 million. To the extent that we remain a smaller reporting company, we will have reduced disclosure requirements for our public filings,

including: (1) less extensive narrative disclosure than required of other reporting companies, particularly in the description of executive compensation and (2) the requirement to provide only two years of audited financial statements, instead of three years. In addition, until such time as the public float of our common stock exceeds $75 million, we will be a non-accelerated filer and will not be required to comply with the auditor attestation requirements of Section 404(b) of the Sarbanes Oxley Act.

**Employees**

The Company currently has three employees. The business of the Company is managed primarily by the Company's Chief Executive Officer and the Chief Financial Officer. In addition, the Company has four additional directors that are compensated with stock issuances that assist in guiding the Company in medical advancements, regenerative medicine deployment and strategic direction. Additional directors that may be added, and current officers and directors and such officers or directors which may join the Company in the future, may become employees of the Company at a future point in time.

**Item 1A. Risk Factors.**

*The following are certain risk factors that could affect our business, financial condition and results of operations. The risks that are highlighted below are not the only ones that we face. You should carefully consider each of the following risks and all of the other* 

*information contained in this Registration Statement.*

Discussion of our business and operations included in this registration statement should be read together with the risk factors set forth below. They describe various risks and uncertainties to which we are or may become subject. These risks and uncertainties, together with other factors described elsewhere in this report, have the potential to affect our business, financial condition, results of operations, cash flows, strategies or prospects in a material and adverse manner. New risks may emerge at any time, and we cannot predict those risks or estimate the extent to which they may affect our financial performance. Each of the risks described below could adversely impact the value of our securities. These statements, like all statements in this report, speak only as of the date of this registration statement (unless another date is indicated), and we undertake no obligation to update or revise the statements in light of future developments.

We cannot assure you that we will be successful in our business or in the commercialization of the Company's future products or services or that they will be profitable for the Company.

The Company has generated limited revenue from operations upon which an evaluation of our registration statement can be made. The Company's prospects must be considered keeping in mind the risks, expenses and difficulties frequently encountered in the establishment of a new business in a constantly changing industry. There can be no assurance that the Company will be able to maintain profitable operations in the foreseeable future, if at all.

The Company has identified a number of specific risk areas that may affect our operations and results in the future:

***Investing in our Common Stock involves a high degree of risk. You should carefully consider the risks described below with all of the other information included in this registration statement before making an investment decision. If any of the possible adverse events described below actually occurs, our business, results of operations or financial condition would likely suffer. In such an event, the market price of our Common Stock could decline and you could lose all or part of your investment.***

[**Table of Contents**](#a_012)

**Risks Related to Our Industry**

If our competitors market products that are less expensive, safer or more effective than our products or the ones we have in development, or that reach the market before our products or product candidates, we may be at a competitive disadvantage. The market may choose competitive products or choose not to use our products at all for any number of reasons due to familiarity with or pricing of competitive products. The failure of any of our products or product candidates to compete with products marketed by our competitors would impair our ability to generate revenue, which would have a material adverse effect on our future business, financial condition and results of operations.

**We expect to compete with several companies and our competitors may:**

&nbsp;&nbsp;&nbsp;&nbsp;· develop and market products that are less expensive or more effective than our future products;

&nbsp;&nbsp;&nbsp;&nbsp;· commercialize competing products before we or our partners can launch any products developed from our product candidates;

&nbsp;&nbsp;&nbsp;&nbsp;· operate larger research and development programs or have substantially greater financial resources than we do;

&nbsp;&nbsp;&nbsp;&nbsp;· have greater success in recruiting skilled technical and scientific workers from the limited pool of available talent;

&nbsp;&nbsp;&nbsp;&nbsp;· more effectively negotiate third-party and strategic relationships; and

&nbsp;&nbsp;&nbsp;&nbsp;· take advantage of acquisition or other opportunities more readily than we can.

**Risks Related to Our Products**

***Our products participate in a market considered by many to represent new classes of therapy that the marketplace may not understand or accept. Furthermore, the success of our products is dependent on wider acceptance by the medical community and consumer understanding and acceptance.***

 ****

While our products have had some commercial success to date, the broader market may not understand or accept our products. Our products represent new treatments, approaches or therapies and compete with a number of conventional products and therapies manufactured and marketed by others. The nature of our products creates significant challenges with regard to product development and optimization, manufacturing, and regulations. In addition, third-party reimbursement and coverage by health insurance providers is currently undetermined. As a result, the commercialization of our current products and the development pathway for our potential new products may be subject to increased scrutiny, as compared to the pathway for conventional products and therapies already accepted in the marketplace.

***While the osteopathic, regenerative and alternative medicine market segment is growing, the degree of market acceptance of any of our marketed or potential new products will depend on the continued growth and acceptance of these approaches, as well as a number of factors, including:***

 ****

&nbsp;&nbsp;&nbsp;&nbsp;· The clinical safety and effectiveness of our products and their demonstrated advantage over alternative treatment methods;

&nbsp;&nbsp;&nbsp;&nbsp;· Our ability to demonstrate to healthcare providers that our products provide a therapeutic advancement over standard of care treatment
or other competitive products and methods;

&nbsp;&nbsp;&nbsp;&nbsp;· Our ability to educate healthcare providers on the autologous use of human tissue;

&nbsp;&nbsp;&nbsp;&nbsp;· Our ability to educate healthcare providers on the benefits and appropriate use of our human tissue products;

&nbsp;&nbsp;&nbsp;&nbsp;· Our ability to educate healthcare providers and patients and the safety associated with our products, and;

&nbsp;&nbsp;&nbsp;&nbsp;· Our ability to meet supply and demand and develop a continuously growing group of medical professionals familiar with and committed
to the use of our products.

[**Table of Contents**](#a_012)

***Market acceptance of any future product candidates, if approved, will not be fully known until after they are launched and may be negatively affected by a potentially poor safety experience and the track record of other similar products and product candidates.***

If the medical community or patients do not accept the safety and effectiveness of our products, it could negatively affect our ability to sell those products, which would have a material adverse impact on our business, financial condition and operations.

**Risks Related to our Business and Strategy** 

***Although we reported net income for the three months ended September 30, 2025, we have incurred losses in the past and may not achieve consistent profitability for some time or at all.***

We have sustained cumulative losses through the fiscal years ended December 31, 2024 and 2023. For the fiscal years ended December 31, 2024 and 2023, we reported net losses of $181,067 and $0, respectively. The accumulated deficit as of September 30, 2025 was $15,578,018. Our audit firm indicated in its opinion for the fiscal years ended December 31, 2024 and 2023 that there is a substantial risk that we will not be able to continue as a going concern. Our losses have had, and will continue to have, an adverse effect on our financial condition. Any failure to achieve and maintain profitability will continue to have an adverse effect on our financial condition and results of operations and may affect our ability to continue as a going concern.

***The Company may require additional financing to maintain its reporting requirements and administrative expenses.***

The Company's historic financial performance and limited revenue to date may not be sufficient to fund the costs associated with the reporting obligations under the Exchange Act, and other administrative costs associated with our corporate existence. We believe that our most recent profitability trend can be maintained and will continue to provide sufficient funds to pay accounting and professional fees and other expenses to fulfill our reporting obligations under the Exchange Act; however, in the event that our available funds prove to be insufficient, we will be required to seek additional financing. Our failure to secure additional financing could have a material adverse effect on our ability to pay the accounting and other fees in order to continue to fulfill our reporting obligations and pursue our business plan. We have an existing agreement in place with a line of credit facility to provide funding, but we cannot predict if this facility and be extended/increased or if it will be enough to sustain operational expenses. We currently do not have any arrangements with any bank or financial institution to secure additional financing and such financing may not be available on terms acceptable and in our best interests.

***We rely on a third-party lab to provide us with the products we administer, market and sell. Interruptions in the supply of our products or inventory loss may adversely affect our business, results of operations and financial condition.***

 ****

Our products are manufactured using technically complex processes requiring specialized facilities, highly specific raw materials and other production constraints. The complexity associated with our lab's processes, as well as strict government standards for the manufacture and storage of our products subjects us to production risks. In addition to ongoing production risks, process deviations or unanticipated effects of approved process changes may result in non-compliance with regulatory requirements including stability requirements or specifications. Most of our products must be stored and transported within a specified temperature range. For example, if environmental conditions deviate from that range, our products' remaining shelf-lives could be impaired or their safety and efficacy could be adversely affected, making them unsuitable for use. These deviations may go undetected. The occurrence of actual or suspected production and distribution problems can lead to lost inventories, and in some cases recalls, with consequential reputational damage and the risk of product liability. The investigation and remediation of any identified problems can cause production delays and result in substantial additional expenses. Any future failure in the storage or manufacture of our products or loss in supply could result in a loss of our market share and negatively affect our revenues and operations.

***The FDA may conduct periodic inspections of HCT/P manufacturing facilities, and contract manufacturers' facilities, to assess compliance with cGMP and other requirements.***

Such inspections can occur at any time, with or without written notice, at such frequency as determined by the FDA in its sole discretion. To determine compliance with the applicable provisions, the inspections may include, but are not limited to, an assessment of the establishment's facilities, equipment, finished and unfinished materials, containers, processes, HCT/Ps, procedures, labeling, records, files, papers and controls. If the FDA were to find serious non-compliant manufacturing or processing practices during such an inspection, it could take regulatory actions that could adversely affect our business, results of operations, financial condition, and cash flows.

 ****

 ****

[**Table of Contents**](#a_012)

 ****

***The FDA has broad regulatory compliance and enforcement powers. If the FDA determines that we failed to comply with applicable regulatory requirements, it can take a variety of compliance or enforcement actions, which could materially adversely affect our business such as:***

&nbsp;&nbsp;&nbsp;&nbsp;· Untitled letters, warning letters, fines, injunctions, consent decrees, and civil penalties;

&nbsp;&nbsp;&nbsp;&nbsp;· Unanticipated expenditures to address or defend such actions;

&nbsp;&nbsp;&nbsp;&nbsp;· Recall, withdrawal, administrative detention, seizure, or destruction of our products;

&nbsp;&nbsp;&nbsp;&nbsp;· Operating restrictions, partial suspension or total shutdown of production; or,

&nbsp;&nbsp;&nbsp;&nbsp;· Criminal prosecution.

 ****

***The FDA may in the future determine that certain of our products that are, or are derived from, human cells or tissues, do not qualify for regulation solely under Section 361 of the PHSA, and may require that we revise our labeling and marketing claims for these products or that we suspend sales of such products until FDA pre-market clearance or approval is obtained, which could adversely affect our business, results of operations, and financial condition.***

The products we sell are derived from human tissue. Amniotic and other birth tissue have generally been regulated as HCT/Ps and are therefore eligible to be subject to regulation solely under Section 361 depending on whether the specific product at issue and the claims made for it are consistent with the applicable criteria. HCT/Ps that do not meet these criteria are subject to more extensive regulation as drugs, medical devices, biological products, or combination products. These HCT/Ps must comply with both the FDA's requirements for HCT/Ps and the requirements applicable to biologics, devices, or drugs, as applicable, including pre-market clearance, approval, or licensure from the FDA. Obtaining FDA pre-market clearance, approval, or licensure involves significant time and investment by us.

While we believe that we are currently in material compliance with applicable laws and regulations as historically enforced by the FDA, we cannot assure you that the FDA will agree with our determination; and a determination that we have violated these laws and regulations, or a public announcement that we are being investigated for possible violations, could adversely affect our business, prospects, results of operations, or financial condition.

Any future regulatory changes could also have adverse consequences for us and make it more difficult or expensive for us to conduct our business by requiring pre-market clearance, approval, or licensure and compliance with additional post-market regulatory requirements with respect to our products. For example, the FDA may in the future impose conditions, such as labeling restrictions, or requirements that one or more of our products be manufactured in compliance with current such as those currently applicable to drugs, biologics, or medical devices, which would require significant additional time and cost investments by us. Moreover, increased regulatory scrutiny within the industry in which we operate could lead to increased regulation of HCT/Ps, including Section 361 HCT/Ps, which could ultimately increase our costs and adversely impact our business, results of operations and financial condition.

***If any of our products cause or contribute to a death, serious injury, or adverse reaction, we will be required to report such death, serious injury, or adverse reaction under applicable HCT/P reporting regulations, and such events can result in voluntary corrective actions or agency enforcement actions.***

Under FDA HCT/P reporting regulations, HCT/P manufacturers are required to report to the FDA information that a HCT/P has or may have caused or contributed to a death, serious injury, or adverse reaction. If such a death, serious injury, or adverse reaction were to occur, and we or our collaborators are unable to demonstrate that the adverse events were caused by factors other than our or our collaborator's products, regulatory authorities could order us to remove, recall, destroy, or cease manufacturing the affected HCT/P. Any of these occurrences may harm our and our collaborators' ability to manufacture, identify and develop HCT/Ps, and may significantly harm our business, financial condition, result of operations, and prospects.

***Obtaining and maintaining any necessary regulatory approvals, including conducting clinical trials, for certain of our products or potential products could be expensive and time consuming***.

Where applicable, the process of obtaining regulatory clearances, approvals, or licensures to market a drug, medical device, biological product, or a combination product from the FDA may be costly and time consuming, and such clearances, approvals, or licensures may not be granted on a timely basis, or at all. The FDA may take the position that some of the products that we currently market are not Section 361 HCT/Ps and require, among other things, a New Drug Application, Biologics License Application, 510(k) clearance, or Premarket Approval from the FDA. Some of the future products and enhancements to our current products that we may develop or may acquire and market may require marketing clearance, approval, or licensure from the FDA. However, if required, clearance, approval, or licensure may not be granted with respect to any of our products or enhancements and further FDA review may add delays that could adversely affect our ability to market such products or enhancements.

[**Table of Contents**](#a_012)

If FDA disagrees that any of our products is a Section 361 HCT/P, the process of developing and executing clinical trials and manufacturing processes that would be necessary to support FDA approval, licensure, or clearance would require the expenditure of substantial time, effort and financial resources and may take years to complete, including costs incurred on top of those fees incurred as part of conducting various clinical studies while marketing our products under Section 361. Additionally, the FDA may limit the indications for use or place other conditions on any approvals, licensures, or clearances that could restrict the commercial application of the products. If we do receive approval, licensure, or clearance, some types of changes to the approved, licensed, or cleared product(s), such as adding new indications or doses, manufacturing changes and additional labeling claims, would be subject to further testing requirements and further FDA review and approval. Our revenues could be adversely affected if the FDA limited the indications for use or required other conditions that restrict the commercial application of our products.

Additionally, there are significant costs associated with clinical trials that can be difficult to accurately estimate. Clinical trials may not be successful or may return results that do not support approval, licensure, or clearance. Moreover, the results of early clinical trials are not necessarily predictive of future results, and any product we advance into clinical trials may not have favorable results in later clinical trials. Our interpretation of data and results from our clinical trials does not ensure that we will achieve similar results in future clinical trials. In addition, clinical data are often susceptible to various interpretations and analyses, and many companies that have believed their products performed satisfactorily in earlier clinical trials or retrospective studies have nonetheless failed to replicate results in later clinical trials.

 **

***We may be subject to fines, penalties, injunctions and other sanctions if we are deemed to be promoting our products for uses that require, but lack, regulatory approval.***

 **

The FDA and the FTC regulate the advertising and promotion of HCT/Ps to ensure that the claims made are consistent with those permitted by the PHSA or other applicable laws, that there are adequate and reasonable data to substantiate the claims and that the promotional labeling and advertising is neither false nor misleading in any respect. If the FDA or FTC determines that any of our advertising or promotional claims are false, misleading, not substantiated or not permissible, we may be subject to enforcement actions, including warning letters, and we may be required to revise our promotional claims and make other corrections or restitutions.

As a general rule, FDA regulations require that the marketing of Section 361 HCT/Ps, which do not require FDA licensure, approval, or clearance, only be for homologous uses, and that the promotion of any licensed biological products, approved drugs, or approved or

cleared devices only be for FDA-licensed, -approved, or -cleared indications. Generally, unless they are later licensed, approved, or cleared by FDA for other uses, the FDA contends that we may not make claims about the safety or effectiveness of our Section 361 products, or promote them as safe or effective, for uses other than homologous uses. Such limitations present a risk that the FDA or other federal or state law enforcement authorities could determine that the nature and scope of our sales, marketing and support activities, though designed to comply with all FDA requirements, constitute the promotion of our products for a non-homologous or unapproved use in violation of the federal PHSA or FDCA. We also face the risk that the FDA or other governmental authorities might pursue enforcement based on past activities that we have discontinued or changed, including prior sales activities, marketing materials, arrangements with institutions and doctors, educational and training programs and other activities.

Investigations concerning the promotion of unapproved product uses and related issues are typically expensive, disruptive and burdensome and generate negative publicity. If our promotional activities are found to be in violation of the law, we may face significant legal action, fines, penalties, and even criminal liability and may be required to substantially change our sales, promotion, grant and educational activities. There is also a possibility that we could be enjoined from selling some or all of our products for any unapproved use. In addition, as a result of an enforcement action against us or any of our executive officers, we could be excluded from participation in government healthcare programs such as Medicare and Medicaid.

While we believe we are fully in compliance with the FDA's Guidance on Section 361 HCT/Ps, there can be no assurance that we have correctly interpreted the FDA Guidance, or that we will not need to discontinue marketing a product and/or may be subject to fines, penalties, injunctions, and other sanctions if we are deemed to be promoting the use of our products for unapproved uses. Such regulatory penalties by the FDA could adversely affect our business and results of operations.

 ****

 ****

[**Table of Contents**](#a_012)

 ****

***Increased prices for, or unavailability of, raw materials used in our products could adversely affect our business, results of operations and financial condition.***

Our profitability could be affected by prices of raw materials used in the manufacture of our products. These prices could fluctuate based on a number of factors beyond our control, including changes in supply and demand, general economic conditions, labor costs, fuel related delivery costs, competition, excise and other indirect taxes and government regulation. Due to the highly competitive nature of the healthcare industry and the cost containment efforts of our customers and third-parties, we may be unable to pass along cost increases for key components or raw materials through higher prices to our customers. If the costs of key components or raw materials increases, and we are unable fully to recover these increased costs through price increases or offset these increases through other cost reductions, we could experience lower margins and profitability. Significant increases in the prices of raw materials that cannot be recovered through productivity gains, price increases or other methods could adversely affect our business, results of operations and financial condition.

***We depend on our senior leadership team and may not be able to retain or replace these employees or recruit additional qualified personnel, which would harm our business, results of operations and financial condition.***

Our business and success are materially dependent on attracting and retaining members of our senior leadership team to formulate and execute our business plans. Our future success will also depend, in part, upon our ability to attract and retain skilled personnel, including sales, managerial and technical personnel. There can be no assurance that we will be able to continue to find and attract additional qualified employees to support our expected growth or retain any such personnel.

***We face the risk of product liability claims and may not be able to obtain or maintain adequate product liability insurance.***

While we have had a low product complaint and adverse event rate historically, our business exposes us to the risk of product liability claims that are inherent in the manufacturing, processing and marketing of human tissue products. We may be subject to such claims if our products cause, or appear to have caused, an injury. Claims may be made by patients, healthcare providers or others selling our products. Product liability claims can be expensive to defend (regardless of merit), divert our management's attention, result in substantial damage awards against us, harm our reputation, and generate adverse publicity, which could result in the withdrawal of, or reduced acceptance of, our products in the market.

Although we have product liability insurance that we believe is adequate, this insurance is subject to deductibles and coverage limitations, and we may not be able to maintain this insurance at an acceptable cost or on acceptable terms or be able to secure increased coverage (if needed), nor can we be sure that existing or future claims against us will be covered by our product liability insurance. Moreover, the existing coverage of our insurance or any rights of indemnification and contribution that we may have may not be sufficient to offset existing or future claims. If we are unable to maintain product liability insurance at an acceptable cost or on acceptable terms with adequate coverage or otherwise protect ourselves against potential product liability claims or we underestimate the amount of insurance we need, we could be exposed to significant liabilities, which may harm our business. A product liability claim or other claim with respect to uninsured liabilities or for amounts in excess of insured liabilities could result in significant costs and significant harm to our business. Even if a claim is not successful, defending such claim would be time-consuming and expensive, may damage our reputation in the marketplace, and would likely divert our management's attention.

***A cyberattack or significant disruptions of our information technology systems could adversely affect our business, results of operation and financial condition.***

A cyberattack, a disruption in availability, or the unauthorized alteration of systems or data could adversely affect our business, results of operations and financial condition. We rely on technology for day-to-day operations as well as positioning to enhance our stance in the market. We generate intellectual property that is central to the future success of the business and transmit large amounts of confidential information. Additionally, we collect, store and transmit confidential information of customers, patients, employees and third parties. We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure, and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The continually changing threat landscape of cybersecurity today makes our systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, partners, and vendors, and from attacks by malicious third parties, including supply chain attacks originating at our third-party partners. Such attacks are of ever-increasing levels of sophistication. Attacks are made by individuals or groups that have varying levels of expertise, some of which are technologically advanced and well-funded including, without limitation, nation states, organized criminal groups and hacktivists organizations.

 ****

 ****

[**Table of Contents**](#a_012)

 ****

***If a breach of our measures protecting personal data covered by HIPAA state privacy laws, or state data breach notification laws occurs, we may incur significant liabilities and operational disruptions.***

The Health Insurance Portability and Accountability Act of 1996, as amended, or HIPAA, and the regulations that have been issued under it, impose certain obligations, including mandatory contractual terms, with respect to safeguarding the privacy and security of protected health information. The requirements and restrictions apply to "covered entities" (which include health care providers and insurers) as well as to their "business associates" that receive access to protected health information from such covered entities to provide services to or perform certain activities on their behalf. The statute and regulations also impose notification obligations on covered entities and their business associates in the event of a breach of the privacy or security of protected health information. We provide services to and on behalf of customers that are HIPAA covered entities or business associates and occasionally receive protected health information from such customers in the course of our business. As such, we believe that we are HIPAA business associates and therefore subject to HIPAA's requirements and restrictions with respect to handling such protected health information, and have executed business associate agreements with certain customers. We also collect, use, and disclose personally identifiable information that is governed by state privacy laws, such as the California Consumer Privacy Act, as amended.

The secure processing, storage, maintenance, and transmission of this critical information are vital to our operations and business strategy, and we devote significant resources to protecting such information. Although we take reasonable measures to protect sensitive data from unauthorized access, use, or disclosure, no security measures can guarantee the security of information, and our information technology and infrastructure may be vulnerable to attacks by hackers or viruses or breached due to employee or contractor error, malfeasance or other malicious or inadvertent disruptions. Any such breach or interruption could compromise our networks and the information stored there could be accessed by unauthorized parties, publicly disclosed, lost or stolen. Any such access, breach, or other loss or unauthorized use or disclosure of information could result in legal claims or proceedings, and liability under federal or state laws that protect the privacy or security of identifiable information, such as HIPAA, state privacy laws, and state data breach notification laws, and regulatory penalties. Notice of breaches may be required to affected individuals, the Secretary of Health and Human Services or other state, federal or foreign regulators, and for extensive breaches, notice may need to be made to the media or state attorneys general. Such a notice could harm our reputation and our ability to compete.

Unauthorized access, loss or dissemination could also disrupt our operations (including our ability to conduct our analysis, provide test results, bill payors or patients, process claims and appeals, provide customer assistance, conduct research and development activities, collect, process and prepare company financial information, provide information about our tests and other patient and health care provider education and outreach efforts through our website, and manage the administrative aspects of our business) and damage our reputation, any of which could adversely affect our business. There can be no assurance that we will be successful in preventing cyberattacks or successfully mitigating their effects. To the extent that any disruption or security breach results in a loss of or damage to our data or applications or our customers and any other third party's data, or inappropriate disclosure or theft of confidential, proprietary or personal information, we could incur substantial liability, suffer reputational damage or poor financial performance, or become the subject of litigation and/or regulatory actions by state, federal or non-US authorities, any of which could adversely affect our business.

It is possible the data protection laws may be interpreted and applied in a manner that is inconsistent with our practices. If so, this could result in government-imposed fines or orders requiring that we change our practices, which could adversely affect our business. In addition, these privacy regulations may differ from country to country and state to state, and may vary based on whether testing is performed in the United States or in the local country. Complying with these various laws and regulations could cause us to incur substantial costs or require us to change our business practices and compliance procedures in a manner adverse to our business. Further, compliance with data protection laws and regulations could require us to take on more onerous obligations in our contracts, restrict our ability to collect, use and disclose data, or in some cases, impact our ability to operate in certain jurisdictions. We can provide no assurance that we are or will remain in compliance with diverse privacy and security requirements in all of the jurisdictions in which we do business. If we fail to comply or are deemed to have failed to comply with applicable privacy protection laws and regulations such failure could result in government enforcement actions and create liability for us, which could include substantial civil and/or criminal penalties, as well as private litigation and/or adverse publicity that could negatively affect our operating results and business.

 ****

***Public health pandemics or outbreaks could adversely impact our business.***

Our operations may be affected by the outbreak of public health pandemics or outbreaks. The ultimate disruption which may be caused by any particular outbreak is uncertain; however, it may result in a material adverse impact on our financial position, operations and cash flows. Possible areas that may be affected include, but are not limited to, negative impact on our workforce, unavailability of professional services and other resources, disruption in supply chain that may interrupt the supply of human tissue component needed to manufacture our products, restrictions imposed by local governments, or disruption to credit markets necessary for the success of our business model.

[**Table of Contents**](#a_012)

***We will continue to incur costs and demands upon management as a result of complying with the laws and regulations affecting public companies*.**

As a public company, we will continue to incur significant legal, accounting and other expenses, including costs associated with public company reporting requirements. We will also continue to incur costs associated with corporate governance requirements, including requirements under the Sarbanes-Oxley Act, as well as rules implemented by the SEC or other regulators. These rules and regulations may also make it difficult and expensive for us to obtain directors' and officers' liability insurance. As a result, it may be more difficult for us to attract and retain qualified individuals to serve on our board of directors or as executive officers.

**Risks Related to the Ownership of Our Capital Stock**

The stock market, particularly in recent years, has experienced significant volatility. Factors that could cause this volatility in the market price of our Common Stock include:

&nbsp;&nbsp;&nbsp;&nbsp;· failure or discontinuation of any of our research; delays in establishing new strategic relationships;

&nbsp;&nbsp;&nbsp;&nbsp;· delays in the development or commercialization of our potential products;

&nbsp;&nbsp;&nbsp;&nbsp;· market conditions and issuance of new or changed securities analysts' reports or recommendations;
actual and anticipated fluctuations in our financial and operating results;

&nbsp;&nbsp;&nbsp;&nbsp;· developments or disputes concerning our intellectual property or other proprietary rights; introduction
of technological innovations or new commercial products by us or our competitors; issues in manufacturing our potential products;

&nbsp;&nbsp;&nbsp;&nbsp;· litigation or public concern; and additions or departures of key personnel.

These and other external factors may cause the market price and demand for our Common Stock to fluctuate substantially, which may limit or prevent investors from readily selling their shares of Common Stock and may otherwise negatively affect the liquidity of our Common Stock. In the past, when the market price of a stock has been volatile, holders of that stock have instituted securities class action litigation against the company that issued the stock. If any of our stockholders brought a lawsuit against us, we could incur substantial costs defending the lawsuit. Such a lawsuit could also divert the time and attention of our management.

***We have not and do not anticipate paying any dividends on our common stock.***

 ****

We have not paid any dividends on our common stock to date and it is not anticipated that any dividends will be paid to holders of our common stock in the foreseeable future. While our future dividend policy will be based on the operating results and capital needs of the business, it is currently anticipated that any earnings will be retained to finance our future expansion and for the implementation of our business plan. As an investor, you should take note of the fact that a lack of a dividend can further affect the market value of our stock, and could significantly affect the value of any investment in our Company.

***We are subject to the reporting requirements of federal securities laws, this can be expensive and may divert resources from other projects, thus impairing our ability to grow.***

We are subject to the information and reporting requirements of the Exchange Act, and other federal securities laws. The costs of preparing and filing annual and quarterly reports, proxy statements and other information with the SEC and furnishing audited reports to stockholders will cause our expenses to be higher than they would have been if we had remained privately held.

 ****

***If we fail to maintain proper and effective internal controls, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, our ability to operate our business and investors' views of us.***

We will be required to comply with Section 404 of the Sarbanes-Oxley Act. Section 404 of the Sarbanes-Oxley Act requires public companies to conduct an annual review and evaluation of their internal controls and attestations of the effectiveness of internal controls by independent auditors. Ensuring that we have adequate internal financial and accounting controls and procedures in place so that we can produce accurate financial statements on a timely basis is a costly and time-consuming effort that will need to be evaluated frequently. Our failure to maintain the effectiveness of our internal controls could have a material adverse effect on our business.

We could lose investor confidence in the accuracy and completeness of our financial reports, which could have an adverse effect on the price of our common stock. In addition, if our efforts to comply with new or changed laws, regulations, and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

 **

 ****

 **

[**Table of Contents**](#a_012)

 **

***Due to our small number of employees and resources, and limited number of accounting personnel, the Company's Board of Directors has four directors and does not have an audit committee or an independent audit committee financial expert we have limited segregation of duties, as a result, there would be insufficient independent review of duties performed.***

 **

Because of these inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Because of the inherent limitations of internal control, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process. Therefore, it is possible to design into the process safeguards to reduce, though not eliminate, this risk.

***The limited trading market for our common stock results in limited liquidity for shares of our common stock and significant volatility in our stock price.***

 ****

Although prices for our shares of common stock are quoted on the OTC Markets, there is little current trading and no assurance can be given that an active public trading market will develop or, if developed, that it will be sustained. The OTC is generally regarded as a less efficient and less prestigious trading market than other national markets. There is no assurance if or when our common stock will be quoted on another more prestigious exchange or market. Active trading markets generally result in lower price volatility and more efficient execution of buy and sell orders. The absence of an active trading market reduces the liquidity of our common stock.

The market price of our stock is likely to be highly volatile because for some time there will likely be a thin trading market for the stock, which causes trades of small blocks of stock to have a significant impact on our stock price. As a result of the lack of trading activity, the quoted price for our common stock on the OTC is not necessarily a reliable indicator of its fair market value. Further, if we cease to be quoted, holders of our common stock would find it more difficult to dispose of, or to obtain accurate quotations as to the market value of, our common stock, and the market value of our common stock would likely decline.

 **

***Our Common Stock is currently deemed a "penny stock," which makes it more difficult for our investors to sell their shares.***

 **

Our Common Stock is subject to the "penny stock" rules adopted under Section 15(g) of the Exchange Act. The penny stock rules generally apply to companies whose common stock is not listed on The NASDAQ Stock Market or other national securities exchange and trades at less than $4.00 per share, other than companies that have had average revenue of at least $6,000,000 for the last three years or that have tangible net worth of at least $5,000,000 ($2,000,000 if the company has been operating for three or more years).

These rules require, among other things, that brokers who trade penny stock to persons other than "established customers" complete certain documentation, make suitability inquiries of investors and provide investors with certain information concerning trading in the security, including a risk disclosure document and quote information under certain circumstances. Many brokers have decided not to trade penny stocks because of the requirements of the penny stock rules and, as a result, the number of broker-dealers willing to act as market makers in such securities is limited. If we remain subject to the penny stock rules for any significant period, it could have an adverse effect on the market, if any, for our securities. If our securities are subject to the penny stock rules, investors will find it more difficult to dispose of our securities.

 **

***Offers or availability for sale of a substantial number of shares of our Common Stock may cause the price of our Common Stock to decline.***

 **

If our stockholders sell substantial amounts of our Common Stock in the public market upon the expiration of any statutory holding period, under Rule 144, or issued upon the exercise of outstanding options or warrants, it could create a circumstance commonly referred to as an "overhang" and in anticipation of which the market price of our Common Stock could fall. The existence of an overhang, whether or not sales have occurred or are occurring, also could make more difficult our ability to raise additional financing through the sale of equity or equity-related securities in the future at a time and price that we deem reasonable or appropriate.

 **

 ****

 **

[**Table of Contents**](#a_012)

 ****

***The market for our Common Stock may be thinly traded, so you may be unable to sell at or near ask prices or at all if you need to sell your shares to raise money or otherwise desire to liquidate your shares.***

The market for our Common Stock may be thinly traded on the OTC Markets, meaning that the number of persons interested in purchasing our shares at or near ask prices at any given time may be relatively small or non-existent. This situation is attributable to several factors, including the fact that we are a small company that is relatively unknown to stock analysts, stockbrokers, institutional investors, and others in the investment community. Even if we came to such persons' attention, they tend to be risk-averse and would be reluctant to follow an unproven company such as ours or purchase or recommend the purchase of our shares until we became more seasoned and viable. Consequently, there may be periods of several days or more when trading activity in our shares is minimal or non-existent compared to a seasoned issuer, which has a large and steady volume of trading activity that will generally support continuous sales without an adverse effect on our share price. We cannot assure you that a broader or more active public trading market for our common shares will develop or be sustained or that current trading levels will be maintained.

 ****

***The availability of shares for sale in the future could reduce the market price of our Common Stock.***

In the future, we may issue securities to raise cash for acquisitions or otherwise. We may also acquire interests in other companies by using a combination of cash and Common Stock or just Common Stock. We may also issue securities convertible into our Common Stock. Any of these events may dilute your ownership interest in our Company and adversely impact our Common Stock's price. Also, sales of a substantial amount of our Common Stock in the public market or the perception that these sales may occur could reduce our Common Stock's market price and impair our ability to raise additional capital through the sale of our securities.

 ****

***Because directors and officers currently and for the foreseeable future will continue to control the Company, it is not likely that you will be able to elect directors or have any say in the policies of the Company.***

Our shareholders are not entitled to cumulative voting rights. Consequently, the election of directors and all other matters requiring shareholder approval will be decided by majority vote. The directors, officers and affiliates beneficially own a majority of our outstanding Preferred Stock voting rights. Due to such significant ownership position held by our insiders, new investors may not be able to affect a change in our business or management, and therefore, shareholders would have no recourse as a result of decisions made by management.

***You may experience dilution of your ownership interests because of the future issuance of additional shares of our common stock.***

In the future, we may issue our authorized but previously unissued equity securities, resulting in the dilution of the ownership interests of our present stockholders. We may issue additional shares of our common stock or other securities that are convertible into or exercisable for our common stock in connection with hiring or retaining employees, future acquisitions, future sales of our securities for capital raising purposes, or for other business purposes. The future issuance of any such additional shares of our common stock may create downward pressure on the trading price of the common stock. We will need to raise additional capital in the near future to meet our working capital needs, and there can be no assurance that we will not be required to issue additional shares, warrants or other convertible securities in the future in conjunction with capital raising efforts, including at a price (or exercise or conversion prices) below the price an investor paid for stock.

 **

***You could lose all of your investment.***

 **

An investment in our securities is speculative and involves a high degree of risk. Potential investors should be aware that the value of an investment in the Company may go down as well as up. In addition, there can be no certainty that the market value of an investment in the Company will fully reflect its underlying value. You could lose your entire investment.

***We are a "smaller reporting company" and will be exempt from certain disclosure requirements, which could make our common stock less attractive to potential investors.***

Rule 12b-2 of the Exchange Act a "smaller reporting company" means an issuer that is not an investment company, an asset-backed issuer, or a majority-owned subsidiary of a parent that is not a smaller reporting company and that:

---

| |
|:---|
| Had a public float of less than $250 million; or |
| Had annual revenues of less than $100 million and either: |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;No public float; or |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A public float of less than $700 million. |

---

[**Table of Contents**](#a_012)

Whether an issuer is a smaller reporting company is determined on an annual basis.

As a smaller reporting company, we will not be required and may not include a Compensation Discussion and Analysis section in our proxy statements; we will provide only two years of financial statements; and we need not provide the table of selected financial data. We also will have other "scaled" disclosure requirements that are less comprehensive than issuers that are not smaller reporting companies which could make our common stock less attractive to potential investors, which could make it more difficult for our stockholders to sell their shares.

***Provisions of our Certificate of Incorporation, as amended, and Bylaws may delay or prevent a take-over which may not be in the best interests of our shareholders.***

Provisions of our Certificate of Incorporation and Bylaws may be deemed to have anti-takeover effects, which include, among others, when and by whom special meetings of our shareholders may be called, and may delay, defer or prevent a takeover attempt. In addition, our Certificate of Incorporation authorizes the issuance of shares of preferred stock with such rights and preferences as may be determined from time to time by our board of directors in their sole discretion. Our board may, without shareholder approval, issue shares of preferred stock with dividends, liquidation, conversion, voting or other rights that could adversely affect the voting power or other rights of the holders of our common stock.

**Item 2. Financial Information.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF**

**FINANCIAL CONDITION AND RESULTS OF OPERATIONS**

The following presentation of management's discussion and analysis of the Company's financial condition and results of operations should be read in conjunction with the Company's consolidated financial statements, the accompanying notes thereto and other financial information appearing elsewhere in this Registration Statement. This section and other parts of this Registration Statement contain forward-looking statements that involve risks and uncertainties. The Company's actual results may differ significantly from the results discussed in the forward-looking statements.

**Results of Operations**

*<u>For the nine months ended September 30, 2025 and 2024 (unaudited and unreviewed)</u>*

 

*Revenues*

For the nine months ended September 30, 2025 and 2024, we generated total revenue of $637,145 and $2,513, respectively. The majority of our revenue originated from our biologic products ($428,260) by Adia Labs, the administration of medical procedures ($198,600) by Adia Med clinics, as well as the sales of supplements ($3,330), shipping income ($4,688), and the provision of other services of $2,267.

*Cost of Revenues*

For the nine months ended September 30, 2025 and 2024, our cost of revenue was $393,685 and $363, respectively. Our cost of supplements was $892, cost of procedures was $136,427, and cost of biologics was $256,366 for the nine months ended September 30, 2025.

 

*Gross Profit*

For the nine months ended September 30, 2025 and 2024, our gross profit was $243,460 and $2,150, respectively.

 

 

[**Table of Contents**](#a_012)

 

*Operating Expenses* 

 

The following is a tabular breakdown of our operating expenses for the three and nine months ended September 30, 2025 and 2024:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended**<br> **September 30,** | **For the Three Months Ended**<br> **September 30,** | **For the Nine Months Ended <br>September 30,** | **For the Nine Months Ended <br>September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Operating Expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | $47462 | $6677 | $114421 | $21116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 23794 | 21362 | 54979 | 21530 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment leases | 6696 |  | 20088 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal and professional fees | 11162 | 11750 | 104976 | 43283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Licenses | 433 |  | 2688 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Office supplies | 7513 |  | 9940 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 12228 |  | 29144 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rent | 16240 |  | 48242 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shared-based compensation |  |  | 10000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1261 | – | 3178 | – |
| **Total Operating Expenses** | $126789 | $39789 | $397656 | $85929 |

---

For the nine months ended September 30, 2025 and 2024, we incurred total operating expenses of $397,656 and $85,929, respectively. For the nine months ended September 30, 2025, these operating expenses consisted primarily of general and administrative expenses ($114,421), advertising and promotion expenses ($54,979), legal and professional fees ($104,976), rent ($48,242), research and development ($29,144), share-based compensation ($10,000), and depreciation and amortization expense ($3,178). For the nine months ended September 30, 2024, these operating expenses consisted primarily of general and administrative expenses ($21,116), and legal and professional fees ($43,283), and advertising and promotion ($21,530).

*Other Income (Expenses)*

For the nine months ended September 30, 2025 and 2024, we had other expenses comprised of interest expenses to related parties on our line of credit facility of $22,160, and interest income of $250. For the nine months ended September 30, 2024, we had other expenses comprised of interest expenses to related parties on our line of credit facility of $3,132.

 

*<u>Liquidity and Capital Resources (unaudited and unreviewed)</u>*

For the nine months ended September 30, 2025, we had a net loss of $176,106. For the nine months ended September 30, 2025, we had an increase in depreciation and amortization expense of $3,178, an increase in the amortization of operating lease right-of-use asset of $6,535, an increase in share-based compensation of $10,000, an increase in accrue interest – related party of $22,160, a decrease in accounts payable of $2,805, an increase in accounts receivable of $105,72 (of which approximately $66,800 is attributable to the sale of Biolete to Cement Factory for which we hold a receivable for the inventory transfer to Cement Factory) , a decrease in prepaid expenses of $23,380, a decrease in inventory of $97,506, and a decrease in operating lease liabilities of $12,683. As a result, we had net cash used in operating activities of $109,190 for the nine months ended September 30, 2025.

For the nine months ended September 30, 2024, we had a net loss of $86,911. For the nine months ended September 30, 2024, we had an increase in share-based compensation of $30,857, and increase in accrued interest – related party of $3,132, an increase in accounts payable of $90. As a result, we had $52,832 cash used in operating activities.

 

 

 

[**Table of Contents**](#a_012)

 

*Investing Activities*

For the nine months ended September 30, 2025, we had an increase in our fixed assets of $13,200, an increase in loans of $25,000 to one of our start-up clinic, and a decrease in our intangible assets of $6,149. As a result, we had net cash used in investing activities of $32,051.

For the nine months ended September 30, 2024, we had investing activities of $22,752 associated with the Biolete, LLC acquisition, and as a result had $22,752 cash used in investing activities.

 

*Financing Activities*

For the nine months ended September 30, 2025, we had proceeds from drawing on our line of credit with a related party of $231,471, made payments toward our finance lease liability of $12,683, and had proceeds from the sale of our common stock of $70,000. As a result, we had net cash provided by financing activities of $288,788.

For the nine months ended September 30, 2024, we had proceeds from drawing on our line of credit with a related party of $149,006, and had net proceeds from the sale of our common stock of $25,000 (8,000,000 shares as part of the Reg A offering of $40,000 with offering costs of $15,000). As a result, we had net cash provided by financing activities of $174,006.

*<u>For the years ended December 31, 2024 and 2023</u>*

 

*Revenue*

For the years ended December 31, 2024 and 2023, we generated total revenue of $6,380 and $0, respectively. 100% of which was generated by the sale of supplements.

*Gross Profit*

For the years ended December 31, 2024 and 2023, our cost of revenue was $4,186 and $0, respectively, comprised of cost for supplement. As a result, our gross profit for the year ended December 31, 2024 and 2023, was $2,194 and $0, respectively.

*Operating Expenses*

The following is a tabular breakdown of our operating expenses for the years ended December 31, 2024 and 2023:

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2024** | **2023** |
| **Operating Expenses** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | $29977 | $– |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 36534 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal and professional fees | 68559 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rent | 10583 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 30857 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 433 | – |
| **Total Operating Expenses** | $176943 | $– |

---

For the years ended December 31, 2024 and 2023, we incurred total operating expenses of $176,943 and $0. For the year ended December 31, 2024, these operating expenses consisted of general and administrative expenses ($29,977), advertising and promotion expenses ($36,534), legal and professional fees ($68,559), rent ($10,583), share-based compensation ($30,857), and depreciation and amortization expense ($433).

[**Table of Contents**](#a_012)

*Other Expenses*

For the years ended December 31, 2024 and 2023, we had other expenses of $6,318 and $0, respectively. For the year ended December 31, 2024, other expenses was comprised of interest expenses on our line of credit facility with a related party.

*<u>Liquidity and Capital Resources</u>*

For the year ended December 31, 2024, we had a net loss of $181,067. For the year ended December 31, 2024, we had an increase in depreciation and amortization expense of $433, an increase in the amortization of operating lease right-of-use asset of $8,387, an increase in share-based compensation of $30,857, an increase in accrue interest – related party of $6,318, an increase in accounts payable of $4,876, an increase in security deposits of $10,000, an increase in prepaid expenses of $45,185, an increase in inventory of $136,886, and an increase in operating lease liabilities of $13,209. As a result, we had net cash used in operating activities of $335,476 for the year ended December 31, 2024.

For the year ended December 31, 2023, we had $0 income, and as a result $0 cash used in operating activities.

 

*Investing Activities*

For the year ended December 31, 2024, we had an increase in our fixed assets of $21,831 and an increase in intangible assets (investment in trademarks) of $4,149. As a result, we had net cash used in investing activities of $25,980.

For the year ended December 31, 2023, we had no investing activities, and as a result had $0 cash used in investing activities.

 

*Financing Activities*

For the year ended December 31, 2024, we had net proceeds from the sale of our common stock of $25,000 (8,000,000 shares as part of the Reg A offering of $40,000 with offering costs of $15,000), made a deposit on our lease liability for equipment financing of $25,000, and we had an increase in our related party payables of $367,279. As a result, we had net cash provided by financing activities of $367,279.

For the year ended December 31, 2023, we had no financing activities, and as a result we had $0 cash used in financing activities.

**Plan of Operation**

Over the next twelve months, we expect to incur costs and expenses related to:

· maintaining our corporate existence, such as annual fees due to the State of Nevada and any other state in which we conduct business;

· filing periodic reports under the Exchange Act, including filing, accounting and legal fees;

· operating our business in a proper and ethical manner.

We expect to incur costs associated with filing reports under the Exchange Act over the next twelve months of approximately $100,000. Costs associated with operating our business based upon current operating expenses are projected to be in the range of $450,000 to $750,000. We anticipate our cost of revenue to be approximately 35% to 45% of revenue. Based upon our performance during 2025 year to date, we anticipate that our expense should be able to satisfied by our profitability, although this can not be assured. If you are unable to cover our expenses with our gross profit, we may be required to obtain capital from third parties.

[**Table of Contents**](#a_012)

**Going Concern**

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has begun generating revenues during the nine months ended September 30, 2025 totaling $637,145, with an associated net loss of $176,106, and at September 30, 2025, the Company has an accumulated deficit of $15,754,124. These interim 2025 figures have not been audited or reviewed by an independent public accounting firm. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.

Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth. The Company continued the use of its Reg A filing to raise additional capital; the Company received $40,000 in investments, offset by $15,000 in offering costs, towards this registration during the year ended December 31, 2024, and raised an additional $70,000 (unaudited and unreviewed) in investments during the nine months ended September 30, 2025.

In addition, the Company is aggressively executing on its clinic expansion plan. The addition of clinics throughout the United States will allow for a greater based that will purchase and subsequently administer our biologic products to consumers/patients, thereby increasing our revenue going forward.

**Off-balance Sheet Arrangements**

As of September 30, 2025, we did not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

**Critical Accounting Policies**

<u>Basis of Presentation</u>

The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented. Our financials statements have been audited for the years ended December 31, 2024 and 2023; however, our financial statements have not been reviewed or audited for the nine months ended September 30, 2025 and 2024.

<u>Use of Estimates</u>

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

[**Table of Contents**](#a_012)

<u>Principles of Consolidation</u>

The consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Biolete, LLC, Adia Med of Winter Park, LLC and Adia Labs, LLC). All intercompany balances and transactions have been eliminated.

<u>Cash and Cash Equivalents</u>

The Company accounts for cash and cash equivalents under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 305, "*Cash and Cash Equivalents,*" and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

<u>Advertising and Promotion Costs</u>

Advertising and promotion costs are expensed as incurred. During the nine months ended September 30, 2025 and 2024, this cost was $54,979 and $21,530, respectively.

<u>Revenue Recognition</u>

The Company records transactions in accordance with ASU 2014-09, *"Revenue from Contracts with Customers"* and all subsequent amendments to the ASU (collectively, "ASC 606"). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our operations currently generate revenues from the sale of supplements, medical procedures, the sale of our biologic products, and services rendered. During the nine months ended September 30, 2025 and 2024, the Company had revenues of $637,145 and $2,513, respectively. Revenue was generated from the following four sources:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30,**<br> **2025** | **September 30,**<br> **2025** | **September 30,<br> 2024** | **September 30,<br> 2024** |
| Sales of supplements, net of discounts | $3330 | 0.5% | $2513 | 100.0% |
| Medical procedures | 198600 | 31.2% |  | 0.0% |
| Sales of biologics | 428260 | 67.2% |  | 0.0% |
| Shipping and delivery | 4688 | 0.7% |  | 0.0% |
| Services | 2267 | 0.4% | – | 0.0% |
| **Total Fixed Assets, Net** | $**637145** | 100.0% | $2513 | 100.0% |

---

During the years ended December 31, 2024 and 2023, the Company had revenues of $6,380 and $0, respectively from the sale of supplements.

<u>Costs of Revenues</u>

Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was is the cost of our supplement products, the fees associated with the administration of medical procedures, the cost of our biologic products and miscellaneous merchant service fees. For the nine months ended September 30, 2025 and 2024, cost of revenue was $393,685 and $363, respectively. Cost of revenue was as a result of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30,**<br> **2025** | **September 30,**<br> **2025** | **September 30, <br> 2024** | **September 30, <br> 2024** |
| Cost of supplements | $892 | 0.2% | $363 | 0.0% |
| Fees for administration of medical procedures | 136427 | 34.7% |  | 0.0% |
| Cost of biologics | 256366 | 65.1% |  | 0.0% |
| Cost of services | – | 0.0% | – | 0.0% |
| **Total Fixed Assets, Net** | $**393685** | 100.0% | $363 | 100.0% |

---

[**Table of Contents**](#a_012)

Cost of revenue was limited to the cost of supplements, for the years ended December 31, 2024 and 2023, cost of supplements was $4,186 and $0, respectively.

<u>Income Taxes and Valuation Allowance</u>

The Company accounts for income taxes under ASC 740, "*Income Taxes"*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company's deferred tax assets were offset by a full valuation allowance at December 31, 2024.

<u>Financial Instruments</u>

ASC 820, *"Fair Value Measurements and Disclosures,"* defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2025. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

The Company does not have any assets or liabilities measured at fair value on a recurring basis.

<u>Related Parties</u>

The Company follows ASC 850-10, *"Related Party Disclosures,"* for the identification of related parties and disclosure of related party transactions. The Company leases office space from an entity that is controlled by the CEO and Director of the Company. In addition this related party has provided working capital to the Company on the line of credit facility it has extended to the Company.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

[**Table of Contents**](#a_012)

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

<u>Commitments and Contingencies</u>

The Company follows ASC 450-20, "*Loss Contingencies*," to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

<u>Earnings (loss) per share</u>

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) excluded for the nine months ended September 30, 2025 and 2024, are 67,000,000 and 60,000,000, respectively.

<u>Inventory</u>

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at September 30, 2025.

<u>Investments</u>

In accordance with ASC 321, *"Investments – Equity Securities,"* our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability.

<u>Leases</u>

In February 2016, the FASB issued Accounting Standards Update ("ASU") 2016-02, *"Leases"* Topic 842, which amends the guidance in former ASC Topic 840, Leases ("ASC 840"). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use ("ROU") assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

[**Table of Contents**](#a_012)

The Company's ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.

In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.

<u>Loss Contingencies</u>

From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the consolidated balance sheet.

<u>Fixed Assets</u>

The Company follows ASC 360, "*Property, Plant, and Equipment,"* for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (3 to 7 years for equipment). Depreciation expense for the nine months ended September 30, 2025 and 2024, was $3,178 and $0, respectively.

<u>Intangible Assets</u>

Definite life intangible assets at September 30, 2025, included trademarks and brand names recognized as part of the Biolete acquisition. Intangible assets are recorded at cost. Trademarks and brand names represent the estimated fair value of these items at the date of acquisition, and are amortized on a straight-line basis over their estimated useful life. Trademarks and brand names are assigned a life of 10 years.

<u>Long-lived Assets</u>

Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

<u>Segment Reporting</u>

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Biolete, Adia Med and Adia Labs as the Company's operating segments.

[**Table of Contents**](#a_012)

The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company's ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.

The Company has three operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. The Biolete segment comprises the sale of supplements and had $1,328 and $73,974 of total assets at September 30, 2025 and December 31, 2024, respectively. Adia Med performs stem cell treatments to patients and had $288,481 and $323,590 of total assets at September 30, 2025 and December 31, 2024, respectively. Adia Labs procures and sells stem cell products to outside clinics or to Adia Med, and had $101,040 and $139,250 of total assets at September 30, 2025 and December 31, 2024, respectively. Unallocated assets held at the corporate level totaled $385,366 and $129,367 at September 30, 2025 and December 31, 2024, respectively.

The Company chooses to disclose the following in its segment reporting requirements for the nine months ended September 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***For the nine months ended September 30, 2025*** | | | | | |
|  | **Unallocated**<br>**Corporate**<br>**Overhead** |<br>**Biolete** |<br>**ADIA**<br>**Med** |<br>**ADIA**<br>**Labs** |<br>**Totals** |
| **Segment Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of products and services | $2267 | $3330 | $198960 | $432588 | $637145 |
| **Total Segment Revenue** | 2267 | 3330 | 198960 | 432588 | 637145 |
| **Cost of Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | – | 994 | 137094 | 255597 | 393685 |
| **Gross Profit** | 2267 | 2336 | 61866 | 176991 | 243460 |
| **Operating Expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 189880 | 2227 | 148035 | 2535 | 342677 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 27616 | 67 | 22230 | 5066 | 54979 |
| **Segment Operating Expenses** | 217496 | 2294 | 170265 | 7601 | 397656 |
| **Segment Profit (Loss)** | $(215229) | $41 | $(108398) | $169390 | $(154196) |

---

The Company chooses to disclose the following in its segment reporting requirements for the year ended December 31, 2024:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***For the year ended December 31, 2024*** | | | | | |
|  | **Unallocated**<br>**Corporate**<br>**Overhead** |<br>**Biolete** |<br>**ADIA**<br>**Med** |<br>**ADIA**<br>**Labs** |<br>**Totals** |
| **Segment Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of supplements, net of discounts | $– | $6380 | $– | $– | $6380 |
| **Total Segment Revenue** |  | 6380 |  |  | 6380 |
| **Cost of Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of supplements | – | 4186 | – | – | 4186 |
| **Gross Profit** | – | 2194 | – | – | 2194 |
| **Operating Expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 112990 | 5052 | 20420 | 1947 | 140409 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 12606 | 22981 | 947 | – | 36534 |
| **Segment Operating Expenses** | 125596 | 28033 | 21367 | 1947 | 176943 |
| **Segment Loss** | $(125596) | $(25839) | $(21367) | $(1947) | $(174749) |

---

[**Table of Contents**](#a_012)

<u>Stock-Based Compensation</u>

FASB ASC 718 *"Compensation – Stock Compensation,"* prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 "*Equity – Based Payments to Non-Employees*." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the nine months ended September 30, 2025 and 2024, the Company had share-based compensation of $10,000 and $0, respectively. At September 30, 2025, and December 31, 2024, the Company recorded shares to be issued totaling $120,357 and $110,357, respectively.

<u>Recently Issued Accounting Pronouncements</u>

We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. Effective January 1, 2024, we adopted and retroactively applied ASU 2023-07, *"Segment Reporting."*

**Item 3. Properties.**

On November 1, 2024, the Company entered into a lease for 2,125 square feet of office space at 1561 W. Fairbanks Avenue, Winter Park, FL, 32789. This address is the Company's principal place of business. The Company began occupying the space in January 2025 and this facility will be used as a medical clinic to perform treatments and procedures, for patients with autoimmune disorders, utilizing autologous hematopoietic stem cell transplantation (AHSCT) for multiple sclerosis.

As of the date of this report, the Company maintains a separate mailing address at 4421 Gabriella Lane, Winter Park, Florida, 32792.

**Item 4. Security Ownership of Certain Beneficial Owners and Management.**

The following table sets forth certain information regarding beneficial ownership of our voting stock as of November 20, 2025, by:

· Each director and each of our Named Executive Officers,

· All executive officers and directors as a group, and

· Each person known by us to be the beneficial owner of more than 5% of our outstanding common stock.

As of November 20, 2025, there were 94,404,696 shares of our Class A Common Stock, 0 shares of our Class B Common Stock, 1 share of our Special 2022 Series A Preferred Stock, 0 shares of our Series A Preferred Stock, and 1,750,000 shares of our Series C Preferred Stock outstanding.

The number of shares of stock beneficially owned by each person is determined under the rules of the SEC and the information is not necessarily indicative of beneficial ownership for any other purpose. Under such rules, beneficial ownership includes any shares as to which such person has sole or shared voting power or investment power and also any shares which the individual has the right to acquire within 60 days after November 20, 2025, through the exercise of any stock option, warrant or other right. Unless otherwise indicated, each person has sole investment and voting power (or shares such power with his or her spouse) with respect to the shares set forth in the following table. The inclusion herein of any shares deemed beneficially owned does not constitute an admission of beneficial ownership of those shares.

[**Table of Contents**](#a_012)

---

| | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| Name and address of Beneficial Owner | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> | Amount of Beneficial Ownership<sup>(1)</sup> |  |  |  |  |  |  |
|  | Class A Common Stock<sup>(2)</sup> | Class B Common Stock<sup>(3)</sup> | Special 2022 Series A Preferred Stock<sup>(4)</sup> | Special 2022 Series A Preferred Stock<sup>(4)</sup> | Series A Preferred Stock<sup>(5)</sup> | Series C Preferred Stock<sup>(6)</sup> | Series C Preferred Stock<sup>(6)</sup> | Percent of Class A Common Stock<sup>(2)</sup> | Percent of Class B Common Stock<sup>(3)</sup> | Percent of Special 2022 Series A Preferred Stock<sup>(4)</sup> | Percent of Series A Preferred Stock<sup>(5)</sup> | Percent of Series C Preferred Stock<sup>(6)</sup> | Percent of Total Voting Stock |
| ***Named Executive Officers and Directors:*** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Legends Investment Properties<br> (owner: Larry Powalisz)<br> Chairman of the Board<br> 4421 Gabriella Lane<br> Winter Park, FL 32792 | 0 | 0 | 1 | (7) | 0 | 7500000 | (8) | 0.0% | 0.0% | 100% | 0.0% | 51.3% | 66.7% |
| Rebecca Miller<br> Chief Financial Officer<br>4421 Gabriella Lane<br> Winter Park, FL 32792 | 0 | 0 | 0 |  | 0 | 2500000 | (8) | 0.0% | 0.0% | 0.0% | 0.0% | 17.1% | 2.3% |
| Richard Edwards, DO<br> Director<br>1201 S Orlando Ave #132<br> Maitland, FL 32751 | 0 | 0 | 0 |  | 0 | 250000 | (8) | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.23% |
| Monica Sher, MD<br> Director<br>1201 S Orlando Ave #132<br> Maitland, FL 32751 | 0 | 0 | 0 |  | 0 | 250000 | (8) | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.23% |
| Kalpesh Barot, MD<br> Director<br>922 Lucerne Terrace<br> Orlando, FL 32806 | 0 | 0 | 0 |  | 0 | 250000 | (8) | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.23% |
| Evan Thomas, MD, Ph.D.<br> Director<br>1561 W. Fairbanks Avenue<br> Suite205<br> Winter Park, Florida 32789 | 0 | 0 | 0 |  | 0 | 250000 | (8) | 0.0% | 0.0% | 0.0% | 0.0% | 1.7% | 0.23% |
| All executive officers and directors as a group<br> (6 persons) | 0 | 0 | 1 | (7) | 0 | 11000000 | (8) | 0.0% | 0.0% | 100% | 0.0% | 75.2% | 69.9% |
| ***5% Stockholders:*** |  |  |  |  |  |  |  |  |  |  |  |  |  |
| Leo's New Company<br> (owner: Miguel Santana) | 14300000 | 0 | 0 |  | 0 | 0 |  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 13.1% |
| Warp Speed Funding<br> (owner: Robbie Guess) | 7700000 | 0 | 0 |  | 0 | 0 |  | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 7.1% |
| Kevin Masson | 0 | 0 | 0 |  | 0 | 875000 |  | 0.0% | 0.0% | 0.0% | 0.0% | 5.98% | 0.8% |
| Michael Hancock | 0 | 0 | 0 |  | 0 | 875000 |  | 0.0% | 0.0% | 0.0% | 0.0% | 5.98% | 0.8% |
| Cement Factory<br> (owner: AJ Sims)<br>| 0 | 0 | 0 |  | 0 | 1875000 |  | 0.0% | 0.0% | 0.0% | 0.0% | 12.82% | 1.7% |

---

[**Table of Contents**](#a_012)

(1) Except
 as otherwise indicated, we believe that the beneficial owners of each class of stock listed above, based on information furnished
 by such owners, have sole investment and voting power with respect to such shares, subject to community property laws where applicable.
 Beneficial ownership is determined in accordance with the rules of the Securities and Exchange Commission and generally includes
 voting or investment power with respect to securities. Stock subject to options or warrants currently exercisable or exercisable
 within 60 days, are deemed outstanding for purposes of computing the percentage ownership of the person holding such option or warrants,
 but are not deemed outstanding for purposes of computing the percentage ownership of any other person.

(2) Based
 on 94,404,695 shares of Class A Common Stock outstanding on November 20, 2025.

(3) Based
 on 0 shares of Class B Common Stock outstanding on November 20, 2025.

(4) Based
 on 1 share of Special 2022 Series A Preferred Stock outstanding on November 20, 2025.

(5) Based
 on 0 shares of Series A Preferred Stock outstanding on November 20, 2025.

(6) Based
 on 1,750,000 shares of Series C Preferred Stock outstanding on November 20, 2025; an additional 1,000,000 shares of Series C Preferred
 to be issued to a total of 4 directors of the Company (250,000 shares each); 1,875,000 shares of Series C Preferred to
 be issued for the membership interest in Cement Factory; and, per their employment agreements, two officers of the Company are entitled
 to the option to purchase a total of 10,000,000 shares of the Company's Series C Preferred Stock, however, the Company is obligated
 to issue these shares at some point in the future, regardless if the options are exercised by the Company or not. This
 equates to the equivalent of 14,625,000 shares of Series C Preferred Stock outstanding now or in the near future if all shares were
 issued.

(7) Represents 1
 share of Special 2022 Series A Preferred Stock owned by Legends Investment Properties which is owned by Larry Powalisz, the CEO and
 Chairman of the Board of the Company, which is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred
 Stock (including on an as converted basis), and can be converted into 60,000,000 shares of common stock, subject to customary adjustments
 for stock splits, etc..

(8) Each
 share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation
 for their vote. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class. Each share
 of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock.

**Item 5. Directors and Executive Officers.**

The following table sets forth the names, ages, positions and dates of appointment of our current directors and executive officers.

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Age** | **Position** | **Date Appointed** |
| Larry Powalisz | 62 | Chairman of the Board, CEO | January 2024 |
| Rebecca Miller | 50 | Chief Executive Officer | January 2024 |

---

Since January 2024, Mr. Powalisz has served as our Chairman of the Board and Chief Executive Officer. Mr. Powalisz has been involved in many startup operations and successful business ventures for the past 25+ years.

Mr. Powalisz has not been involved in any negative legal proceedings as enumerated in Item 401(f) of Regulation S-K in the past 10 years.

Ms. Miller has served as the Company's Chief Financial Officer since January 2024. She has been involved with many of the business ventures involving Mr. Powalisz for the past 15+ years.

[**Table of Contents**](#a_012)

**Item 6. Executive Compensation.**

<u>2024 Summary Compensation Table</u>

The following table sets forth information with respect to the compensation awarded or paid to our named executive officers during the fiscal years ended December 31, 2024 and 2023 (collectively, the "named executive officers") for all services rendered in all capacities to us in fiscal 2024 and 2023.

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| **Name and Principal Position** | **Year** | **Salary**<br> **($)** | **Bonus**<br> **($)** | **Stock**<br> **Awards**<br> **($)** | **Option**<br> **Awards**<br> **($)** | **Non-Equity**<br> **Incentive Plan Compensation**<br> **($)** | **Nonqualified Deferred Compensation Earnings**<br> **($)** | **All Other Compensation**<br> **($)** | **Total**<br> **($)** |
| Larry Powalisz | 2024 | 0<sup>(1)</sup> | 0 | 0 | 0<sup>(2)</sup> | 0 | 0 | 0 | 0 |
| Chief Executive Officer | 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Rebecca Miller | 2024 | 0<sup>(1)</sup> | 0 | 0 | 0<sup>(2)</sup> | 0 | 0 | 0 | 0 |
| Chief Executive Officer | 2023 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |

---

(1) No
 compensation has been paid to date to Mr. Powalisz and Ms. Miller and the Company has not entered into any compensation agreements
 with Mr. Powalisz or Ms. Miller.

(2) Mr.
 Powalisz and Ms. Miller have each been entitled (during the nine months ended September 30, 2025) the option to purchase a total
 of 10,000,000 shares of the Company's Series C Preferred Stock, however, the Company is obligated to issue these shares at
 some point in the future, regardless if the options are exercised by the Company or not.

<u>Officer and Director Compensation</u>

The Company's officers and directors are not compensated for their services at this time. Each director is granted 250,000 shares of the Company's Series C Preferred stock upon appointment. They are eligible to receive additional stock or stock options from time to time as the Company and its Board of Directors determine is appropriate.

**Item 7. Certain Relationships and Related Transactions, and Director Independence.**

<u>Related Party Transactions</u>

On June 30, 2024, the Company entered into an agreement with the Chief Executive Officer of the Company for an unsecured $500,000 line of credit facility, total credit was increased to $750,000 with the addition of another $250,000 line of credit facility on June 12, 2025, bearing the same terms as the original line of credit. The line of credit bears interest of 6% per annum calculated on a daily basis, and there is no stated maturity date. The entire unpaid principal balance plus any accrued but unpaid interest shall be due and payable twelve months from the date of receipt of demand of payment by the lender. The monies that had been advanced by the Chief Executive Officer of the Company up to June 30, 2024 were transferred to this line of credit facility. The aggregate of the advances were $154,065 of which the Company paid back $2,560, resulting in a total of $151,505 being extended on the line of credit facility at June 30, 2024.

During the balance of the year ended December 31, 2024, additional advances on the line of credit totaled $223,548, and additional payments were made in the aggregate amount of $6,524. During the nine months ended September 30, 2025, the Company received additional advances of $239,311, and made payments to the lender of $7,840. At September 30, 2025, the total outstanding principal balance on this line of credit facility was $600,000. For the nine months ended September 30, 2025, interest expense was $22,160 and total accrued interest at September 30, 2025, was $28,478 (unaudited and unreviewed).

The above amounts and terms of the transactions are not necessarily typical of agreements entered into by third parties.

[**Table of Contents**](#a_012)

<u>Independent Directors and Independent Director Compensations</u>

We have four independent directors on our board.

Each director agrees to perform such tasks as may be necessary to fulfill Director's obligations as a member of the Board and its committees and serve as a director so long as they are duly appointed or elected and qualified in accordance with the applicable provisions of the Company's Articles of Incorporation and Bylaws and any necessary approval by the Company's stockholders and/or Board, and until such time as Director resigns, fails to stand for election, fails to be elected by the stockholders of the Company or is removed from Director's position. Director may at any time and for any reason resign or be removed from such position consistent with the Articles of Incorporation and Bylaws of the Company in which event the Company shall have no additional obligations under its agreement with the Director.

Upon acceptance of their appointment to the board of directors, the Company is committed to issuing each director 250,000 shares of the Company's Series C Preferred Stock, and as of the date of this registration statement, all of the shares due to the four directors, remain unissued. The Company is not committed to providing any monetary compensation to its independent directors.

The following is a summary of each independent director:

**Dr. Evan Thomas, MD, PhD.** – Dr. Thomas serves as Chief Medical Officer of the Renaissance Institute of Precision Oncology & Radiosurgery. He is recognized for his expertise in central nervous system (CNS) and functional radiosurgery, utilizing stereotactic radiosurgery (SRS) and stereotactic body radiotherapy (SBRT) to treat complex conditions. Dr. Thomas has pioneered Joint Glow, a groundbreaking therapy utilizing advanced radiotherapy for joint disorders, an innovative approach rare among U.S. physicians. His global influence includes clinical trial leadership, peer-reviewed publications, and lectures in over 15 countries. Dr. Thomas serves as the Company's Medical Director, and will guide Adia Med's clinical operations, finalize AHSCT protocols, and oversee Adia Med's other specialized therapies ensuring exceptional patient care.

**Dr. Kalpesh Barot, MD** – Dr. Barot is a distinguished oncologist from the Southwest Cancer, Dr. Barot's resume and extensive expertise in oncology brings invaluable insight to ADIA's mission to advance healthcare solutions. Dr. Barot's focus is to oversee ADIA's aHSCT treatments, a cutting-edge therapy designed to offer new hope for patients suffering from Multiple Sclerosis (MS). Dr. Barot's role is pivotal to enhance the aHSCT protocols and ensuring the highest standards of care for patients undergoing this transformative treatment.

**Dr. Monica Sher, MD** – Dr. Monica Sher is instrumental in the establishment of policies and procedures for our aHSCT program for MS patients. Dr. Sher has extensive experience and expertise in the field of medicine with a background in Internal Medicine and a passion for health and wellness, and will assist in leading ADIA's efforts in advancing aHSCT therapies for MS. Dr. Sher aligns perfectly with our strategy of improving the lives of patients through stem cell therapy and cutting-edge medical interventions like aHSCT.

**Dr. Richard Edwards, DO** – Dr. Edwards is a distinguished osteopathic physician with a unique perspective and approach. His extensive background in osteopathic medicine and his dedication to patient-centered care align with ADIA's mission to deliver comprehensive and individualized treatment plans and will assist in the recruitment of oncologists to administer aHSCT treatments.

<u>Audit Committee and Audit Committee financial expert</u>

We have established an audit committee, which consists of our Chairman of the Board, the CFO and all four independent directors, however, <u>we do not have</u> a financial expert serving on our Board of Directors.

Our audit committee is authorized to:

&nbsp;&nbsp;&nbsp;&nbsp;· approve and retain the independent auditors to conduct the annual audit of our financial statements;

&nbsp;&nbsp;&nbsp;&nbsp;· review the proposed scope and results of the audit;

&nbsp;&nbsp;&nbsp;&nbsp;· review and pre-approve audit and non-audit fees and services;

&nbsp;&nbsp;&nbsp;&nbsp;· review accounting and financial controls with the independent auditors and our financial and accounting
staff;

&nbsp;&nbsp;&nbsp;&nbsp;· review and approve transactions between us and our directors, officers, and affiliates;

&nbsp;&nbsp;&nbsp;&nbsp;· recognize and prevent prohibited non-audit services;

&nbsp;&nbsp;&nbsp;&nbsp;· establish procedures for complaints received by us regarding accounting matters; and

&nbsp;&nbsp;&nbsp;&nbsp;· oversee internal audit functions, if any.

[**Table of Contents**](#a_012)

**Item 8. Legal Proceedings.**

*Recent proceedings are listed below.*

<u>Custodianship</u>

This legal action is discussed in Item 1 under the title Custodian.

<u>Cancellation of Shares</u>

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company's issued and outstanding shares of Common Stock, held by Lotus Fund ("Lotus") (10,495,165 shares), and Jason S. Coombs ("Coombs") (5,000,000 shares), as well as the certain issued and outstanding shares of Series A Preferred Shares. Lotus, Coombs and Singhal (collectively the "Claimants") were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

**Item 9. Market Price of and Dividends on the Registrant's Common Equity and Related Stockholder Matters.**

<u>Market Information</u>

Our common stock is quoted on the OTC QB tier of the OTC Markets Group under the symbol "ADIA." The OTC Market is a computer network that provides information on current "bids" and "asks," as well as volume information.

The following table sets forth the range of high and low closing bid quotations for our common stock for each of the periods indicated as reported by the OTC Markets. These quotations reflect inter-dealer prices, without retail mark-up, mark-down or commission and may not necessarily represent actual transactions.

---

| | | |
|:---|:---|:---|
|  | **Bid Prices** | **Bid Prices** |
|  | **Low** | **High** |
| **FISCAL YEAR DECEMBER 31, 2023** |  |  |
| First Quarter (January 1, 2023 to March 31, 2023) | $0.0060 | $0.1700 |
| Second Quarter (April 1, 2023 to June 30, 2023) | $0.0121 | $0.0594 |
| Third Quarter (July 1, 2023 to September 30, 2023) | $0.0131 | $0.0295 |
| Fourth Quarter (October 1, 2023 to December 31, 2023) | $0.0111 | $0.0217 |
| **FISCAL YEAR ENDING DECEMBER 31, 2024** |  |  |
| First Quarter (January 1, 2024 to March 31, 2024) | $0.0091 | $0.0250 |
| Second Quarter (April 1, 2024 to June 30, 2024) | $0.0060 | $0.0200 |
| Third Quarter (July 1, 2024 to September 30, 2024) | $0.0046 | $0.0159 |
| Fourth Quarter (October 1, 2024 to December 31, 2024) | $0.0026 | $0.0108 |
| **YEAR TO DATE ENDING DECEMBER 31, 2025** |  |  |
| First Quarter (January 1, 2025 to March 31, 2025) | $0.0060 | $0.1720 |
| Second Quarter (April 1, 2025 to June 30, 2025) | $0.0177 | $0.0900 |
| Third Quarter (July 1, 2025 to September 30, 2025) | $0.0227 | $0.0680 |
| Fourth Quarter (October 1, 2025 to November 20, 2025) | $0.0250 | $0.0660 |

---

[**Table of Contents**](#a_012)

On November 20, 2025, the closing bid price of our common stock as reported on the OTC Markets was $0.045. As of November 20, 2025, there were approximately 172 holders of record of our common stock, including multiple beneficial holders at depositories, banks and brokers listed as a single holder in the street name of each respective depository, bank or broker.

<u>Dividend Policy</u>

We have never declared or paid cash dividends on our capital stock, and we currently have no plans to do so. Our current policy is to retain all of our earnings to finance future growth and pay down our existing indebtedness.

**Item 10. Recent Sales of Unregistered Securities.**

<u>Common Stock</u>

On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $40,000 in investments, offset by $15,000 in offering costs, resulting in subsequent issuance of 8,000,000 shares of the Company's Class A Common Stock.

On June 6, 2025, the Company received an investment on its Reg A registration statement in the amount of $38,500, resulting in shares to be issued of 7,700,000 shares of the Company's Class A Common Stock.

On June 11, 2025, the Company received an investment on its Reg A registration statement in the amount of $31,500, resulting in shares to be issued of 6,300,000 shares of the Company's Class A Common Stock.

<u>Preferred Stock</u>

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock.

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024, the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company's Series C Preferred Stock to be issued at a future date.

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of the Company. As of the date of this registration statement, the 250,000 shares of its Series C Preferred Stock remain unissued.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of the Company. As of the date of this registration statement, the 250,000 shares of its Series C Preferred Stock remain unissued.

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of the Company. As of the date of this registration statement, the 250,000 shares of its Series C Preferred Stock remain unissued.

At the nine months ended September 30, 2025, per their employment agreements, two officers of the Company were entitled to the option to purchase a total of 10,000,000 shares of the Company's Series C Preferred Stock, however, the Company is obligated to issue these shares at some point in the future, regardless if the options are exercised by the Company or not.

[**Table of Contents**](#a_012)

**Item 11. Description of Registrant's Securities to be Registered.**

<u>General</u>

 

As of the date of this Registration Statement, the Company has 900,000,000 authorized shares of common stock, $0.001 par value per share and 100,000,000 authorized shares of preferred stock, $0.001 par value per share, designated in the following manner:

&nbsp;&nbsp;&nbsp;&nbsp;· Class A Common Stock, 800,000,000 shares authorized, par value $0.001, 94,404,696 shares outstanding;

&nbsp;&nbsp;&nbsp;&nbsp;· Class B Common Stock, 100,000,000 shares authorized, par value $0.001, 0 shares outstanding;

&nbsp;&nbsp;&nbsp;&nbsp;· Special 2022 Series A Preferred Stock, 1 shares authorized, par value $0.001, 1 share outstanding;

&nbsp;&nbsp;&nbsp;&nbsp;· Series A Preferred Stock, 10,000,000 shares authorized, par value $0.001, 0 shares outstanding;

&nbsp;&nbsp;&nbsp;&nbsp;· Series C Preferred Stock, 89,999,999 shares authorized, par value $0.001, 1,750,000 shares outstanding;

<u>Common Stock</u>

The Company has 900,000,000 authorized common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

The Company has two common stock designations; Class A Common Stock with 800,000,000 shares authorized, and Class B Common Stock with 100,000,000 shares authorized.

<u>Class A Common Stock</u>: Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders' meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.

[**Table of Contents**](#a_012)

On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $40,000 in investments, offset by $15,000 in offering costs, resulting in subsequent issuance of 8,000,000 shares of the Company's Class A Common Stock.

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company's issued and outstanding shares of Common Stock, held by Lotus Fund ("Lotus") (10,495,165 shares), and Jason S. Coombs ("Coombs") (5,000,000 shares), as well as the certain issued and outstanding shares of Series A Preferred Shares. Lotus, Coombs and Singhal (collectively the "Claimants") were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

On June 6, 2025, the Company received an investment on its Reg A registration statement in the amount of $38,500, resulting in shares to be issued of 7,700,000 shares of the Company's Class A Common Stock.

On June 11, 2025, the Company received an investment on its Reg A registration statement in the amount of $31,500, resulting in shares to be issued of 6,300,000 shares of the Company's Class A Common Stock.

At September 30, 2025 and December 31, 2024, there were 94,404,696 and 95,899,861 Class A Common Shares issued and outstanding, respectively.

At September 30, 2025 and December 31, 2024, there were no Class B Common Shares issued and outstanding.

<u>Preferred Stock</u> 

There are 100,000,000 shares of preferred stock authorized, par value $.001 per share (the "Preferred Stock"), issuable in one or more series; (a) the Company designated one (1) share of Preferred Stock as "Special 2022 Series A Preferred Stock" possessing super-voting rights; (b) the Company designated 10,000,000 shares of Series A Preferred Stock; and (c) the Company designated 89,999,999 shares of Series C Preferred Stock.

<u>Special 2022 Series A Preferred Stock.</u> The designation of this class of preferred stock shall be "Special 2022 Series A Preferred Stock," par value $.001 per share (the "Special 2022 Series A Preferred Stock"). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1). (A) Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights: (1) Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis)) entitled to vote at each meeting of shareholders of the Corporation (and written actions of shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares. (2) Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class. (B) Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred stock can affect the conversion at any time. The conversion into common is a right and is not required. (C) Dividends; Liquidation. The shares of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof and shall not participate in any proceeds available to the Corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation. (D) No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.

[**Table of Contents**](#a_012)

<u>Series A Preferred Stock</u>. The designation of this class of preferred stock shall be "Series A Preferred Stock," par value $.001 per share (the "Series A Preferred Stock"). The number of authorized shares of Series A Preferred Stock is ten million (10,000,000). Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class. (c) Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the "Liquidation Rate") before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.

<u>Series C Preferred Stock</u>. The designation of this class of preferred stock shall be "Series C Preferred Stock," par value $.001 per share (the "Series C Preferred Stock"). The number of authorized shares of Series C Preferred Stock is eighty-nine million, nine hundred ninety-nine thousand, nine hundred and ninety nine (89,999,999). Each share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class. Liquidation

Rights - Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of the Company's common stock multiplied by the Conversion Rate. Conversion Rate – Each share of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock.

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock.

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024, the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company's Series C Preferred Stock to be issued at a future date.

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On May 5, 2025, the Company retired and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void certain shares of the Company's issued and outstanding shares of Common Stock. In addition, the lawsuit sought an order declaring as void a total of 10,000,000 shares of the Company's issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal ("Singhal"). The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

At the nine months ended September 30, 2025, per their employment agreements, two officers of the Company were entitled to the option to purchase a total of 10,000,000 shares of the Company's Series C Preferred Stock, however, the Company is obligated to issue these shares at some point in the future, regardless if the options are exercised by the Company or not.

At September 30, 2025 and December 31, 2024, there is one (1) share of Special 2022 Series A Preferred issued and outstanding.

At September 30, 2025 and December 31, 2024, there are zero and 10,000,000 shares of Series A Preferred issued and outstanding, respectively.

At September 30, 2025 and December 31, 2024, there are 1,750,000 shares of Series C Preferred issued and outstanding.

[**Table of Contents**](#a_012)

<u>Anti-Takeover Effects of Provisions of the Nevada Revised Statutes and our Certificate of Incorporation and Bylaws</u>

Provisions of the Nevada Revised Statutes and our Certificate of Incorporation and Bylaws could make it more difficult to acquire the Company by means of a tender offer, a proxy contest or otherwise, or to remove incumbent officers and directors. These provisions, summarized below, are expected to discourage certain types of coercive takeover practices and takeover bids that our board of directors may consider inadequate and to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of increased protection of our ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging takeover or acquisition proposals because, among other things, negotiation of these proposals could result in improved terms for our stockholders.

*Nevada Anti-Takeover Statute*

 

Nevada Revised Statutes sections 78.378 to 78.3793 provide state regulation over the acquisition of a controlling interest in certain Nevada corporations unless the articles of incorporation or bylaws of the corporation provide that the provisions of these sections do not apply. Our articles of incorporation and bylaws do not state that these provisions do not apply. The statute creates a number of restrictions on the ability of a person or entity to acquire control of a Nevada company by setting down certain rules of conduct and voting restrictions in any acquisition attempt, among other things. The statute is limited to corporations that are organized in the state of Nevada and that have 200 or more stockholders, at least 100 of whom are stockholders of record and residents of the State of Nevada; and does business in the State of Nevada directly or through an affiliated corporation. Because of these conditions, the statute currently does not apply to our company.

*Exclusive Forum Provision*

 

Our Bylaws do not provide an exclusive forum provision.

*Amendments to Our Articles of Incorporation* 

 

Our articles of incorporation reserve the right to amend, alter, change, or repeal any provision contained in our articles of incorporation, as prescribed by statute. Under the Nevada Revised Statutes section 78.390, except as provided in sections 77.340, 78.209, or Chapter 92A, the Board of Directors must adopt a resolution setting forth the amendment proposed and submit the proposed amendment to the shareholders for approval. If stockholders holding shares in the corporation representing at least a majority of the voting power, or such greater proportion of the voting power as may be required in the case of a vote by classes or series, as provided in subsections 2 and 4 (of Nevada Revised Statutes section 78.390), or as may be required by the provisions of the articles of incorporation, have approved the amendment, an officer of the corporation shall sign a certificate setting forth the amendment, or setting forth the articles of incorporation as amended, and the vote by which the amendment was adopted. The aforementioned certificate must be filed with the Secretary of State. Subsection 2 states that except as otherwise provided in this subsection, if any proposed amendment would adversely alter or change any preference or any relative or other right given to any class or series of outstanding shares, then, in addition to any approval otherwise required, the amendment must be approved by the holders of shares representing a majority of the voting power of each class or series adversely affected by the amendment regardless of limitations or restrictions on the voting power thereof. The amendment does not have to be approved by the holders of shares representing a majority of the voting power of each class or series whose preference or rights are adversely affected by the amendment if the articles of incorporation specifically deny the right to vote on such an amendment. Subsection 4 states that different series of the same class of shares do not constitute different classes of shares for the purpose of voting by classes except when the series is adversely affected by an amendment in a different manner than other series of the same class.

*Vacancies in the Board of Directors*

 

Our Bylaws provide that, any vacancy occurring on the board of directors and any directorship to be filled by reason of an increase in the board of directors may be filled by the affirmative vote of a majority of the remaining directors, although less than a quorum, or by a sole remaining director. Such newly elected director shall hold such office until his successor is elected and qualified or until his earlier resignation or removal.

 

 

 

[**Table of Contents**](#a_012)

 

*Special Meetings of Stockholders*

 

Per Nevada Revised Statutes, unless otherwise provided in the articles of incorporation or bylaws, the entire board of directors, any two directors or the president may call annual and special meetings of the stockholders and directors. Our articles of incorporation do not provide for special meetings. Under our Bylaws, special meetings of the stockholders, for any purpose or purposes, unless otherwise prescribed by statute or by the articles of incorporation, may be called by the president and shall be called by the president or secretary if requested in writing by the holders of not less than one-tenth (1/10) of all the shares entitled to vote at the meeting. Such request shall state the purpose or purposes of the proposed meeting. Written notice stating the place, date and hour of the meeting and, in case of a special meeting, the purpose or purposes for which the meeting is called, shall be given not less than ten nor more than sixty days before the date of the meeting, except as otherwise required by statute or the articles of incorporation, either personally, by mail or by a form of electronic transmission consented to by the stockholder, to each stockholder of record entitled to vote at such meeting.

*No Cumulative Voting*

 

The Nevada Revised Statutes provides that the articles of incorporation of any corporation may provide that at all elections of directors of the corporation each holder of stock possessing voting power is entitled to as many votes as equal the number of his or her shares of stock multiplied by the number of directors to be elected, and that the holder of stock may cast all of his or her votes for a single director or may distribute them among the number to be voted for or any two or more of them, as the holder of stock may see fit. To exercise the right of cumulative voting, one or more of the stockholders requesting cumulative voting must give written notice to the president or secretary of the corporation that the stockholder desires that the voting for the election of directors be cumulative. Our Certificate of Incorporation does not provide for cumulative voting.

<u>Limitations on Directors' Liability; Indemnification of Directors and Officers</u>

Our Certificate of Incorporation and Bylaws contain provisions indemnifying our directors and officers to the fullest extent permitted by law. Per the Nevada Revised Statutes, except as otherwise provided in Nevada Revised Statutes 35.230, 90.660, 91.250, 452.200, 452.270, 668.045 and 694A.030, or unless the articles of incorporation or an amendment thereto, in each case filed on or after October 1, 2003, provide for greater individual liability, a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless: (a) The presumption that good faith, on an informed basis and with a view to the interests of the corporation has been rebutted; and (b) It is proven that: (1) The director's or officer's act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and (2) Such breach involved intentional misconduct, fraud or a knowing violation of law.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers or persons controlling the Company pursuant to the foregoing provisions, we understand that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

**Item 12. Indemnification of Directors and Officers.**

The Nevada Revised Statutes, our Certificate of Incorporation, and Bylaws provide for indemnification of our directors and officers for liabilities and expenses that they may incur in such capacities. In general, directors and officers are indemnified with respect to actions taken in good faith in a manner reasonably believed to be in, or not opposed to, the best interests of the registrant and, with respect to any criminal action or proceeding, actions that the indemnitee had no reasonable cause to believe were unlawful.

Our Certificate of Incorporation provides that "[t]he personal liability of the directors of the Corporation is hereby eliminated to the fullest extent permitted by the General Corporation Law of the State of Nevada, as then same may be amended and supplemented. Any repeal or amendment of this [language] by the stockholders of the Company shall be prospective."

[**Table of Contents**](#a_012)

Our Bylaws provide that the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of the Corporation) by reason of the fact that he is or was a director or officer of the Corporation, or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, association or other enterprise, against expenses (including attorneys' fees), judgments, fines and amounts paid in settlement actually and reasonably incurred by him in connection with which action, suit or proceeding, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his conduct was unlawful. The termination of any action, suit or proceeding by judgment, order, settlement, conviction or upon plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he reasonably believed to be in or not opposed to the best interests of the Corporation and, with respect to any criminal action or proceeding, that he had reasonable cause to believe that his conduct was unlawful.

Our Bylaws also provide that the Corporation shall indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action or suit by or in the right of the Corporation to procure a judgment in its favor by reason of the fact that he is or was a director or officer of the Corporation, or, while a director or officer of the Corporation, is or was serving at the request of the Corporation as a director, officer, employee or agent of another corporation, partnership, joint venture, trust, association or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by him in connection with the defense or settlement of such action or suit, if he acted in good faith and in a manner he reasonably believed to be in or not opposed to the best

interests of the Corporation, except that no indemnification shall be made in respect of any claim, issue or matter as to which such person shall have been adjudged to be liable to the Corporation unless and only to the extent that the court in which such action or suit was brought shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which the court shall deem proper.

Per the Nevada Revised Statutes, except as otherwise provided in Nevada Revised Statutes 35.230, 90.660, 91.250, 452.200, 452.270, 668.045 and 694A.030, or unless the articles of incorporation or an amendment thereto, in each case filed on or after October 1, 2003, provide for greater individual liability, a director or officer is not individually liable to the corporation or its stockholders or creditors for any damages as a result of any act or failure to act in his or her capacity as a director or officer unless: (a) The presumption that good faith, on an informed basis and with a view to the interests of the corporation has been rebutted; and (b) It is proven that: (1) The director's or officer's act or failure to act constituted a breach of his or her fiduciary duties as a director or officer; and (2) Such breach involved intentional misconduct, fraud or a knowing violation of law.

Insofar as indemnification for liabilities arising under the Securities Act may be permitted to our directors, officers, and controlling persons pursuant to the foregoing provisions, or otherwise, we have been advised that, in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment of expenses incurred or paid by a director, officer or controlling person in a successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, we will, unless in the opinion of our counsel that the matter has been settled by controlling precedent, submit to the court of appropriate jurisdiction the question whether such indemnification by the Company is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**Item 13. Financial Statements and Supplementary Data.**

The information required by this item is contained under Item 15 of this Registration Statement (and the financial statements referenced therein). That section is incorporated herein by reference.

**Item 14. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.**

None.

[**Table of Contents**](#a_012)

**Item 15. Financial Statements and Exhibits.**

***a.***  ***Financial Statements*** 

**ADIA NUTRITION, INC.** 

**CONSOLIDATED FINANCIAL STATEMENTS**

**SEPTEMBER 30, 2025 and 2024**

**(unaudited and unreviewed)**

---

| | |
|:---|:---|
|  | Pages |
| [Consolidated Balance Sheets as of September 30, 2025 (unaudited and unreviewed) and December 31, 2024](#a_001) | F-2 |
| [Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (unaudited and unreviewed)](#a_008) | F-3 |
| [Consolidated Statements of Stockholders' Equity (Deficit) for the three and nine months ended September 30, 2025 and 2024 (unaudited and unreviewed)](#a_009) | F-4 |
| [Consolidated Statements of Cash flows for the nine months ended September 30, 2025 and 2024 (unaudited and unreviewed)](#a_010) | F-5 |
| [Notes to the Unaudited and Unreviewed Consolidated Financial Statements](#a_011) | F-6 to F-19 |

---

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED BALANCE SHEETS**

---

| | | |
|:---|:---|:---|
|  | **September 30,**<br> **2025**<br>**(unaudited and<br> unreviewed)** | **December 31,**<br>**2024**<br> **(Audited)** |
| **<u>ASSETS</u>** |  |  |
| **Current Assets** |  |  |
| Cash | $153870 | $6323 |
| Accounts receivable | 105721 |  |
| Inventory |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory on-hand |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Supplements | 797 | 67636 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Biologics | 108583 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-paid inventory | – | 139250 |
|  | 109380 | 206886 |
| Prepaid expenses | 21805 | 45184 |
| **Total Current Assets** | 390776 | 258393 |
| Investment in non-consolidated entity | 79500 | 79500 |
| Start-up clinic loans | 25000 |  |
| Intangible assets – trademarks, net of amortization |  | 5910 |
| Deposits | 10000 | 10000 |
| Fixed assets, net of depreciation | 31776 | 21637 |
| Right-of-use asset |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating, net | 121372 | 160447 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance, net | 117611 | 130294 |
|  | 238983 | 290741 |
| **Total Assets** | $776035 | $666181 |
| **<u>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</u>** |  |  |
| **Current Liabilities** |  |  |
| Accounts payable | $2428 | $4876 |
| Accrued interest – related party | 28478 | 6318 |
| Lease liability – current portion |  |  |
| Operating | 56094 | 51535 |
| Finance | 18590 | 17264 |
| **Total Current Liabilities** | 74684 | 79993 |
| Related party payables | 600000 | 368529 |
| Long-term lease liabilities, net of current portion |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating | 66990 | 104089 |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance | 74021 | 88030 |
|  | 141011 | 192119 |
| **Total Liabilities** | 846601 | 640641 |
| **Stockholders' Equity (Deficit)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Special 2022 Series A Preferred Stock, $0.001 par value, 1 share authorized, issued and outstanding at September 30, 2025 and December 31, 2024. | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock, $0.001 par value, 10,000,000 shares authorized, zero and 10,000,000 issued and outstanding at September 30, 2025 and December 31, 2024, respectively. |  | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock, $0.001 par value, 89,999,999 shares authorized, 1,750,000 shares issued and outstanding at September 30, 2025 and December 31, 2024. | 1750 | 1750 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class A Common Stock, $0.001 par value; 800,000,000 shares authorized, 94,404,696 and 95,899,861 shares issued and outstanding, at September 30, 2025 and December 31, 2024, respectively. | 94405 | 95900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B Common Stock, $0.001 par value; 100,000,000 shares authorized, zero issued and outstanding, at September 30, 2025 and December 31, 2024. |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares to be issued | 120357 | 110357 |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 15467045 | 15385550 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (15754124) | (15578018) |
| **Total Stockholders' Equity (Deficit)** | (70566) | 25540 |
| **Total Liabilities and Stockholders' Equity (Deficit)** | $776035 | $666181 |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(unaudited and unreviewed)**

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **For the Three Months Ended**<br> **September 30,** | **For the Three Months Ended**<br> **September 30,** | **For the Nine Months Ended**<br> **September 30,** | **For the Nine Months Ended**<br> **September 30,** |
|  | **2025** | **2024** | **2025** | **2024** |
| **Revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of supplements, net of discounts | $1231 | $2513 | $3330 | $2513 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medical procedures | 101900 |  | 198600 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of biologics | 257860 |  | 428260 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shipping and delivery | 3400 |  | 4688 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Services | – | – | 2267 | – |
| **Total Revenue** | 364391 | 2513 | 637145 | 2513 |
| **Cost of Revenue** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Supplements | 368 | 363 | 892 | 363 |
| &nbsp;&nbsp;&nbsp;&nbsp;Procedures | 44840 |  | 136427 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Biologics | 107998 | – | 256366 | – |
| **Total Cost of Revenue** | 153206 | 363 | 393685 | 363 |
| **Gross Profit** | 211185 | 2150 | 243460 | 2150 |
| **Operating Expenses** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 47462 | 6677 | 114421 | 21116 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 23794 | 21362 | 54979 | 21530 |
| &nbsp;&nbsp;&nbsp;&nbsp;Equipment leases | 6696 |  | 20088 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal and professional fees | 11162 | 11750 | 104976 | 43283 |
| &nbsp;&nbsp;&nbsp;&nbsp;Licenses | 433 |  | 2688 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Office supplies | 7513 |  | 9940 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Research and development | 12228 |  | 29144 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rent | 16240 |  | 48242 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shared-based compensation |  |  | 10000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 1261 | – | 3178 | – |
| **Total Operating Expenses** | 126789 | 39789 | 397656 | 85929 |
| **Profit (Loss) from Operations** | 84396 | (37639) | (154196) | (83779) |
| **Other Income (Expense)** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 250 |  | 250 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense – related party | (9074) | (2291) | (22160) | (3132) |
| **Total Other Income (Expense)** | (8824) | (2291) | (21910) | (3132) |
| **Net Income (Loss) Before provision for Income Taxes** | 75572 | (39930) | (176106) | (86911) |
| **Provision for Income Taxes** | – | – | – | – |
| **NET INCOME (LOSS)** | $75572 | $(39930) | $(176106) | $(86911) |
| Net Income (Loss) Per Share: Basic and Diluted | $0.00 | $(0.00) | $(0.00) | $(0.00) |
| Weighted Average Number of Shares Outstanding: Basic and Diluted | 94404696 | 87899861 | 93323448 | 87899861 |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF STOCK<br> STOCKHOLDERS' EQUITY (DEFICIT)**

**(unaudited and unreviewed)**

**For the Three and Nine Months Ended September 30, 2025 and 2024**

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Special 2022 Series A Preferred** | **Special 2022 Series A Preferred** | **Series A Preferred** | **Series A Preferred** | **Series C Preferred** | **Series C Preferred** | **Shares to be issued** | **Shares to be issued** | **Class A**<br> **Common Stock** | **Class A**<br> **Common Stock** | **Class B**<br> **Common Stock** | **Class B**<br> **Common Stock** | | | |
|  | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Additional Paid-In**<br>**Capital**<br> **($)** | **Accumulated**<br>**Deficit**<br> **($)** | **Total**<br> **Stockholders'**<br> **Equity**<br>**(Deficit)**<br> **($)** |
| **Balance December 31, 2024** | 1 | 1 | 10000000 | 10000 | 1750000 | 1750 | 2625000 | 110357 | 95899861 | 95900 |  |  | 15385550 | (15578018) | 25540 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (116219) | (116219) |
| **Balance March 31, 2025** | 1 | 1 | 10000000 | 10000 | 1750000 | 1750 | 2625000 | 110357 | 95899861 | 95900 |  |  | 15385550 | (15694237) | (90679) |
| Cancellation of shares via court order |  |  | (10000000) | (10000) |  |  |  |  | (15495165) | (15495) |  |  | 25495 |  |  |
| Shares to be issued for subscriptions – Common Stock |  |  |  |  |  |  | 14000000 | 66500 |  |  |  |  |  |  | 66500 |
| Share-based compensation – Preferred C |  |  |  |  |  |  | 10000000 | 10000 |  |  |  |  |  |  | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (135459) | (135459) |
| **Balance June 30, 2025** | 1 | 1 |  |  | 1750000 | 1750 | 26625000 | 186857 | 80404696 | 80405 |  |  | 15411045 | (15829696) | (149638) |
| Shares issued for subscriptions – Common Stock |  |  |  |  |  |  | (14000000) | (66500) | 14000000 | 14000 |  |  | 56000 |  | 3500 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net income** | – | – | – | – | – | – | – | – | – | – | – | – | – | 75572 | 75572 |
| **Balance September 30, 2025** | 1 | 1 | – | – | 1750000 | 1750 | 12625000 | 120357 | 94404696 | 94405 | – | – | 15467045 | (15753944) | (70566) |

---

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Special 2022 Series A Preferred** | **Special 2022 Series A Preferred** | **Series A Preferred** | **Series A Preferred** | **Series C Preferred** | **Series C Preferred** | **Shares to be issued** | **Shares to be issued** | **Class A**<br> **Common Stock** | **Class A**<br> **Common Stock** | **Class B**<br> **Common Stock** | **Class B**<br> **Common Stock** | | | |
|  | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Additional Paid-In**<br>**Capital**<br> **($)** | **Accumulated**<br>**Deficit**<br> **($)** | **Total**<br> **Stockholders'**<br> **Equity**<br>**(Deficit)**<br> **($)** |
| **Balance December 31, 2023** | 1 | 1 | 10000000 | 10000 |  |  |  |  | 87899861 | 87900 |  |  | 15298300 | (15396951) | (750) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (26244) | (26244) |
| **Balance March 31, 2024** | 1 | 1 | 10000000 | 10000 |  |  |  |  | 87899861 | 87900 |  |  | 15298300 | (15423195) | (26994) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (20736) | (20736) |
| **Balance June 30, 2024** | 1 | 1 | 10000000 | 10000 |  |  |  |  | 87899861 | 87900 |  |  | 15298300 | (15443931) | (47730) |
| Issuance of director shares |  |  |  |  |  |  | 750000 | 750 |  |  |  |  | (750) |  |  |
| Acquisition of Biolete |  |  |  |  | 1750000 | 1750 |  |  |  |  |  |  | 70250 |  | 72000 |
| Investment in Cement Factory |  |  |  |  |  |  | 1875000 | 1875 |  |  |  |  | 77625 |  | 79500 |
| Issuance of Reg A shares |  |  |  |  |  |  |  |  | 8000000 | 8000 |  |  | 32000 |  | 40000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (39930) | (39930) |
| **Balance September 30, 2024** | 1 | 1 | 10000000 | 10000 | 1750000 | 1750 | 2625000 | 2625 | 95899861 | 95900 | – | – | 15477425 | (15483861) | 103840) |

---

See accompanying notes to consolidated financial statements

****

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(unaudited and unreviewed)**

---

| | | |
|:---|:---|:---|
|  | **For the Nine Months Ended September 30,** | **For the Nine Months Ended September 30,** |
|  | **2025** | **2024** |
| **Cash Flows From Operating Activities:** |  |  |
| Net Loss | $(176106) | $(86911) |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operations |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 3178 |  |
| &nbsp;&nbsp;&nbsp;Amortization of operating lease right-of-use asset | 6535 |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 10000 | 30857 |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest – related party | 22160 | 3132 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (2805) | 90 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable | (105721) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 23380 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | 97506 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liability - operating | 12683 | – |
| **Net Cash Used In Operating Activities** | (109190) | (52832) |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of furniture & equipment | (13200) |  |
| &nbsp;&nbsp;&nbsp;Purchase of intangible assets |  | (22752) |
| &nbsp;&nbsp;&nbsp;Loans to start-up clinics | (25000) |  |
| &nbsp;&nbsp;&nbsp;Sale of trademarks | 6149 | – |
| **Net Used In Investing Activities** | (32051) | (22752) |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Note payable – related party | 231471 | 149006 |
| &nbsp;&nbsp;&nbsp;Payments made on lease liability - finance | (12683) | **–** |
| &nbsp;&nbsp;&nbsp;Proceeds from sales of common stock | 70000 | 25000 |
| **Net Cash Provided by Financing Activities** | 288788 | 174006 |
| **Net Increase in Cash** | 147547 | 98422 |
| Cash at Beginning of Period | 6323 | 500 |
| **Cash at End of Period** | $153870 | $98922 |
| **<u>Supplemental disclosure of cash flow information:</u>** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | – | – |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | – | – |
| **<u>Supplemental disclosure of non-cash investing and financing activities:</u>** |  |  |
| &nbsp;&nbsp;&nbsp;Shares to be issued for investment in non-consolidated business entity | $– | $79500 |
| &nbsp;&nbsp;&nbsp;Shares issued for acquisition of Biolete, LLC | $– | 72000 |
| &nbsp;&nbsp;&nbsp;Shares to be issued for compensation | $10000 | $– |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**NOTES TO THE UNAUDITED AND UNREVIEWED CONSOLIDATED FINANCIAL STATEMENTS**

**SEPTEMBER 30, 2025 and 2024**

**<u>NOTE 1 – ORGANIZATION AND BUSINESS</u>**

ADIA Nutrition Inc. (the "Company," "we," "us" or "our"), a Nevada corporation, has a calendar fiscal year and is listed on OTC Markets under the trading symbol ADIA. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2013 to 2022 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In March 2022, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company in June 2022. The Company's Nevada charter was reinstated on June 27, 2022, and all required reports were filed with the State of Nevada soon thereafter. The custodian was not able to recover any of the Company's accounting records from previous management but was able to get the shareholder information hence the Company's outstanding common shares were reflected in the stockholders' equity section of the unaudited financial statements for the year ended December 31, 2022.

The Company was incorporated in the State of Nevada in April 1975 as Domi Associates, Inc. In March 2001, the issuer amended its Articles of Incorporation to change its name to Drilling, Inc. On April 20, 2004, an amendment to the Articles of Incorporation was made to change the name to PIVX Solutions, Inc. In 2012, the issuer changed to ADIA Nutrition, Inc.

On March 14, 2022, UMA LLC, a shareholder of the Company, made a demand to the Company, at the last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. UMA, LLC, made several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked. On, May 6, 2022, UMA, LLC filed a petition against the Company in the District Court of Clark County, Nevada, entitled "In the Matter of ADIA Nutrition Inc., a Nevada corporation", case number A-22-852241-C, along with an Application for Appointment of Custodian,

On June 17, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the "Order"), as Custodian of the Company. Pursuant to the Order, the UMA LLC (the "Custodian") has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit pursuant to, including, but not limited to, issuing shares of stock, and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On June 17, 2022, the Custodian appointed Nikki Lee as the Company's sole officer and director. The Custodian designated one share of preferred stock as Special 2022 Series A Preferred Stock at par value $0.001. The Special 2022 Series A Preferred stock has 60% voting rights over all classes of stock and is convertible into sixty million shares of the Company's common stock. On June 17, 2022, the Custodian granted to itself, one share of Special Series A Preferred Stock.

On June 27, 2022, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company's charter and appointed a new Resident Agent in Nevada.

On August 5, 2022, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with Nairobi Anderson, to sell the Special 2022 Series A Preferred stock, and upon closing, Nairobi Anderson acquired 60% voting control of the Company.

On February 27, 2023, Nairobi Anderson entered into an SPA with The Leonard and Elizabeth Greene Family Trust to sell its share of Special 2022 Series A Preferred stock.

On January 22, 2024, The Leonard and Elizabeth Greene Family Trust sold its Special 2022 Series A Preferred share to Legends Investments Properties, LLC, 100% owned by Larry Powalisz. Leonard Greene resigned as Director and Larry Powalisz was appointed Chief Executive Officer and Director, and Rebecca Miller was appointed as Chief Financial Officer.

 

[**Table of Contents**](#a_012)

 

*ADIA – Going Forward*

ADIA is dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis (MS) patients.

ADIA engages with health insurance companies to advocate for the inclusion and reimbursement of AHSCT treatments for MS patients. The dedicated team navigates the complexities of insurance processes, striving to make these transformative therapies financially accessible to a wider population.

ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients. Through commitment, collaboration, advocacy, and quality care, the Company aims to redefine the standard of treatment for MS and contribute to improved outcomes and quality of life for those affected by the disease.

ADIA is also committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality. The mission is to empower individuals worldwide to prioritize their health and well-being by providing access to premium supplements crafted exclusively from organic ingredients. ADIA has, during the third quarter of 2024, acquired Biolete, LLC (see Note 7 below) and taken an 18% equity position in Cement Factory, LLC (see Note 8 below).

Being dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide AHSCT treatments for MS patients. In late 2024, ADIA formed Adia Med of Winter Park, LLC as the clinic to perform the aforementioned treatments, and Adia Labs, LLC which will procure and sell the products relating to these procedures.

ADIA strives to cultivate a portfolio of brands that exemplify excellence, transparency, and sustainability, ensuring that every product that it offers contributes to the enhancement of the consumers lives.

*ADIA Nutrition – Board of Directors Expansion*

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

**<u>NOTE 2 – GOING CONCERN</u>**

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has begun generating revenues during the nine months ended September 30, 2025 totaling $637,145, with an associated net loss of $176,106, and at September 30, 2025, the Company has an accumulated deficit of $15,754,124. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.

Management anticipates continued growth in revenue and plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide bridge capital, financing of receivables, and operating capital for continued growth. The Company continued the use of its Reg A filing to raise additional capital; the Company received $40,000 in investments, offset by $15,000 in offering costs, towards this registration during the year ended December 31, 2024, and raised an additional $70,000 in investments during the nine months ended September 30, 2025.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

[**Table of Contents**](#a_012)

**<u>NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u>**

<u>Basis of Presentation</u>

The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented. Our financials not been reviewed or audited for the nine months ended September 30, 2025 and 2024.

<u>Use of Estimates</u>

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Principles of Consolidation</u>

The consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Biolete, LLC, Adia Med of Winter Park, LLC and Adia Labs, LLC). All intercompany balances and transactions have been eliminated.

<u>Cash and Cash Equivalents</u>

The Company accounts for cash and cash equivalents under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 305, "*Cash and Cash Equivalents,*" and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

<u>Advertising and Promotion Costs</u>

Advertising and promotion costs are expensed as incurred. During the nine months ended September 30, 2025 and 2024, this cost was $54,979 and $21,530, respectively.

<u>Revenue Recognition</u>

The Company records transactions in accordance with ASU 2014-09, *"Revenue from Contracts with Customers"* and all subsequent amendments to the ASU (collectively, "ASC 606"). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

[**Table of Contents**](#a_012)

Our operations currently generate revenues from the sale of supplements, medical procedures, the sale of our biologic products, and services rendered. During the nine months ended September 30, 2025 and 2024, the Company had revenues of $637,145 and $2,513, respectively. Revenue was generated from the following four sources:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30,**<br> **2025** | **September 30,**<br> **2025** | **September 30,<br> 2024** | **September 30,<br> 2024** |
| Sales of supplements, net of discounts | $3330 | 0.5% | $2513 | 100.0% |
| Medical procedures | 198600 | 31.2% |  | 0.0% |
| Sales of biologics | 428260 | 67.2% |  | 0.0% |
| Shipping and delivery | 4688 | 0.7% |  | 0.0% |
| Services | 2267 | 0.4% | – | 0.0% |
| **Total Fixed Assets, Net** | $**637145** | 100.0% | $2513 | 100.0% |

---

<u>Costs of Revenues</u>

Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was is the cost of our supplement products, the fees associated with the administration of medical procedures, the cost of our biologic products and miscellaneous merchant service fees. For the nine months ended September 30, 2025 and 2024, cost of revenue was $393,685 and $363, respectively. Cost of revenue was as a result of the following:

---

| | | | | |
|:---|:---|:---|:---|:---|
|  | **September 30,**<br> **2025** | **September 30,**<br> **2025** | **September 30,<br> 2024** | **September 30,<br> 2024** |
| Cost of supplements | $892 | 0.2% | $363 | 0.0% |
| Fees for administration of medical procedures | 136427 | 34.7% |  | 0.0% |
| Cost of biologics | 256366 | 65.1% |  | 0.0% |
| Cost of services | – | 0.0% | – | 0.0% |
| **Total Fixed Assets, Net** | $**393685** | 100.0% | $363 | 100.0% |

---

<u>Income Taxes and Valuation Allowance</u>

The Company accounts for income taxes under ASC 740, "*Income Taxes"*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company's deferred tax assets were offset by a full valuation allowance at December 31, 2024.

[**Table of Contents**](#a_012)

<u>Financial Instruments</u>

ASC 820, *"Fair Value Measurements and Disclosures,"* defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2025. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

The Company does not have any assets or liabilities measured at fair value on a recurring basis.

<u>Related Parties</u>

The Company follows ASC 850-10, *"Related Party Disclosures,"* for the identification of related parties and disclosure of related party transactions. The Company leases office space from an entity that is controlled by the CEO and Director of the Company. In addition this related party has provided working capital to the Company on the line of credit facility it has extended to the Company.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

[**Table of Contents**](#a_012)

<u>Commitments and Contingencies</u>

The Company follows ASC 450-20, "*Loss Contingencies*," to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

<u>Earnings (loss) per share</u>

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) excluded for the nine months ended September 30, 2025 and 2024, are 67,000,000 and 60,000,000, respectively.

<u>Inventory</u>

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at September 30, 2025.

<u>Investments</u>

In accordance with ASC 321, *"Investments – Equity Securities,"* our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. (See Note 8.)

<u>Leases</u>

In February 2016, the FASB issued Accounting Standards Update ("ASU") 2016-02, *"Leases"* Topic 842, which amends the guidance in former ASC Topic 840, Leases ("ASC 840"). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use ("ROU") assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

The Company's ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.

[**Table of Contents**](#a_012)

In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.

<u>Loss Contingencies</u>

From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the consolidated balance sheet.

<u>Fixed Assets</u>

The Company follows ASC 360, "*Property, Plant, and Equipment,"* for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (3 to 7 years for equipment). Depreciation expense for the nine months ended September 30, 2025 and 2024, was $3,178 and $0, respectively.

<u>Intangible Assets</u>

Definite life intangible assets at September 30, 2025, included trademarks and brand names recognized as part of the Biolete acquisition. Intangible assets are recorded at cost. Trademarks and brand names represent the estimated fair value of these items at the date of acquisition, and are amortized on a straight-line basis over their estimated useful life. Trademarks and brand names are assigned a life of 10 years.

<u>Long-lived Assets</u>

Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

<u>Segment Reporting</u>

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Biolete, Adia Med and Adia Labs as the Company's operating segments.

[**Table of Contents**](#a_012)

<u>Stock-Based Compensation</u>

FASB ASC 718 *"Compensation – Stock Compensation,"* prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 "*Equity – Based Payments to Non-Employees*." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the nine months ended September 30, 2025 and 2024, the Company had share-based compensation of $10,000 and $0, respectively. At September 30, 2025, and December 31, 2024, the Company recorded shares to be issued totaling $120,357 and $110,357, respectively.

<u>Recently Issued Accounting Pronouncements</u>

We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. We recently adopted and retroactively applied ASU 2023-07, *"Segment Reporting."*

**<u>NOTE 4 - INVENTORY</u>**

Inventory consists of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,** <br> **2025** | **December 31, <br> 2024** |
| Biolete finished goods inventory (supplements) | $797 | $67636 |
| Biologic products | 108583 | 139250 |
| **Total Inventory** | $**109380** | $**206886** |

---

**<u>NOTE 5 – FIXED ASSETS, NET</u>**

Fixed assets, net, consists of the following:

---

| | | |
|:---|:---|:---|
|  | **September 30,** <br> **2025** | **December 31, <br> 2024** |
| Furniture and fixtures | $5332 | $5332 |
| Machinery and equipment | 29698 | 16499 |
| Property and equipment, gross | 35030 | 21831 |
| Less: Accumulated depreciation | (3074) | (194) |
| **Total Fixed Assets, Net** | $**31956** | $**21637** |

---

[**Table of Contents**](#a_012)

**<u>NOTE 6 – INTANGIBLE ASSETS, NET</u>**

At September 30, 2025, the Company no longer has any intangible assets. The Company sold all of its trademarks on the Biolete supplement product line to Cement Factory, in which the Company continues to hold an 18% membership interest.

**<u>NOTE 7 – ACQUISITION OF NEW BUSINESS</u>**

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC, a company involved in the development and sale of a protein coffee with mushroom extracts. This acquisition was treated as an asset acquisition valued at $72,000, in which the Company received $70,000 in inventory, and a trademark on the product valued at $2,000. Subsequently, we invested additional monies to acquire additional trademarks. Consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock. Going forward from the acquisition date the revenue and expenses associated with the Biolete brand have been consolidated with the Company's reported financials.

On September 30, 2025, the Company sold Biolete, LLC to Cement Factory, in which the Company continues to hold an 18% membership interest. The Company sold the inventory on hand at cost totaling $66,192, all associated trademarks on the Biolete brands net of depreciation totaling $5,463, and the cost of the investment into the Biolete website totaling $706, as a result the Company is holding a receivable in the amount of $72,361.

**<u>NOTE 8 – INVESTMENT IN NON-CONSOLIDATED BUSINESS ENTITY</u>**

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition, a health and wellness company. Consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024, the agreement for the acquisition of the membership interest in Cement Factory Nutrition was rescinded and replaced with the acquisition of 18% membership interest in Cement Factory, LLC. Going forward, the Company will receive 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. Our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. To date, Cement Factory has not generated a profit; as a result, for the nine months ended September 30, 2025, the Company did not receive any dividend income.

**<u>NOTE 9 – RELATED PARTY TRANSACTIONS</u>**

During the fiscal year ended December 31, 2023, an Officer of the Company assisted in funding the Company's operating expenses for which the Company issued a demand note. The note had no interest obligations and was not convertible into the Company's stock and does not have a maturity date. As of December 31, 2023, the Officer had advanced a total of $1,250 which is presented as related party payables in the accompanying 2023 consolidated balance sheet. On January 22, 2024, as part of the change in control to present management, the Company repaid the (now) former Officer $1,250. As of September 30, 2025, and December 31, 2024, the balance due is $0.

On June 30, 2024, the Company entered into an agreement with the Chief Executive Officer of the Company for an unsecured $500,000 line of credit facility, total credit was increased to $750,000 with the addition of another $250,000 line of credit facility on June 12, 2025, bearing the same terms as the original line of credit. The line of credit bears interest of 6% per annum calculated on a daily basis, and there is no stated maturity date. The entire unpaid principal balance plus any accrued but unpaid interest shall be due and payable twelve months from the date of receipt of demand of payment by the lender. The monies that had been advanced by the Chief Executive Officer of the Company up to June 30, 2024 were transferred to this line of credit facility. The aggregate of the advances were $154,065 of which the Company paid back $2,560, resulting in a total of $151,505 being extended on the line of credit facility at June 30, 2024. During the balance of the year ended December 31, 2024, additional advances on the line of credit totaled $223,548, and additional payments were made in the aggregate amount of $6,524. During the nine months ended September 30, 2025, the Company received additional advances of $239,311, and made payments to the lender of $7,840. At September 30, 2025, the total outstanding principal balance on this line of credit facility was $600,000. For the nine months ended September 30, 2025, interest expense was $22,160, and total accrued interest at September 30, 2025, was $28,478.

The above amounts and terms of the transactions are not necessarily typical of agreements entered into by third parties.

[**Table of Contents**](#a_012)

**<u>NOTE 10 – START-UP LOAN TO CLINICS</u>**

On July 15, 2025, the Company provided a start-up loan to Aspire Regenerative Therapy in the amount of $25,000. The terms of the loan are for the principal to be repaid in 5 years at 6% interest per annum. The Company has agreed to receive interest only payment for the first year. At September 30, 2025, the total outstanding principal balance on this loan was $25,000. For the nine months ended September 30, 2025, interest income was $250.

**<u>NOTE 11 - LEASES</u>**

The Company has an operating lease for office space and a finance lease for equipment. Leasing arrangements require fixed payments and also include an amount that is probable and will be owed under residual value guarantees, if applicable. Lease payments also include payments related to purchase or termination options when the lessee is reasonably certain to exercise the option or is reasonably certain not to exercise the option, respectively. The Company's lease agreements do not contain any material restrictive covenants. The leases have remaining terms of 3 to 5 years. Total rent expense incurred on the operating lease for the nine months ended September 30, 2025, was $15,872. The Company executed a finance lease during the year ended December 31, 2024, the lease period commenced January 1, 2025, the amortization and interest expense associated with the finance lease for the nine months ended September 30, 2025 was $12,683 and $7,405 respectively.

The Company's right-of-use assets and lease liabilities and other disclosures at September 30, 2025, are as follows:

---

| | | |
|:---|:---|:---|
|  | **Operating<br> Lease** | **Finance<br> Lease** |
| Right-of-use assets obtained in exchange for new lease liabilities | $168833 | $130294 |
| Weighted-average remaining lease term | 3 years | 5 years |
| Weighted average discount rate | 7.9% | 9.9% |

---

---

| | | |
|:---|:---|:---|
|  | **Operating<br> Lease** | **Finance<br> Lease** |
| Right-of-use assets | $160447 | $130294 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Less: amortization | 39075 | 12683 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease assets, net | $121372 | $117611 |
| Lease liabilities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities, current | $56094 | $18590 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liabilities, long-term | 66990 | 74021 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total lease obligation | $123084 | $92611 |

---

Future payments of lease liabilities at September 30, 2025 are as follows:

---

| | | |
|:---|:---|:---|
| **Year Ending December 31,** | **Operating**<br> **Lease** | **Finance**<br> **Lease** |
| 2025 | $15714 | $6696 |
| 2026 | 63791 | 26784 |
| 2027 | 54482 | 26784 |
| 2028 |  | 26784 |
| 2029 |  | 26784 |
| Thereafter | – | – |
|  | 133987 | 113832 |
| Less interest | (10903) | (21221) |
| Total | $123084 | 92611 |

---

[**Table of Contents**](#a_012)

**<u>NOTE 12 – STOCKHOLDERS' EQUITY</u>**

<u>Common Stock</u>

The Company has 900,000,000 authorized common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

The Company has two common stock designations; Class A Common Stock with 800,000,000 shares authorized, and Class B Common Stock with 100,000,000 shares authorized.

<u>Class A Common Stock</u>: Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders' meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.

On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $40,000 in investments, offset by $15,000 in offering costs, resulting in subsequent issuance of 8,000,000 shares of the Company's Class A Common Stock.

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company's issued and outstanding shares of Common Stock, held by Lotus Fund ("Lotus") (10,495,165 shares), and Jason S. Coombs ("Coombs") (5,000,000 shares), as well as the certain issued and outstanding shares of Series A Preferred Shares. Lotus, Coombs and Singhal (collectively the "Claimants") were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

[**Table of Contents**](#a_012)

On June 6, 2025, the Company received an investment on its Reg A registration statement in the amount of $38,500 in investments, offset by $15,000 in offering costs, resulting in shares to be issued of 7,700,000 shares of the Company's Class A Common Stock.

On June 11, 2025, the Company received an investment on its Reg A registration statement in the amount of $31,500 in investments, offset by $15,000 in offering costs, resulting in shares to be issued of 6,300,000 shares of the Company's Class A Common Stock.

At September 30, 2025 and December 31, 2024, there were 94,404,696 and 95,899,861 Class A Common Shares issued and outstanding, respectively.

At September 30, 2025 and December 31, 2024, there were no Class B Common Shares issued and outstanding.

<u>Preferred Stock</u> 

There are 100,000,000 shares of preferred stock authorized, par value $.001 per share (the "Preferred Stock"), issuable in one or more series; (a) the Company designated one (1) share of Preferred Stock as "Special 2022 Series A Preferred Stock" possessing super-voting rights; (b) the Company designated 10,000,000 shares of Series A Preferred Stock; and (c) the Company designated 89,999,999 shares of Series C Preferred Stock.

<u>Special 2022 Series A Preferred Stock.</u> The designation of this class of preferred stock shall be "Special 2022 Series A Preferred Stock," par value $.001 per share (the "Special 2022 Series A Preferred Stock"). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1). (A) Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights: (1) Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis)) entitled to vote at each meeting of shareholders of the Corporation (and written actions of shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares. (2) Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class. (B) Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred stock can affect the conversion at any time. The conversion into common is a right and is not required. (C) Dividends; Liquidation. The shares of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof and shall not participate in any proceeds available to the Corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation. (D) No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.

<u>Series A Preferred Stock</u>. The designation of this class of preferred stock shall be "Series A Preferred Stock," par value $.001 per share (the "Series A Preferred Stock"). The number of authorized shares of Series A Preferred Stock is ten million (10,000,000). Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class. (c) Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the "Liquidation Rate") before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.

[**Table of Contents**](#a_012)

<u>Series C Preferred Stock</u>. The designation of this class of preferred stock shall be "Series C Preferred Stock," par value $.001 per share (the "Series C Preferred Stock"). The number of authorized shares of Series C Preferred Stock is eighty-nine million, nine hundred ninety-nine thousand, nine hundred and ninety nine (89,999,999). Each share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class. Liquidation

Rights - Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of the Company's common stock multiplied by the Conversion Rate. Conversion Rate – Each share of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock.

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock.

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024, the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company's Series C Preferred Stock to be issued at a future date.

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On May 5, 2025, the Company retired and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void certain shares of the Company's issued and outstanding shares of Common Stock. In addition, the lawsuit sought an order declaring as void a total of 10,000,000 shares of the Company's issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal ("Singhal"). The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

At the nine months ended September 30, 2025, per their employment agreements, two officers of the Company were entitled to the option to purchase a total of 10,000,000 shares of the Company's Series C Preferred Stock, however, the Company is obligated to issue these shares at some point in the future, regardless if the options are exercised by the Company or not.

At September 30, 2025 and December 31, 2024, there is one (1) share of Special 2022 Series A Preferred issued and outstanding.

At September 30, 2025 and December 31, 2024, there are zero and 10,000,000 shares of Series A Preferred issued and outstanding, respectively.

At September 30, 2025 and December 31, 2024, there are 1,750,000 shares of Series C Preferred issued and outstanding.

[**Table of Contents**](#a_012)

**<u>NOTE 13 – SEGMENT REPORTING</u>**

The Company has three operating segments: (1) Biolete, (2) Adia Med, and (3) Adia Labs. The Biolete segment comprises the sale of supplements and had $797 and $67,636 of total assets at September 30, 2025 and December 31, 2024, respectively. Adia Med performs stem cell treatments to patients and had $288,481 and $323,590 of total assets at September 30, 2025 and December 31, 2024, respectively. Adia Labs procures and sells stem cell products to outside clinics or to Adia Med, and had $101,040 and $139,250 of total assets at September 30, 2025 and December 31, 2024, respectively. Unallocated assets held at the corporate level totaled $385,366 and $129,367 at September 30, 2025 and December 31, 2024, respectively.

The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company's ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.

The Company chooses to disclose the following in its segment reporting requirements for the unaudited and unreviewed nine months ended September 30, 2025:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| ***For the nine months ended September 30, 2025*** | | | | | |
|  | **Unallocated**<br>**Corporate**<br>**Overhead** |<br>**Biolete** |<br>**ADIA**<br>**Med** |<br>**ADIA**<br>**Labs** |<br>**Totals** |
| **Segment Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of products and services | $2267 | $3330 | $198960 | $432588 | $637145 |
| **Total Segment Revenue** | 2267 | 3330 | 198960 | 432588 | 637145 |
| **Cost of Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of goods sold | – | 994 | 137094 | 255597 | 393685 |
| **Gross Profit** | 2267 | 2336 | 61866 | 176991 | 243460 |
| **Operating Expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 189403 | 2227 | 148035 | 2535 | 342200 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 27617 | 67 | 22230 | 5066 | 54980 |
| **Segment Operating Expenses** | 217020 | 2294 | 170265 | 7601 | 397180 |
| **Segment Profit (Loss)** | $(214753) | $41 | $(108398) | $169390 | $(153720) |

---

At the nine months ended September 30, 2024, the Company was a single segment Company.

**<u>NOTE 14 – COMMITMENTS AND CONTINGENCIES</u>**

On May 5, 2025, the Company retired 15,495,165 shares of its Common Stock and declared void 10,000,000 shares of the Company Series A Preferred Shares. Initially, on May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,495,165 shares of the Company's issued and outstanding shares of Common Stock, held by Lotus Fund ("Lotus") (10,495,165 shares), and Jason S. Coombs ("Coombs") (5,000,000 shares). In addition, the lawsuit seeks an order declaring as void a total of 10,000,000 shares of the Company's issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal ("Singhal"). Lotus, Coombs and Singhal (collectively the "Claimants") were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County. This matter was settled in favor of the Company on May 5, 2025.

[**Table of Contents**](#a_012)

**<u>NOTE 15 – INCOME TAXES</u>**

A reconciliation of statutory income tax rate to effective tax rate was as follows for each of the periods presented:

---

| | | |
|:---|:---|:---|
|  | **For the year ended December 31, 2024** | **For the year ended December 31, 2023** |
| Federal income taxes at statutory rate | 21.0% | 21.0% |
| State income taxes at statutory rate | 5.5% | 5.5% |
| Valuation allowance | (26.5%) | (26.5%) |
| Effective tax rate | 0.0% | 0.0% |

---

As of December 31, 2024 and 2023, the Company had a net operating loss for tax purposes of $181,067 and $0, respectively.

The Company's policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2024 and 2023, the Company did not recognize any interest or penalties in its consolidated statement of operations, nor did it have any interest or penalties accrued on its consolidated balance sheets at December 31, 2024 and 2023, relating to unrecognized tax benefits.

Under the provisions of ASC 740, *"Accounting for Uncertainty in Income Taxes,"* the Company identified no significant uncertain tax positions for 2023 and 2024. The Company files income tax returns in U.S. jurisdiction. There are no federal or state income tax examinations underway for these, and tax returns for the current year are still open to examination as neither year, nor the years prior have been filed with the appropriate taxing authorities.

Utilization of our net operating losses (NOL) carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. At the time of closing the consolidated books, the Company had not yet completed a study to determine the extent of the limitation based on ownership changes that may have occurred. As of December 31, 2024, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $15,578,018, expiring in the year 2039, that may be used to offset future taxable income, but could be limited under Section 382.

The Company's deferred taxes as of December 31, 2024 and 2023, consist of the following:

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023** |
| **Non-Current deferred tax asset:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carry-forwards | $15578018 | $15396951 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax provision (U.S. federal and state combined) tax rate | 26.5% | 26.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax asset | 4128175 | 4080192 |
| **Valuation allowance** | (4128175) | (4080192) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Net non-current deferred tax asset | $– | $– |

---

**<u>NOTE 16 – SUBSEQUENT EVENTS</u>**

Management has evaluated subsequent events through the date these consolidated financial statements were available to be issued. Based on our evaluation, the following material events have occurred that require further disclosure:

&nbsp;&nbsp;&nbsp;&nbsp;· On October 13, 2025, the Company appointed Dr. Evan Thomas, MD, PhD. as an Independent Medical Director
for the Company's medical division, Adia Med. The Company will issue 250,000 shares of its Series C Preferred Stock at a future
date.

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.** 

**CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 and 2023**

---

| | |
|:---|:---|
|  | Pages |
| [Report of Independent Registered Public Accounting Firm](#a_002) | F-22 |
| [Consolidated Balance Sheets as of December 31, 2024 and 2023](#a_003) | F-23 |
| [Consolidated Statements of Operations for the years ended December 31, 2024 and 2023](#a_004) | F-24 |
| [Consolidated Statements of Stockholders' Equity (Deficit) for the years ended December 31, 2024 and 2023](#a_005) | F-25 |
| [Consolidated Statements of Cash flows for the years ended December 31, 2024 and 2023](#a_006) | F-26 |
| [Notes to the Audited Consolidated Financial Statements](#a_007) | F-27 to F-38 |

---

[**Table of Contents**](#a_012)

![A close-up of a logo AI-generated content may be incorrect.](image_001.jpg)

REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

To the Board of Directors and

&nbsp;&nbsp;&nbsp;&nbsp;Stockholders of Adia Nutrition, Inc.

**Opinion on the Financial Statements**

We have audited the accompanying consolidated balance sheets of Adia Nutrition, Inc. (the Company) as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders' equity (deficit), and cash flows for each of the years in the two-year period ended December 31, 2024, and the related notes (collectively referred to as the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the years in the two-year period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.

**Substantial Doubt about the Company's Ability to Continue as a Going Concern**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2, the Company has generated only nominal revenues during 2024 and has an accumulated deficit of $15,578,018. These factors raise substantial doubt about the Company's ability to continue as a going concern. Our opinion is not modified with respect to that matter.

**Basis for Opinion**

These consolidated financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

![](image_002.jpg)

![A close up of a logo AI-generated content may be incorrect.](image_003.jpg)

We have served as the Company's auditor since 2025.

Tampa, Florida

April 1, 2025

**3702 W Spruce St #1430** i **Tampa, Florida 33607** i **+1.813.441.9707**

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED BALANCE SHEETS**

**(Audited)**

---

| | | |
|:---|:---|:---|
|  | **December 31,**<br>**2024** | **December 31,**<br>**2023** |
| **<u>ASSETS</u>** |  |  |
| **Current Assets** |  |  |
| Cash | $6323 | $500 |
| Inventory |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventory on-hand | 67636 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Pre-paid inventory | 139250 | – |
|  | 206886 |  |
| Prepaid expenses | 45184 | – |
| **Total Current Assets** | 258393 | 500 |
| Investment in non-consolidated entity | 79500 |  |
| Intangible assets – trademarks, net of amortization | 5910 |  |
| Deposits | 10000 |  |
| Fixed assets, net of depreciation | 21637 |  |
| Right-of-use asset |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating, net | 160447 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance, net | 130294 | – |
|  | 290741 | – |
| **Total Assets** | $666181 | $500 |
| **<u>LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)</u>** |  |  |
| **Current Liabilities** |  |  |
| Accounts payable | $4876 | $– |
| Accrued interest – related party | 6318 |  |
| Lease liability – current portion |  |  |
| Operating | 51535 |  |
| Finance | 17264 | – |
| **Total Current Liabilities** | 79993 |  |
| Related party payables | 368529 | 1250 |
| Long-term lease liabilities, net of current portion |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Operating | 104089 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Finance | 88030 | – |
|  | 192119 | – |
| **Total Liabilities** | 640641 | 1250 |
| Commitments and Contingencies (Note 13) |  |  |
| **Stockholders' Equity (Deficit)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Special 2022 Series A Preferred Stock, $0.001 par value, 1 share authorized, issued and outstanding at December 31, 2024 and 2023. | 1 | 1 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series A Preferred Stock, $0.001 par value, 10,000,000 shares authorized, issued and outstanding at December 31, 2024 and 2023. | 10000 | 10000 |
| &nbsp;&nbsp;&nbsp;&nbsp;Series C Preferred Stock, $0.001 par value, 89,999,999 shares authorized, 1,750,000 and 0 shares issued and outstanding at December 31, 2024 and 2023, respectively. | 1750 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Class A Common Stock, $0.001 par value; 800,000,000 shares authorized, 95,899,861 and 87,899,861 issued and outstanding, at December 31, 2024 and 2023, respectively. | 95900 | 87900 |
| &nbsp;&nbsp;&nbsp;&nbsp;Class B Common Stock, $0.001 par value; 100,000,000 shares authorized, zero issued and outstanding, at December 31, 2024 and 2023. |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Shares to be issued (Series C Preferred) | 110357 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Additional paid-in capital | 15385550 | 15298300 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accumulated deficit | (15578018) | (15396951) |
| **Total Stockholders' Equity (Deficit)** | 25540 | (750) |
| **Total Liabilities and Stockholders' Equity (Deficit)** | $666181 | $500 |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF OPERATIONS**

**(Audited)**

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2024** | **2023** |
| **Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of supplements, net of discounts | $6380 | $– |
| **Total Revenue** | 6380 |  |
| **Cost of Revenue** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of supplements | 4186 | – |
| **Gross Profit** | 2194 | – |
| **Operating Expenses** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 29977 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 36534 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Legal and professional fees | 68559 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Rent | 10583 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Share-based compensation | 30857 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 433 | – |
| **Total Operating Expenses** | 176943 | – |
| **Loss from Operations** | (174749) |  |
| **Other Income (Expense)** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense – related party | (6318) | – |
| **Total Other Income (Expense)** | (6318) | – |
| **Net Loss Before provision for Income Taxes** | (181067) |  |
| **Provision for Income Taxes** | – | – |
| **NET LOSS** | $(181067) | $– |
| Net Loss Per Share: Basic and Diluted | $(0.00) | $(0.00) |
| Weighted Average Number of Shares Outstanding: Basic and Diluted | 91735477 | 87899861 |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF STOCK<br> STOCKHOLDERS' EQUITY (DEFICIT)**

**(Audited)**

**For the Years Ended December 31, 2024 and 2023**

---

| | | | | | | | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Special 2022 Series A Preferred** | **Special 2022 Series A Preferred** | **Series A Preferred** | **Series A Preferred** | **Series C Preferred** | **Series C Preferred** | **Shares to be issued** | **Shares to be issued** | **Class A**<br> **Common Stock** | **Class A**<br> **Common Stock** | **Class B**<br> **Common Stock** | **Class B**<br> **Common Stock** | | | |
|  | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Shares** | **Amount ($)** | **Additional Paid-In**<br>**Capital**<br> **($)** | **Accumulated**<br>**Deficit**<br> **($)** | **Total**<br> **Stockholders'**<br> **Equity**<br>**(Deficit)**<br> **($)** |
| **Balance December 31, 2022** | 1 | 1 | 10000000 | 10000 |  |  |  |  | 87899861 | 87900 |  |  | 15298300 | (15396951) | (750) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| **Balance December 31, 2023** | 1 | 1 | 10000000 | 10000 | – | – | – | – | 87899861 | 87900 | – | – | 15298300 | (15396951) | (750) |
| Shares issued for acquisition |  |  |  |  | 1750000 | 1750 |  |  |  |  |  |  | 70250 |  | 72000 |
| Shares to be issued – investment |  |  |  |  |  |  | 1875000 | 79500 |  |  |  |  |  |  | 79500 |
| Share-based compensation |  |  |  |  |  |  | 750000 | 30857 |  |  |  |  |  |  | 30857 |
| Shares issued for subscription, net of offering costs of $15,000 |  |  |  |  |  |  |  |  | 8000000 | 8000 |  |  | 17000 |  | 25000 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net loss** | – | – | – | – | – | – | – | – | – | – | – | – | – | (181067) | (181067) |
| **Balance December 31, 2024** | 1 | 1 | 10000000 | 10000 | 1750000 | 1750 | 2625000 | 110357 | 95899861 | 95900 | – | – | 15385550 | (15578018) | 25540 |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**CONSOLIDATED STATEMENTS OF CASH FLOWS**

**(Audited)**

---

| | | |
|:---|:---|:---|
|  | **For the Years Ended December 31,** | **For the Years Ended December 31,** |
|  | **2024** | **2023** |
| **Cash Flows From Operating Activities:** |  |  |
| Net Loss | $(181067) | $– |
| &nbsp;&nbsp;&nbsp;Adjustments to reconcile net loss to net cash used in operations |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 433 |  |
| &nbsp;&nbsp;&nbsp;Amortization of operating lease right-of-use asset | 8387 |  |
| &nbsp;&nbsp;&nbsp;Share-based compensation | 30857 |  |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accrued interest – related party | 6318 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | 4876 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Deposits | (10000) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | (45185) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Inventory | (136886) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Lease liability - operating | (13209) | – |
| **Net Cash Used In Operating Activities** | (335476) | – |
| **Cash Flows From Investing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Purchase of fixed assets | (21831) |  |
| &nbsp;&nbsp;&nbsp;Purchase of intangible assets | (4149) | – |
| **Net Used In Investing Activities** | (25980) |  |
| **Cash Flows From Financing Activities:** |  |  |
| &nbsp;&nbsp;&nbsp;Proceeds from sale of common shares | 25000 |  |
| &nbsp;&nbsp;&nbsp;Payments made on lease liability - finance | (25000) | **–** |
| &nbsp;&nbsp;&nbsp;Related party payables | 367279 | – |
| **Net Cash Provided by Financing Activities** | 367279 | – |
| **Net Increase in Cash** | 5823 |  |
| Cash at Beginning of Year | 500 | 500 |
| **Cash at End of Year** | $6323 | $500 |
| **<u>Supplemental disclosure of cash flow information:</u>** |  |  |
| &nbsp;&nbsp;&nbsp;Cash paid for interest | – | – |
| &nbsp;&nbsp;&nbsp;Cash paid for taxes | – | – |
| **<u>Supplemental disclosure of non-cash investing and financing activities:</u>** |  |  |
| &nbsp;&nbsp;&nbsp;Shares to be issued for investment in non-consolidated business entity | $79500 | $– |
| &nbsp;&nbsp;&nbsp;Shares issued for acquisition of Biolete, LLC | $72000 | $– |
| &nbsp;&nbsp;&nbsp;Operating right-of-use asset obtained though operating lease obligation | $168833 | $– |
| &nbsp;&nbsp;&nbsp;Finance right-of-use asset obtained through finance lease obligation | $130294 | $– |

---

See accompanying notes to consolidated financial statements

[**Table of Contents**](#a_012)

**ADIA NUTRITION, INC.**

**NOTES TO THE AUDITED CONSOLIDATED FINANCIAL STATEMENTS**

**DECEMBER 31, 2024 and 2023**

(**Audited)**

**<u>NOTE 1 – ORGANIZATION AND BUSINESS</u>**

ADIA Nutrition Inc. (the "Company," "we," "us" or "our"), a Nevada corporation, has a calendar fiscal year and is listed on OTC Markets under the trading symbol ADIA. The Company had abandoned its business and failed to take steps to dissolve, liquidate and distribute its assets. It had also failed to meet the required reporting requirements with the Nevada Secretary of State, hold an annual meeting of stockholders and pay its annual franchise tax from 2013 to 2022 which resulted in its Nevada charter being revoked. The Company also failed to provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act. In March 2022, a shareholder filed a petition for custodianship with the District Court, Clark County, Nevada and was appointed as the custodian of the Company in June 2022. The Company's Nevada charter was reinstated on June 27, 2022, and all required reports were filed with the State of Nevada soon thereafter. The custodian was not able to recover any of the Company's accounting records from previous management but was able to get the shareholder information hence the Company's outstanding common shares were reflected in the stockholders' equity section of the unaudited financial statements for the year ended December 31, 2022.

The Company was incorporated in the State of Nevada in April 1975 as Domi Associates, Inc. In March 2001, the issuer amended its Articles of Incorporation to change its name to Drilling, Inc. On April 20, 2004, an amendment to the Articles of Incorporation was made to change the name to PIVX Solutions, Inc. In 2012, the issuer changed to ADIA Nutrition, Inc.

On March 14, 2022, UMA LLC, a shareholder of the Company, made a demand to the Company, at the last address of record, to comply with the Nevada Secretary of State statues N.R.S. 78.710 and N.R.S. 78.150. UMA, LLC, made several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked. On, May 6, 2022, UMA, LLC filed a petition against the Company in the District Court of Clark County, Nevada, entitled "In the Matter of ADIA Nutrition Inc., a Nevada corporation", case number A-22-852241-C, along with an Application for Appointment of Custodian,

On June 17, 2022, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of UMA LLC, (the "Order"), as Custodian of the Company. Pursuant to the Order, the UMA LLC (the "Custodian") has the authority to take any actions on behalf of the Company, which are reasonable, prudent or for the benefit pursuant to, including, but not limited to, issuing shares of stock, and issuing new classes of stock, as well as entering in contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On June 17, 2022, the Custodian appointed Nikki Lee as the Company's sole officer and director. The Custodian designated one share of preferred stock as Special 2022 Series A Preferred Stock at par value $0.001. The Special 2022 Series A Preferred stock has 60% voting rights over all classes of stock and is convertible into sixty million shares of the Company's common stock. On June 17, 2022, the Custodian granted to itself, one share of Special Series A Preferred Stock.

On June 27, 2022, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company's charter and appointed a new Resident Agent in Nevada.

On August 5, 2022, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with Nairobi Anderson, to sell the Special 2022 Series A Preferred stock, and upon closing, Nairobi Anderson acquired 60% voting control of the Company.

On February 27, 2023, Nairobi Anderson entered into an SPA with The Leonard and Elizabeth Greene Family Trust to sell its share of Special 2022 Series A Preferred stock.

On January 22, 2024, The Leonard and Elizabeth Greene Family Trust sold its Special 2022 Series A Preferred share to Legends Investments Properties, LLC, 100% owned by Larry Powalisz. Leonard Greene resigned as Director and Larry Powalisz was appointed Chief Executive Officer and Director, and Rebecca Miller was appointed as Chief Financial Officer.

 

 

[**Table of Contents**](#a_012)

 

*ADIA – Going Forward*

ADIA is dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide Autologous Hematopoietic Stem Cell Transplantation (AHSCT) treatments for Multiple Sclerosis (MS) patients.

ADIA engages with health insurance companies to advocate for the inclusion and reimbursement of AHSCT treatments for MS patients. The dedicated team navigates the complexities of insurance processes, striving to make these transformative therapies financially accessible to a wider population.

ADIA envisions a future where AHSCT is a widely accessible and transformative treatment option for MS patients. Through commitment, collaboration, advocacy, and quality care, the Company aims to redefine the standard of treatment for MS and contribute to improved outcomes and quality of life for those affected by the disease.

ADIA is also committed to revolutionizing the supplement industry through strategic acquisitions and investments in companies that uphold the highest standards of integrity and quality. The mission is to empower individuals worldwide to prioritize their health and well-being by providing access to premium supplements crafted exclusively from organic ingredients. ADIA has, during the third quarter of 2024, acquired Biolete, LLC (see Note 7 below) and taken an 18% equity position in Cement Factory, LLC (see Note 8 below).

Being dedicated to revolutionizing healthcare through innovative partnerships. The primary focus is to work closely with healthcare providers and health insurance companies to facilitate and provide AHSCT treatments for MS patients. In late 2024, ADIA formed Adia Med of Winter Park, LLC as the clinic to perform the aforementioned treatments, and Adia Labs, LLC which will procure and sell the products relating to these procedures.

ADIA strives to cultivate a portfolio of brands that exemplify excellence, transparency, and sustainability, ensuring that every product that it offers contributes to the enhancement of the consumers lives.

*ADIA Nutrition – Board of Directors Expansion*

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

**<u>NOTE 2 – GOING CONCERN</u>**

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has generated only nominal revenues to date and at December 31, 2024, has an accumulated deficit of $15,578,018, and a net operating loss of $181,067 for the year ended December 31, 2024. These factors, among others, raise substantial doubt about the ability of the Company to continue as a going concern for a reasonable period of time. The Company's continuation as a going concern for one year after the audit report is dependent upon, among other things, its ability to generate greater revenues and its ability to obtain capital from third parties. No assurance can be given that the Company will be successful in these efforts.

Management plans to utilize the funding resources it has available (i.e., its line of credit facility) as well as the continued identification of adequate sources of funding to provide operating capital for continued growth. The Company plans to continue the use of its Reg A filing to raise additional capital; the Company has received $40,000 in investments, offset by $15,000 in offering costs, towards this registration during the year ended December 31, 2024.

The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

[**Table of Contents**](#a_012)

**<u>NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</u>**

<u>Basis of Presentation</u>

The Company's consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP").The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management further acknowledges that it is solely responsible for adopting sound accounting practices, establishing and maintaining a system of internal accounting control and preventing and detecting fraud. The Company's system of internal accounting control is designed to assure, among other items, that (1) recorded transactions are valid; (2) valid transactions are recorded; and (3) transactions are recorded in the proper period in a timely manner to produce consolidated financial statements which present fairly the financial condition, results of operations and cash flows of the Company for the respective periods being presented.

<u>Use of Estimates</u>

The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date the consolidated financial statements and the reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Principles of Consolidation</u>

The consolidated financial statements have been prepared in accordance with GAAP. The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries (Biolete, LLC, Adia Med of Winter Park, LLC and Adia Labs, LLC). All intercompany balances and transactions have been eliminated.

<u>Cash and Cash Equivalents</u>

The Company accounts for cash and cash equivalents under Financial Accounting Standards Board ("FASB") Accounting Standards Codification ("ASC") 305, "*Cash and Cash Equivalents,*" and considers all highly liquid investments with an original maturity of three months or less to be cash equivalents.

<u>Advertising and Promotion Costs</u>

Advertising and promotion costs are expensed as incurred. During the years ended December 31, 2024 and 2023, this cost was $36,534 and $0, respectively.

<u>Revenue Recognition</u>

The Company records transactions in accordance with ASU 2014-09, *"Revenue from Contracts with Customers"* and all subsequent amendments to the ASU (collectively, "ASC 606"). In accordance with ASC 606, revenues are recognized when control of the promised goods or services is transferred to our customers, in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services.

Our operations currently generate revenues exclusively from the sale of supplements. During the years ended December 31, 2024 and 2023, the Company had revenues of $6,380 and $0, respectively from the sale of supplements.

<u>Costs of Revenues</u>

Our policy is to recognize costs of revenue in the same manner in conjunction with revenue recognition. Cost of revenues include the costs directly attributable to revenue. Cost of revenue was limited to the cost of supplements, for the years ended December 31, 2024 and 2023, cost of supplements was $4,186 and $0, respectively.

[**Table of Contents**](#a_012)

<u>Income Taxes and Valuation Allowance</u>

The Company accounts for income taxes under ASC 740, "*Income Taxes"*. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. All of the Company's deferred tax assets were offset by a full valuation allowance at December 31, 2024.

<u>Financial Instruments</u>

ASC 820, *"Fair Value Measurements and Disclosures,"* defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:

Level 1 - Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2 - Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.

Level 3 - Inputs that are both significant to the fair value measurement and unobservable.

Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of December 31, 2024. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments.

The Company does not have any assets or liabilities measured at fair value on a recurring basis.

<u>Related Parties</u>

The Company follows ASC 850-10, *"Related Party Disclosures,"* for the identification of related parties and disclosure of related party transactions. The Company leases office space from an entity that is controlled by the CEO and Director of the Company. In addition this related party has provided working capital to the Company on the line of credit facility it has extended to the Company.

Pursuant to ASC 850-10-20, related parties include: a) affiliates of the Company; b) principal owners of the Company; c) management of the Company; d) other parties with which the Company may deal if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests; and e) other parties that can significantly influence the management or operating policies of the transacting parties or that have an ownership interest in one of the transacting parties and can significantly influence the other to an extent that one or more of the transacting parties might be prevented from fully pursuing its own separate interests.

[**Table of Contents**](#a_012)

Material related party transactions are required to be disclosed in the consolidated financial statements, other than compensation arrangements, expense allowances, and other similar items in the ordinary course of business. However, disclosure of transactions that are eliminated in the preparation of consolidated or combined financial statements is not required in those statements. The disclosures shall include: a) the nature of the relationship(s) involved; b) a description of the transactions, including transactions to which no amounts or nominal amounts were ascribed, for each of the periods for which statements of operation are presented, and such other information

deemed necessary to an understanding of the effects of the transactions on the financial statements; c) the dollar amounts of transactions for each of the periods for which statements of operations are presented and the effects of any change in the method of establishing the terms from that used in the preceding period; and d) amounts due from or to related parties as of the date of each balance sheet presented and, if not otherwise apparent, the terms and manner of settlement.

<u>Commitments and Contingencies</u>

The Company follows ASC 450-20, "*Loss Contingencies*," to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

<u>Earnings (loss) per share</u>

Basic income (loss) per share is computed by dividing net income (loss) attributable to common stockholders by the weighted average common shares outstanding for the period. Diluted income (loss) per share is computed giving effect to all potentially dilutive common shares. Potentially dilutive common shares may consist of incremental shares issuable upon the exercise of stock options and warrants and upon the conversion of notes. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The number of potentially dilutive common shares (if the preferred shares were converted) excluded for the years ended December 31, 2024 and 2023 are 67,000,000 and 60,000,000, respectively.

<u>Inventory</u>

Inventories are carried at the lower of cost and net realizable value. Cost is determined using the first-in, first-out method. Net realizable value is the estimated selling price in the ordinary course of business, less the estimated costs of applicable variable selling expenses. Management periodically evaluates if a reserve is necessary, and management determined that a reserve was not necessary at December 31, 2024.

<u>Investments</u>

In accordance with ASC 321, *"Investments – Equity Securities,"* our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. The original agreement entered into was rescinded, and replaced with an agreement to acquire an 18% membership interest in Cement Factory, LLC, allowing the Company to receive an 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. (See Note 8.)

<u>Leases</u>

In February 2016, the FASB issued Accounting Standards Update ("ASU") 2016-02, *"Leases"* Topic 842, which amends the guidance in former ASC Topic 840, Leases ("ASC 840"). The new standard increases transparency and comparability most significantly by requiring the recognition by lessees of right-of-use ("ROU") assets and lease liabilities on the balance sheet for all leases longer than 12 months. Under the standard, disclosures are required to meet the objective of enabling users of financial statements to assess the amount, timing, and uncertainty of cash flows arising from leases. For lessees, leases will be classified as finance or operating, with classification affecting the pattern and classification of expense recognition in the income statement, over the expected term on a straight-line basis. We determine if an arrangement is a lease at inception. The Company recognizes ROU assets and lease liabilities for leases with terms greater than 12 months or leases that contain a purchase option that is reasonably certain to be exercised. Leases are classified as either finance or operating leases. This classification dictates whether lease expense is recognized based on an effective interest method or on a straight-line basis over the term of the lease. Operating leases are included in operating lease ROU assets and operating lease liabilities on our consolidated balance sheets. Finance leases are included in finance lease assets, current finance lease liabilities, and long-term finance lease liabilities on our consolidated balance sheets.

[**Table of Contents**](#a_012)

The Company's ROU assets and lease liabilities are recognized on the lease commencement date in an amount that represents the present value of future lease payments over the lease term. The Company utilizes its collateralized incremental borrowing rate commensurate to the lease term as the discount rate for its leases unless the Company can specifically determine the lessor s implicit rate. Certain lease contracts contain non-lease components such as maintenance and utilities. The Company has made a policy election to not separate the lease and non-lease components, and thus recognize a single lease component for all of its right-of-use assets and liabilities.

In evaluating contracts to determine if they qualify as a lease, the Company considers factors such as if it has obtained substantially all of the rights to the underlying asset through exclusivity, if the Company can direct the use of the asset by making decisions about how and for what purpose the asset will be used and if the lessor has substantive substitution rights. Furthermore, the Company assesses whether it is reasonably certain to exercise options to extend or terminate a lease considering all relevant factors that create economic incentive to exercise such options, including asset, contract, market, and entity-based factors. These evaluations may require significant judgment.

<u>Loss Contingencies</u>

From time to time the Company may be subject to various legal proceedings and claims that arise in the ordinary course of business. On at least a quarterly basis, consistent with ASC 450-20-50-1C, if the Company determines that there is a reasonable possibility that a material loss may have been incurred, or is reasonably estimable, regardless of whether the Company accrued for such a loss (or any portion of that loss), the Company will confer with its legal counsel, consistent with ASC 450. If the material loss is determinable or reasonably estimable, the Company will record it in its accounts and as a liability on the consolidated balance sheet.

<u>Fixed Assets</u>

The Company follows ASC 360, "*Property, Plant, and Equipment,"* for its fixed assets. Equipment is stated at cost less accumulated depreciation. Depreciation is calculated on a straight-line basis over the estimated useful lives of the assets (3 to 7 years for equipment). Depreciation expense for the years ended December 31, 2024 and 2023 was $194 and $0, respectively.

<u>Intangible Assets</u>

Definite life intangible assets at December 31, 2024, include trademarks and brand names recognized as part of the Biolete acquisition. Intangible assets are recorded at cost. Trademarks and brand names represent the estimated fair value of these items at the date of acquisition, and are amortized on a straight-line basis over their estimated useful life. Trademarks and brand names are assigned a life of 10 years.

<u>Long-lived Assets</u>

Long-lived assets such as fixed assets and identifiable intangibles are reviewed for impairment whenever facts and circumstances indicate that the carrying value may not be recoverable. When required impairment losses on assets to be held and used are recognized based on the fair value of the asset. The fair value is determined based on estimates of future cash flows, market value of similar assets, if available, or independent appraisals, if required. If the carrying amount of the long-lived asset is not recoverable from its undiscounted cash flows, an impairment loss is recognized for the difference between the carrying amount and fair value of the asset. When fair values are not available, the Company estimates fair value using the expected future cash flows discounted at a rate commensurate with the risk associated with the recovery of the assets. We did not recognize any impairment losses for any periods presented.

[**Table of Contents**](#a_012)

<u>Segment Reporting</u>

Operating segments are components of an enterprise about which separate financial information is available and is evaluated regularly by management, namely the Chief Operating Decision Maker ("CODM") of an organization, in order to determine operating and resource allocation decisions. By this definition, the Company has identified its Chief Executive Officer as the CODM. The CODM has identified Biolete, Adia Med and Adia Labs as the Company's operating segments.

<u>Stock-Based Compensation</u>

FASB ASC 718 *"Compensation – Stock Compensation,"* prescribes accounting and reporting standards for all stock-based payments award to employees, including employee stock options, restricted stock, employee stock purchase plans and stock appreciation rights, may be classified as either equity or liabilities. The Company determines if a present obligation to settle the share-based payment transaction in cash or other assets exists. A present obligation to settle in cash or other assets exists if: (a) the option to settle by issuing equity instruments lacks commercial substance or (b) the present obligation is implied because of an entity's past practices or stated policies. If a present obligation exists, the transaction should be recognized as a liability; otherwise, the transaction should be recognized as equity.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of FASB ASC 505-50 "*Equity – Based Payments to Non-Employees*." Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date. For the years ended December 31, 2024 and 2023, the Company had share-based compensation of $30,857 and $0, respectively. At December 31, 2024 and 2023, the Company recorded shares to be issued totaling $30,857 and $0, respectively.

<u>Recently Issued Accounting Pronouncements</u>

We have reviewed the FASB issued ASU accounting pronouncements and interpretations thereof that have effectiveness dates during the periods reported and in future periods. The Company has carefully considered the new pronouncements that alter previous generally accepted accounting principles and does not believe that any new or modified principles will have a material impact on the corporation's reported financial position or operations in the near term. The applicability of any standard is subject to the formal review of our financial management and certain standards are under consideration. We recently adopted and retroactively applied ASU 2023-07, *"Segment Reporting."*

**<u>NOTE 4 - INVENTORY</u>**

Inventory consists of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2024** | **December 31,<br> 2023** |
| Biolete finished goods inventory | $67636 | $– |
| Adia Labs biologics (pre-paid inventory received in 2025) | 139250 | – |
| **Total Inventory** | $**206886** | $– |

---

[**Table of Contents**](#a_012)

**<u>NOTE 5 – FIXED ASSETS, NET</u>**

Fixed assets, net, consists of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2024** | **December 31,<br> 2023** |
| Furniture and fixtures | $5332 | $– |
| Machinery and equipment | 16499 | – |
| Property and equipment, gross | 21831 |  |
| Less: Accumulated depreciation | (194) | – |
| **Total Fixed Assets, Net** | $**21637** | $– |

---

**<u>NOTE 6 – INTANGIBLE ASSETS, NET</u>**

Intangible assets, net, consists of the following:

---

| | | |
|:---|:---|:---|
|  | **December 31,<br> 2024** | **December 31,<br> 2023** |
| Trademarks | $6149 | $– |
| Less: Accumulated amortization | (239) | – |
| **Total Intangible Assets, Net** | $**5910** | $– |

---

Amortization expense for intangible assets was $239 and $0 for the years ended December 31, 2024 and 2023, respectively. Future amortization expense for our intangible assets is as follows:

---

| | |
|:---|:---|
| Years ended December 31, |  |
| 2025 | $602 |
| 2026 | 602 |
| 2027 | 602 |
| 2028 | 602 |
| 2029 | 602 |
| Thereafter | 2900 |
| **Total** | $**5910** |

---

**<u>NOTE 7 – ACQUISITION OF NEW BUSINESS</u>**

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC, a company involved in the development of a protein coffee with mushroom extracts. This acquisition was treated as an asset acquisition valued at $72,000, in which the Company received $70,000 in inventory, and a trademark on the product valued at $2,000. Subsequently, we invested additional monies to acquire additional trademarks. Consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock. Going forward from the acquisition date the revenue and expenses associated with the Biolete brand have been consolidated with the Company's reported financials.

[**Table of Contents**](#a_012)

**<u>NOTE 8 – INVESTMENT IN NON-CONSOLIDATED BUSINESS ENTITY</u>**

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition, a health and wellness company. Consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024, the agreement for the acquisition of the membership interest in Cement Factory Nutrition was rescinded and replaced with the acquisition of 18% membership interest in Cement Factory, LLC. Going forward, the Company will receive 18% dividend income from Cement Factory paid annually at the end of each calendar year based on profitability. Our investment in Cement Factory, LLC is stated at cost, as our investment in this entity constitutes less than 20% in Cement Factory, LLC and does not provide the Company control over this entity. To date, Cement Factory has not generated a profit; as a result, for the year ended December 31, 2024, the Company did not receive any dividend income.

**<u>NOTE 9 – RELATED PARTY TRANSACTIONS</u>**

During the fiscal year ended December 31, 2023, an Officer of the Company assisted in funding the Company's operating expenses for which the Company issued a demand note. The note had no interest obligations and was not convertible into the Company's stock and does not have a maturity date. As of December 31, 2023, the Officer had advanced a total of $1,250 which is presented as related party payables in the accompanying 2023 consolidated balance sheet. On January 22, 2024, as part of the change in control to present management, the Company repaid the (now) former Officer $1,250. As of December 31, 2024, the balance due is $0.

On June 30, 2024, the Company entered into an agreement with the Chief Executive Officer of the Company for an unsecured $500,000 line of credit facility. The line of credit bears interest of 6% per annum calculated on a daily basis, and there is no stated maturity date. The entire unpaid principal balance plus any accrued but unpaid interest shall be due and payable twelve months from the date of receipt of demand of payment by the lender. The monies that had been advanced by the Chief Executive Officer of the Company up to June 30, 2024 were transferred to this line of credit facility. The aggregate of the advances were $154,065 of which the Company paid back $2,560, resulting in a total of $151,505 being extended on the line of credit facility at June 30, 2024. During the balance of the year ended December 31, 2024, additional advances on the line of credit totaled $223,548, and additional payments were made in the aggregate amount of $6,524. At December 31, 2024, the total outstanding principal balance on this line of credit facility was $368,529. For the year ended December 31, 2024, interest expense was $6,318, and total accrued interest at December 31, 2024, was $6,318.

The above amounts and terms of the transactions are not necessarily typical of agreements entered into by third parties.

**<u>NOTE 10 - LEASES</u>**

The Company has an operating lease for office space and a finance lease for equipment. Leasing arrangements require fixed payments and also include an amount that is probable and will be owed under residual value guarantees, if applicable. Lease payments also include payments related to purchase or termination options when the lessee is reasonably certain to exercise the option or is reasonably certain not to exercise the option, respectively. The Company's lease agreements do not contain any material restrictive covenants. The leases have remaining terms of 3 to 5 years. Total rent expense incurred on the operating lease for the year ended December 31, 2024 was $10,583. The Company executed a finance lease during the year ended December 31, 2024, the lease period commences January 1, 2025, as a result, there are no amortization or interest expenses associated with the finance lease.

[**Table of Contents**](#a_012)

The Company's right-of-use assets and lease liabilities and other disclosures as of and for the year ended December 31, 2024, are as follows:

---

| | | |
|:---|:---|:---|
|  | **Operating <br>Lease** | **Finance <br>Lease** |
| Right-of-use assets obtained in exchange for new lease liabilities | $168833 | $130294 |
| Weighted-average remaining lease term | 3 years | 5 years |
| Weighted average discount rate | 7.9% | 9.9% |

---

---

| | | |
|:---|:---|:---|
|  | **Operating <br>Lease** | **Finance <br>Lease** |
| Right-of-use assets | $168833 | $130294 |
| &nbsp;&nbsp;&nbsp;Less: amortization | 8386 | – |
| &nbsp;&nbsp;&nbsp;Lease assets, net | $160447 | $130294 |
| Lease liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Lease liabilities, current | $51535 | $17264 |
| &nbsp;&nbsp;&nbsp;Lease liabilities, long-term | 104089 | 88030 |
| &nbsp;&nbsp;&nbsp;Total lease obligation | $155624 | $105294 |

---

Future payments of lease liabilities at December 31, 2024 are as follows:

---

| | | |
|:---|:---|:---|
| **Year Ending December 31,** | **Operating**<br> **Lease** | **Finance**<br> **Lease** |
| 2025 | $56798 | $26784 |
| 2026 | 63791 | 26784 |
| 2027 | 54482 | 26784 |
| 2028 |  | 26784 |
| 2029 |  | 26784 |
| Thereafter | – | – |
|  | 175071 | 133920 |
| Less interest | (19447) | (28626) |
| Total | $155624 | $105294 |

---

**<u>NOTE 11 – STOCKHOLDERS' EQUITY</u>**

<u>Common Stock</u>

The Company has 900,000,000 authorized common shares with a par value of $0.001 per share. Each common share entitles the holder to one vote, in person or proxy, on any matter on which action of the stockholders of the corporation is sought.

The Company has two common stock designations; Class A Common Stock with 800,000,000 shares authorized, and Class B Common Stock with 100,000,000 shares authorized.

[**Table of Contents**](#a_012)

<u>Class A Common Stock</u>: Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders' meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.

On July 9, 2024, the Company received an investment on its Reg A registration statement in the amount of $40,000 in investments, offset by $15,000 in offering costs, resulting in subsequent issuance of 8,000,000 shares of the Company's Class A Common Stock.

At December 31, 2024 and 2023, there were 95,899,861 and 87,899,861 Class A Common Shares issued and outstanding, respectively.

At December 31, 2024 and 2023, there were no Class B Common Shares issued and outstanding.

<u>Preferred Stock</u> 

There are 100,000,000 shares of preferred stock authorized, par value $.001 per share (the "Preferred Stock"), issuable in one or more series; (a) the Company designated one (1) share of Preferred Stock as "Special 2022 Series A Preferred Stock" possessing super-voting rights; (b) the Company designated 10,000,000 shares of Series A Preferred Stock; and (c) the Company designated 89,999,999 shares of Series C Preferred Stock.

<u>Special 2022 Series A Preferred Stock.</u> The designation of this class of preferred stock shall be "Special 2022 Series A Preferred Stock," par value $.001 per share (the "Special 2022 Series A Preferred Stock"). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1). (A) Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights: (1) Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis)) entitled to vote at each meeting of shareholders of the Corporation (and written actions of

[**Table of Contents**](#a_012)

shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares. (2) Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class. (B) Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred stock can affect the conversion at any time. The conversion into common is a right and is not required. (C) Dividends; Liquidation. The shares of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof and shall not participate in any proceeds available to the Corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation. (D) No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.

<u>Series A Preferred Stock</u>. The designation of this class of preferred stock shall be "Series A Preferred Stock," par value $.001 per share (the "Series A Preferred Stock"). The number of authorized shares of Series A Preferred Stock is ten million (10,000,000). Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class. (c) Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the "Liquidation Rate") before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.

<u>Series C Preferred Stock</u>. The designation of this class of preferred stock shall be "Series C Preferred Stock," par value $.001 per share (the "Series C Preferred Stock"). The number of authorized shares of Series C Preferred Stock is eighty-nine million, nine hundred ninety-nine thousand, nine hundred and ninety nine (89,999,999). Each share of Series C Preferred Stock shall entitle the holder to one (1) vote on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series C Preferred Stock shall vote together with the shares of Common Stock as one class. Liquidation Rights - Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of the Company's common stock multiplied by the Conversion Rate. Conversion Rate – Each share of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock.

On July 11, 2024, the Company acquired a 100% membership interest in Biolete, LLC; consideration provided for this acquisition was the issuance of 1,750,000 shares of the Company's Series C Preferred Stock.

On July 29, 2024, the Company acquired a 7% membership interest in Cement Factory Nutrition; consideration provided for this acquisition was the issuance of 1,875,000 shares of the Company's Series C Preferred Stock. On September 24, 2024 the acquisition of the 7% interest in Cement Factory Nutrition was rescinded and these shares were returned and a new agreement was made to acquire and 18% membership interest in Cement Factory, LLC; consideration provided for this acquisition was the reservation of 1,875,000 shares of the Company's Series C Preferred Stock to be issued at a future date.

On August 19, 2024, the Company appointed Monica Sher, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

On September 10, 2024, the Company appointed Richard Edwards, DO as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

[**Table of Contents**](#a_012)

On September 23, 2024, the Company appointed Kalpesh Barot, MD as a Director of Company. The Company will issue 250,000 shares of its Series C Preferred Stock at a future date.

At December 31, 2024 and 2023, there is one (1) share of Special 2022 Series A Preferred issued and outstanding.

At December 31, 2024 and 2023, there are 10,000,000 shares of Series A Preferred issued and outstanding.

At December 31, 2024 and 2023, there are 1,750,000 and zero shares of Series C Preferred issued and outstanding, respectively.

**<u>NOTE 12 – SEGMENT REPORTING</u>**

The Company has three operating segments: (1) Biolete, (2) Adia Meds, and (3) Adia Labs. The Biolete segment comprises the sale of supplements and had $73,974 and $0 of total assets at December 31, 2024 and 2023, respectively. Adia Meds will perform stem cell treatments to patients and had $323,590 and $0 of total assets at December 31, 2024 and 2023, respectively. Adia Meds will procure and sell stem cell products to outside clinics or to Adia Labs, and had $139,450 of total assets at December 31, 2024 and 2023, respectively. Unallocated assets held at the corporate level totaled $129,367 and $500 at December 31, 2024 and 2023, respectively.

The CODM reviews performance based on gross profit (sales less cost of products or services sold), operating profit, and net income (loss). Profitability is important to the Company's ability to grow and expand operations. The Company does not have any operations or sources of revenue outside of the United States. Corporate overhead is not allocated to each segment unless the cost is specifically incurred to support the single segment. This provides the CODM with segment specific costs and profits.

The Company chooses to disclose the following in its segment reporting requirements:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
|  | **Unallocated**<br>**Corporate**<br>**Overhead** |<br>**Biolete** |<br>**ADIA**<br>**Med** |<br>**ADIA**<br>**Labs** |<br>**Totals** |
| **Segment Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Sales of supplements, net of discounts | $– | $6380 | $– | $– | $6380 |
| **Total Segment Revenue** |  | 6380 |  |  | 6380 |
| **Cost of Revenue** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Cost of supplements | – | 4186 | – | – | 4186 |
| **Gross Profit** | – | 2194 | – | – | 2194 |
| **Operating Expenses** |  |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 112990 | 5052 | 20420 | 1947 | 140409 |
| &nbsp;&nbsp;&nbsp;&nbsp;Advertising and promotion | 12606 | 22981 | 947 | – | 36534 |
| **Segment Operating Expenses** | 125596 | 28033 | 21367 | 1947 | 176943 |
| **Segment Loss** | $(125596) | $(25839) | $(21367) | $(1947) | $(174749) |

---

**<u>NOTE 13 – COMMITMENTS AND CONTINGENCIES</u>**

On May 31, 2024, the Company filed a complaint for declaratory relief, seeking an order declaring as void a total of 15,445,165 shares of the Company's issued and outstanding shares of Common Stock, held by Lotus Fund ("Lotus") (10,445,165 shares), and Jason S. Coombs ("Coombs") (5,000,000 shares). In addition, the lawsuit seeks an order declaring as void a total of 10,000,000 shares of the Company's issued and outstanding shares of Series A Preferred Shares, held by Shelly Singhal ("Singhal"). Lotus, Coombs and Singhal (collectively the "Claimants") were issued these shares but the Company deems that they were not properly acquired through any consideration. The lawsuit (Case Number: 2024CA001088, Case Style: ADIA NUTRITION INC -VS- ADIA NUTRITION INC) was filed pursuant to the laws of the State of Florida, and the venue lies in Seminole County.

[**Table of Contents**](#a_012)

**<u>NOTE 14 – INCOME TAXES</u>**

A reconciliation of statutory income tax rate to effective tax rate was as follows for each of the periods presented:

---

| | | |
|:---|:---|:---|
|  | **For the year ended December 31, 2024** | **For the year ended December 31, 2023** |
| Federal income taxes at statutory rate | 21.0% | 21.0% |
| State income taxes at statutory rate | 5.5% | 5.5% |
| Valuation allowance | (26.5%) | (26.5%) |
| Effective tax rate | 0.0% | 0.0% |

---

As of December 31, 2024 and 2023, the Company had a net operating loss for tax purposes of $181,067 and $0, respectively.

The Company's policy is to recognize potential interest and penalties accrued related to unrecognized tax benefits within income tax expense. For the years ended December 31, 2024 and 2023 the Company did not recognize any interest or penalties in its consolidated statement of operations, nor did it have any interest or penalties accrued on its consolidated balance sheets at December 31, 2024 and 2023, relating to unrecognized tax benefits.

Under the provisions of ASC 740, *"Accounting for Uncertainty in Income Taxes,"* the Company identified no significant uncertain tax positions for 2023 and 2024. The Company files income tax returns in U.S. jurisdiction. There are no federal or state income tax examinations underway for these, and tax returns for the current year are still open to examination as neither year, nor the years prior have been filed with the appropriate taxing authorities.

Utilization of our net operating losses (NOL) carryforwards may be subject to a substantial annual limitation due to ownership change limitations that may have occurred or that could occur in the future, as required by Section 382 of the Internal Revenue Code (IRC) of 1986, as amended (the Code), as well as similar state provisions. These ownership changes may limit the amount of NOL carryforwards that can be utilized annually to offset future taxable income. In general, an "ownership change" as defined by Section 382 of the Code results from a transaction or series of transactions over a three-year period resulting in an ownership change of more than 50 percentage points of the outstanding stock of a company by certain stockholders. At the time of closing the consolidated books, the Company had not yet completed a study to determine the extent of the limitation based on ownership changes that may have occurred. As of December 31, 2024, the Company has available for federal income tax purposes a net operating loss carry forward of approximately $15,578,018, expiring in the year 2039, that may be used to offset future taxable income, but could be limited under Section 382.

The Company's deferred taxes as of December 31, 2024 and 2023, consist of the following:

---

| | | |
|:---|:---|:---|
|  | **2024** | **2023** |
| **Non-Current deferred tax asset:** |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net operating loss carry-forwards | $15578018 | $15396951 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax provision (U.S. federal and state combined) tax rate | 26.5% | 26.5% |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred tax asset | 4128175 | 4080192 |
| **Valuation allowance** | (4128175) | (4080192) |
| &nbsp;&nbsp;&nbsp;&nbsp;Net non-current deferred tax asset | $– | $– |

---

**<u>NOTE 15 – SUBSEQUENT EVENTS</u>**

Management has evaluated subsequent events through the date these consolidated financial statements were available to be issued. Based on our evaluation, no material events have occurred that require further disclosure.

 ****

 ****

[**Table of Contents**](#a_012)

 ****

***b) Exhibits***

The following documents are filed as exhibits hereto:

---

| | |
|:---|:---|
| **Exhibit Number** | **Exhibit Description** |
| 3.1 | [Amended and Restated Articles of Incorporation Adia Nutrition 1-22-2024](adia_ex0301.htm) |
| 3.2 | [ADIA – Preferred C Designation](adia_ex0302.htm) |
| 3.1.1 | [Bylaws of Adia Nutrition](adia_ex030101.htm) |
| 4.2.1 | [ADIA – Biolete – Membership Interest Purchase Agreement 7-11-2024](adia_ex040201.htm) |
| 4.2.2 | [ADIA – Cement Factory Signed Membership Interest Agreement 9-24-2024](adia_ex040202.htm) |
| 4.2.3 | [ADIA – Biolete – Sale of Assets to Cement Factory 9-30-2025](adia_ex040203.htm) |
| 5.1.1 | [Sher – Independent Director Agreement 8-19-2024](adia_ex050101.htm) |
| 5.1.2 | [Edwards – Independent Director Agreement 9-10-2024](adia_ex050102.htm) |
| 5.1.3 | [Barot – Independent Director Agreement 9-23-2024](adia_ex050103.htm) |
| 5.1.4 | [Thomas – Independent Director Agreement 10-13-2025](adia_ex050104.htm) |

---

[**Table of Contents**](#a_012)

**SIGNATURES**

Pursuant to the requirements of Section 12 of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | |
|:---|:---|
|  | **ADIA Nutrition, Inc.** |
| Date: December 5, 2025 | By: *<u>/s/ Larry Powalisz</u>* <br> Name: Larry Powlalisz<br> Title: Chief Executive Officer |

---

---

| | |
|:---|:---|
|  | **ADIA Nutrition, Inc.** |
| Date: December 5, 2025 | By: *<u>/s/ Rebecca Miller</u>* <br> Name: Rebecca Miller<br> Title: Chief Financial Officer |

---

## Ex-3

**Exhibit 3.1**

**AMENDED AND RESTATED** 

**ARTICLES OF INCORPORATION**

**OF**

**ADIA NUTRITION, INC.**

**(a Nevada corporation)**

Adia Nutrition Inc. (the "Corporation"), a corporation incorporated under the laws of the State of Nevada on April 24, 1975, as Domi Associates, Inc., hereby amends and restates its Articles of Incorporation, to embody in one document its original articles and the subsequent amendments and restatements thereto, pursuant to Sections 78.390 and 78.403 of the Nevada Revised Statutes ("NRS").

Amended and Restated Articles of Incorporation were approved and adopted by the Board of Directors of the Corporation on June 9, 2023. Upon the recommendation of the Board of Directors, the shareholder of the Corporation holding a majority of the voting power approved and adopted these Amended and Restated Articles of Incorporation by an action by written consent in lieu of a meeting of 60% of the eligible votes on June 9, 2023. As a result, these Amended and Restated Articles of Incorporation were authorized and adopted in accordance with the NRS.

These Amended and Restated Articles of Incorporation correctly set forth the text of the Corporation's Articles of Incorporation as amended up to and by these Amended and Restated Articles of Incorporation.

**ARTICLE 1. NAME OF CORPORATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1.1The name of the corporation is Adia Nutrition, Inc. (the "Corporation").

**ARTICLE 2. DURATION**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2.1The Corporation shall continue in existence perpetually, unless sooner dissolved according to law.

**ARTICLE 3. REGISTERED AGENT AND REGISTERED OFFICE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 3.1The name and address of the Corporation's registered agent and registered office in the State of Nevada are: Premier Legal Group, 1333 N. Buffalo Drive, Suite 210, Las Vegas, Nevada 89128

**ARTICLE 4. PURPOSE**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 4.1The purpose for which the Corporation is to engage in any lawful activity within or without the State of Nevada.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4.2The Corporation may also maintain offices at such other places within our without the State of Nevada as it may, from time to time, determine. Corporate business of every kind and nature may be conducted, and meetings of directors and shareholders may be held, outside the State of Nevada with the same effect as if in the State of Nevada.

**ARTICLE 5. BOARD OF DIRECTORS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5.1<u>Number</u>. The Board of Directors of the Corporation shall consist of such number of persons, not less than one and not to exceed 10, as shall be determined in accordance with the Bylaws of the Corporation from time to time.

**ARTICLE 6. CAPITAL STOCK**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.1<u>Authorized Capital Stock</u>. The aggregate number of shares which the Corporation shall have authority to issue is one billion (1,000,000,000) shares, consisting of (a) eight hundred million (800,000,000) shares of common stock, par value $.001 per share (the "Common Stock" or the "Class A Common Stock"), (b) 100,000,000 shares of common stock par value $.001 per share (the "Class B Common Stock"), issuable in one or more series as hereinafter provided, and (c) one hundred million (100,000,000) shares of preferred stock, par value $.001 per share (the "Preferred Stock"), issuable in one or more series as hereinafter provided.

A description of the classes of shares and a statement of the number of shares in each class and the relative rights, voting power and preferences granted to them, and restrictions imposed on them, are as set forth in this Article 6.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.2<u>Class A Common Stock</u>. Each share of Class A Common Stock shall have, for all purposes, one (1) vote per share. Subject to the preferences applicable to Preferred Stock outstanding at any time, the holders of the shares of Class A Common Stock shall be entitled to receive such dividends and other distributions in cash, property or shares of stock of the Corporation as may be declared thereon by the Board of Directors from time to time out of assets or funds of the Corporation legally available therefrom. The holders of Class A Common Stock issued and outstanding have and possess the right to receive notice of shareholders' meetings and to vote upon the election of directors or upon any other matter as to which approval of the outstanding shares of Class A Common Stock or approval of the common shareholders is required or requested.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.3<u>Class B Common Stock</u>. The shares of Class B Common Stock may be issued from time to time in one or more series. The Board of Directors is authorized, by resolution adopted and filed in accordance with law, to provide for the issue of each series of shares of Class B Common Stock; *provided, however*, that any issuance of shares of Class B Common Stock shall be made only in connection with a special acquisition transaction, as determined by the Board of Directors. Each series of shares of Class B Common Stock:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a)may have such voting powers, full or limited or may be without voting powers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b)may be subject to redemption at such time or times and at such prices as determined by the Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions and at such times, and payable in preference to, or in relation to, the dividends payable on any other class or classes or series of stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)may have such rights upon the dissolution of, or upon any distribution of assets of, the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)may be made convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock of the Corporation or such other corporation or other entity at such price or prices or at such rates of exchange and with such adjustments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)may be entitled to the benefit of a sinking fund to be applied to the purchase or redemption of shares of such series in such amount or amounts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)may be entitled to the benefit of conditions and restrictions upon the creation of indebtedness of the Corporation or any subsidiary, upon the issue of any additional shares (including additional shares of such series or of any other series) and upon the payment of dividends or the making of other distributions on, and the purchase, redemption or other acquisition by the Corporation or any subsidiary of, any outstanding shares of the Corporation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.4<u>Preferred Stock</u>. The shares of Preferred Stock may be issued from time to time in one or more series. The Board of Directors is authorized, by resolution adopted and filed in accordance with law, to provide for the issue of each series of shares of Preferred Stock. Each series of shares of Preferred Stock:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (a)may have such voting powers, full or limited or may be without voting powers;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (b)may be subject to redemption at such time or times and at such prices as determined by the Board of Directors;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)may be entitled to receive dividends (which may be cumulative or non-cumulative) at such rate or rates, on such conditions and at such times, and payable in preference to, or in relation to, the dividends payable on any other class or classes or series of stock;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (d)may have such rights upon the dissolution of, or upon any distribution of assets of, the Corporation;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)may be made convertible into, or exchangeable for, shares of any other class or classes or of any other series of the same or any other class or classes of stock of the Corporation or such other corporation or other entity at such price or prices or at such rates of exchange and with such adjustments;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)may be entitled to the benefit of a sinking fund to be applied to the purchase or redemption of shares of such series in such amount or amounts;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)may be entitled to the benefit of conditions and restrictions upon the creation of indebtedness of the Corporation or any subsidiary, upon the issue of any additional shares (including additional shares of such series or of any other series) and upon the payment of dividends or the making of other distributions on, and the purchase, redemption or other acquisition by the Corporation or any subsidiary of, any outstanding shares of the Corporation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Designation of Special 2022 Series A Preferred Stock</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designation and Amount. The designation of this class of preferred stock shall be "Special 2022 Series A Preferred Stock," par value $.001 per share (the "Series A 2022 Preferred Stock"). The number of authorized shares of Special 2022 Series A Preferred Stock is one (1).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Voting Rights. Except as otherwise required by law, the holder of the share of Special 2022 Series A Preferred Stock shall have the following rights:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)Number of Votes; Voting with Common Stock. Except as provided by Nevada statutes or elsewhere herein, the holder of the Special 2022 Series A Preferred Stock shall vote together with the holders of Preferred Stock (including on an as converted basis), and Common Stock, of the Corporation as a single class. The holder of the share of Special 2022 Series A Preferred Stock is entitled to 60% of all votes (including, but not limited to, Common Stock, and Preferred Stock (including on an as converted basis) entitled to vote at each meeting of shareholders of the Corporation (and written actions of shareholders in lieu of meetings) with respect to any and all matters presented to the shareholders of the Corporation for their action or consideration. The share of Special 2022 Series A Preferred Stock shall not be divided into fractional shares.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)Adverse Effects. The Corporation shall not amend, alter, or repeal the preferences, rights, powers or other terms of the Special 2022 Series A Preferred Stock so as to affect adversely the Special 2022 Series A Preferred Stock, or the holder thereof, without the written consent or affirmative vote of the holder of the Special 2022 Series A Preferred Stock given in writing or by vote at a meeting, consenting or voting (as the case may be) separately as a class.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Conversion. The share of the Special 2022 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 60,000,000 common shares. The holder of the Special 2022 Series A Preferred Stock can affect the conversion at any time. The conversion into common is a right and conversion is not required.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Dividends; Liquidation. The share of Special 2022 Series A Preferred Stock shall not be entitled to any dividends in respect thereof, and shall not participate in any proceeds available to the Corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)No Impairment. The Corporation shall not intentionally take any action which would impair the rights and privileges of the Special 2022 Series A Preferred Stock set forth herein or the rights of the holder thereof. The Corporation will not, by amendment of its articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms to be observed or performed hereunder by the Corporation, but will, at all times, in good faith assist in the carrying out of all the provisions herein and in the taking of all such action as may be necessary or appropriate in order to protect the rights of the holder of the Special 2022 Series A Preferred Stock against impairment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Replacement Certificate. In the event that the holder of the share of the Special 2022 Series A Preferred Stock notifies the Corporation that the stock certificate evidencing the share of the Special 2022 Series A Preferred Stock has been lost, stolen, destroyed or mutilated, the Corporation shall issue a replacement stock certificate evidencing the shares of the Special 2022 Series A Preferred Stock identical in tenor and date to the original stock certificate evidencing the share of the Special 2022 Series A Preferred Stock, provided that the holder executes and delivers to the Corporation an affidavit of lost stock certificate and an agreement reasonably satisfactory to the Corporation to indemnify the Corporation from any loss incurred by it in connection with such Special 2022 Series A Preferred Stock certificate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6.6 <u>Designation of Series A Preferred Stock</u>.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a)Designation and Amount. The designation of this class of preferred stock shall be "Series A Preferred Stock," par value $.001 per share (the "Series A Preferred Stock"). The number of authorized shares of Series A Preferred Stock is ten million (10,000,000).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b)Voting Rights. Each share of Series A Preferred Stock shall entitle the holder to five (5) votes on any matter submitted to the shareholders of the Corporation for their vote, waiver, release or other action, to be considered in connection with the establishment of a quorum, except as may otherwise be expressly required by law or by the applicable stock exchange rules. The holders of Series A Preferred Stock shall vote together with the shares of Common Stock as one class.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(c)Liquidation Rights. Upon the dissolution, liquidation or winding up of the Corporation, whether voluntary or involuntary, the holders of the then-outstanding shares of Series A Preferred Stock shall be entitled to receive out of the assets of the Corporation the sum of $.001 per share (the "Liquidation Rate") before any payment or distribution shall be made on any other class of capital stock of the Corporation ranking junior to the Series A Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1)The sale, conveyance, exchange or transfer (for cash, shares of stock, securities or other consideration) of all or substantially all the property and assets of the Corporation shall be deemed a dissolution, liquidation or winding up of the Corporation for purposes of this paragraph (c), but the merger, consolidation or other combination of the Corporation into or with any other corporation, or the merger, consolidation or other combination of any other corporation into or with the Corporation, shall not be deemed a dissolution, liquidation or winding up, voluntary or involuntary, for purposes of this paragraph (c). As used herein, the "merger, consolidation or other combination" shall include, without limitation, a forward or reverse triangular merger, or stock exchange of the Corporation and any of its subsidiaries with any other corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2)After payment to the holders of the shares of the Series A Preferred Stock of the full preferential amounts fixed by this paragraph (c) for shares of the Series A Preferred Stock, the holders of the Series A Preferred Stock as such shall have no right to claim to any of the remaining assets of the Corporation.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3)In the event the assets of the Corporation available for distribution to the holders of the Series A Preferred Stock upon dissolution, liquidation or winding up of the Corporation shall be insufficient to pay in full all amounts to which such holders are entitled pursuant to this paragraph (c), no distribution shall be made on account of any shares of a class or series of capital stock of th Corporation ranking on a parity with the shares of Series A Preferred Stock, if any, upon such dissolution, liquidation or winding up of the Corporation unless proportionate distributive amounts shall be paid on account of the shares of the Series A Preferred Stock, ratably, in proportion to the full distributive amounts for which holders of all such parity shares are respectively entitled upon such dissolution, liquidation or winding up.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(d)Dividends. Except as provided herein, the holders of the Series A Preferred Stock shall be entitled to receive cash, stock or other property, as dividends, when, as and if declared by the Board of Directors of the Corporation. Series A Preferred Stock shall not participate in any dividend declared with respect to the Common Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(e)Preferred Status. The rights of the shares of the Common Stock shall be subject to the preferences and relative rights of the shares of the Series A Preferred Stock. Without the prior written consent of the holders of not less than a majority of the outstanding shares of the Series A Preferred Stock, the Corporation shall not hereafter authorize or issue additional or other capital stock that is of senior or equal rank to the shares of the Series A Preferred Stock in respect of the preferences as to distributions and payments upon the liquidation, dissolution and winding up of the Corporation described in paragraph (c) above.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(f)Vote to Change the Terms of the Series A Preferred Stock. Without the prior written consent of the holders of not less than a majority of the outstanding shares of the Series A Preferred Stock, the Corporation shall not amend, alter, change or repeal any of the powers, designations, preferences and rights of the Series A Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(g)Lost or Stolen Certificates. Upon receipt by the Corporation of evidence satisfactory to the Corporation of the loss, theft, destruction or mutilation of any Preferred Stock Certificates representing shares of the Series A Preferred Stock, and, in the case of loss, theft or destruction, of any indemnification undertaking or bond, in the Corporation's discretion, by the holder to the Corporation and, in the case of mutilation, upon surrender and cancellation of the Preferred Stock Certificate(s), the Corporation shall execute and deliver new Series A Preferred Stock Certificate(s) of like tenor and date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(h)No Re-issuance of Series A Preferred Stock. No share or shares of the Series A Preferred Stock acquired by the Corporation by reason of redemption, purchase or otherwise shall be re-issued, and all such shares of Series A Preferred Stock shall be cancelled, retired and eliminated from the shares of Series A Preferred Stock, as applicable, which the Corporation shall be authorized to issue. Any such shares of Series A Preferred Stock acquired by the Corporation shall have the status of authorized and unissued shares of Preferred Stock issuable in undesignated Series and may be re-designated and re-issued in any Series other than as Series A Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i)Registered Holders. A holder of Series A Preferred Stock registered on the Corporation's stock transfer books as the owner of shares of Series A Preferred Stock, as applicable, shall be treated as the owner of such shares for all purposes. All notices and all payments required to be mailed to a holder of shares of Series A Preferred Stock shall be mailed to such holder's registered address of the Corporation's stock transfer books, and all dividends and redemption payments to a holder of Series A Preferred Stock made hereunder shall be deemed to be paid in compliance hereof on the date such payments are deposited into the mail addressed to such holder at such holder's registered address on the Corporation's stock transfer books.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(j)Certain Remedies. Any registered holder of shares of Series A Preferred Stock shall be entitled to an injunction or injunctions to prevent breaches of the provisions of this Section 6.6 and to enforce specifically the terms and provisions of this Section 6.6 in any court of the United States or any state thereof having jurisdiction, this being in addition to any other remedy to which such holder may be entitled at law or in equity.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(k)Headings of Subdivisions. The headings of the various subdivisions hereof are for convenience of reference only and shall not affect the interpretation of any of the provisions hereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(l)Severability of Provisions. If any right, preference or limitation of the Series A Preferred Stock set forth herein (as may be amended) from time to time is invalid, unlawful or incapable of being enforced by reason of any rule of law or public policy, such right, preference or limitation (including, without limitation, the dividend rate) shall be enforced to the maximum extent permitted by law and all other rights, preferences and limitation set forth herein (as so amended) which can be given effect without the invalid, unlawful or unenforceable right, preference or limitation herein set forth shall not be deemed dependent upon any other such right, preference or limitation unless so expressed herein.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(m)Ranking. The Series A Preferred Stock shall rank, as to rights upon liquidation, dissolution or winding up, *pari passu* to each other and shall rank senior and prior to (1) the Common Stock and (2) each other class or series of capital stock of the Corporation hereafter created which does not expressly rank *pari passu* with or senior to the Series A Preferred Stock, as applicable.

**ARTICLE 7. NO FURTHER ASSESSMENTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7.1The capital stock, after the amount of the subscription price determined by the board of directors has been paid in money, property, or services, as the Directors shall determine, shall be subject to no further assessment to pay the debts of the Corporation, and no stock issued as fully paid up shall ever be assessable or assessed, and these Articles of Incorporation shall not and cannot be amended, regardless of the vote therefore, so as to amend, modify or rescind this Article 7.

**ARTICLE 8. NO PREEMPTIVE RIGHTS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8.1Except as otherwise set forth herein, none of the shares of the Corporation shall carry with them any preemptive right to acquire additional or other shares of the Corporation and no holder of any stock of the Corporation shall be entitled, as of right, to purchase or subscribe for any part of any unissued shares of stock of the Corporation or for any additional shares of stock, of any class or series, which may at any time be issued, whether now or hereafter authorized, or for any rights, options, or warrants to purchase or receive shares of stock or for any bonds, certificates of indebtedness, debentures, or other securities.

**ARTICLE 9. NO CUMULATIVE VOTING**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9.1There shall be no cumulative voting of shares.

**ARTICLE 10. ELECTION NOT TO BE**

**GOVERNED BY PROVISIONS OF NRS 78.411 TO 78.444**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10.1The Corporation, pursuant to NRS 78.434, hereby elects not to be governed by the provisions of NRS 78.411 to 78.444, inclusive.

**ARTICLE 11. INDEMNIFICATION OF OFFICERS AND DIRECTORS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.1The Corporation shall indemnify its directors, officers, employees, fiduciaries and agents to the fullest extent permitted under the Nevada Revised Statutes.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.2Every person who was or is a party or is threatened to be made a party to or is involved in any action, suit or proceedings, whether civil, criminal, administrative or investigative, by reason of the fact that he or a person for whom he is the legal representative is or was a director or officer of the Corporation or is or was serving at the request of the Corporation as a director or officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise, shall be indemnified and held harmless to the fullest extent legally permissible under the law of the State of Nevada from time to time against all expenses, liability and loss (including attorney's fees, judgments, fines and amounts paid or to be paid in settlement) reasonably incurred or suffered by him in connection therewith. Such right of indemnification shall be a contract right that may be enforced in any manner desired by such person. Such right of indemnification shall not be exclusive of any other right which such directors, officers or representatives may have or hereafter acquire and, without limiting the generality of such statement, they shall be entitled to their respective rights of indemnification under any Bylaw, agreement, vote of stockholders, provision of law or otherwise, as well as their rights under this Article.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.3Without limiting the application of the foregoing, the Board of Directors may adopt Bylaws from time to time with respect to indemnification to provide at all times the fullest indemnification permitted by the law of the State of Nevada and may cause the Corporation to purchase and maintain insurance on behalf of any person who is or was a director or officer of the Corporation as a director of officer of another corporation, or as its representative in a partnership, joint venture, trust or other enterprise against any liability asserted against such person and incurred in any such capacity or arising out of such status, whether or not the Corporation would have the power to indemnify such person.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.4The private property of the Stockholders, Directors and Officers shall not be subject to the payment of corporate debts to any extent whatsoever.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;11.5No director, officer or shareholder shall have any personal liability to the Corporation or its stockholders for damages for breach of fiduciary duty as a director or officer, except that this provision does not eliminate nor limit in any way the liability of a director or officer for:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(a) Acts or omissions which involve intentional misconduct, fraud or a knowing violation of law; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(b) The payment of dividends in violation of Nevada Revised Statutes (N.R.S.) 78.300.

I, the undersigned, being the Chief Executive Officer of Adia Nutrition, Inc., hereby declares and certifies, under penalties of perjury, that this is my act and deed and the facts herein stated are true, and, accordingly, have hereunto set my hand this 19th day of September, 2023.

*<u>/s/ Lenny M. Greene</u>*

Lenny M. Greene

Chief Executive Officer

Adia Nutrition, Inc.

## Ex-3

**Exhibit 3.2**

**ADIA NUTRITION, INC.**

**CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS**

**OF**

**SERIES C PREFERRED STOCK**

PURSUANT TO SECTION 78.1955 OF THE NEVADA REVISED STATUTES

Pursuant to Section 78.1955 of the Nevada Revised Statutes, the undersigned does hereby certify, on behalf of Adia Nutrition, Inc., a Nevada corporation (the ***"Company"***), that the following resolution was duly adopted by the Board of Directors of the Company.

**WHEREAS,** the Articles of Incorporation of the Company, as amended (the ***"Articles of Incorporation"***), authorize the issuance of up to 100,000,000 shares of preferred stock, par value $0.001 per share, of the Company (the ***"Preferred Stock"***) in one or more series, which Preferred Stock shall have such distinctive designation or title, voting powers or no voting powers, and such preferences, rights, qualifications, limitations or restrictions, as shall be stated in such resolution or resolutions providing for the issuance of such class or series of Preferred Stock as may be adopted from time to time by the Board prior to the issuance of any shares thereof; and

**WHEREAS,** it is the desire of the Board of Directors to establish and fix the number of shares to be included in a new series of Preferred Stock and the designation, rights, preferences, powers, restrictions and limitations of the shares of such new series.

**NOW, THEREFORE, IT IS RESOLVED,** that the Board of Directors does hereby provide for the issue of a series of Preferred Stock and does hereby in this Certificate of Designation (this ***"Certificate of Designation"***) establish and fix and herein state and express the designation, rights, preferences, powers, restrictions, and limitations of such series of Preferred Stock as follows:

**TERMS OF SERIES C PREFERRED STOCK**

**Section 1. Designation, Amount and Par Value.** The series of Preferred Stock shall be designated as Series C Preferred Stock (the ***"Series C Preferred Stock"***) and the number of shares so designated shall be Eighty-Nine Million Nine Hundred Ninety-Nine Thousand Nine-Hundred Ninety Nine (89,999,999). Each share of the Series C Preferred Stock shall have a par value of

$0.001.

**Section 2. Fractional Shares.** The Series C Preferred Stock may be issued in fractional shares.

**Section 3. Voting Rights.** Each share the Series C Preferred Stock shall have one (1) vote in all matters requiring shareholder approval.

**Section 4. Dividends.** The Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the dividend on each share of Series C Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 5. Liquidation.** Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of Series C Preferred Stock shall be equal to the amount of the payment on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 6. Conversion and Adjustments.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Conversion Rate.** Each shares of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock (the ***"Conversion Rate"***).

The Conversion Rate shall not be subject to adjustment by a combination of the outstanding shares of the Company's common stock into a smaller number of shares of common stock.

The Conversion Rate shall be subject to adjustment by a subdivision of the outstanding shares of the Company's common stock into a greater number of shares of common stock (the "Common Stock Event") by multiplying the Conversion Rate then in effect by a fraction: (1) the numerator of which shall be the number of shares of Company common stock issued and outstanding immediately prior to such Common Stock Event and (2) the denominator of which shall be the number of shares of Company common stock issued and outstanding immediately after such Common Stock Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Partial Conversion.** A holder of shares of Series C Preferred Stock shall have the right to convert, from time to time, some or all of such holder's shares of Series C Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Adjustment for Merger and Reorganization, etc.** If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger (a ***"Reorganization Event"***) involving the Company in which the Company's common stock (but not the Series C Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Series C Preferred Stock shall be deemed to have been converted into shares of the Company's common stock at the Conversion Rate.

**Section 7. Protection Provisions.** So long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without first obtaining the written consent of the holders of a majority the Series C Preferred Stock, alter or change the rights, preferences or privileges of the Series C Preferred Stock.

**Section 8. Waiver.** Any of the rights, powers or preferences of the holders of the Series C Preferred Stock may be waived by the affirmative consent or vote of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.

**Section 9. No Other Rights or Privileges.** Except as specifically set forth herein, the holder(s) of the shares of Series C Preferred Stock shall have no other rights, privileges or preferences with respect to the Series C Preferred Stock.

**RESOLVED, FURTHER,** that the president, chief executive officer or any vice-president, and the secretary or any assistant secretary, of the Company be and they hereby are authorized and directed to prepare and file this Certificate of Designation of Preferences, Rights and Limitations in accordance with the foregoing resolution and the provisions of the Nevada Revised Statutes.

IN WITNESS WHEREOF, the undersigned has executed this Certificate of Designation this 1st day of July, 2024.

---

| | |
|:---|:---|
| ADIA NUTRITION, INC. | ADIA NUTRITION, INC. |
| By: | /s/ Larry Powalisz |
|  | Larry Powalisz |
|  | Chief Executive Officer |

---

## Exhibit 3.1

**Exhibit 3.1.1**

BYLAWS OF

ADIA NUTRITION, INC.

ARTICLE I

OFFICES

Section 1.01 <u>Location of Offices</u>. The corporation may maintain such offices within or without the State of Nevada as the Board of Directors may from time to time designate or require.

Section 1.02 <u>Principal Office</u>. The address of the principal office of the corporation shall be at the address of the registered office of the corporation as so designated in the office of the Lieutenant Governor/Secretary of State of the state of incorporation, or at such other address as the Board of Directors shall from time to time determine.

ARTICLE II

SHAREHOLDERS

Section 2.01 <u>Annual Meeting</u>. The annual meeting of the shareholders shall be held in June of each year or at such other time designated by the Board of Directors and as is provided for in the notice of the meeting, for the purpose of electing directors and for the transaction of such other business as may come before the meeting. If the election of directors shall not be held on the day designated for the annual meeting of the shareholders, or at any adjournment thereof, the Board of Directors shall cause the election to be held at a special meeting of the shareholders as soon thereafter as may be convenient.

Section 2.02 <u>Special Meetings</u>. Special meetings of the shareholders may be called at any time by the chairman of the board, the president, or by the Board of Directors, or in their absence or disability, by any vice president, and shall be called by the president or, in his or her absence or disability, by a vice president or by the secretary on the written request of the holders of not less than 25% of all the shares entitled to vote at the meeting, such written request to state the purpose or purposes of the meeting and to be delivered to the president, each vice-president, or secretary. In case of failure to call such meeting within 60 days after such request, such shareholder or shareholders may call the same.

Section 2.03 <u>Place of Meetings</u>. The Board of Directors may designate any place, either within or without the state of incorporation, as the place of meeting for any annual meeting or for any special meeting called by the Board of Directors. A waiver of notice signed by all shareholders entitled to vote at a meeting may designate any place, either within or without the state of incorporation, as the place for the holding of such meeting. If no designation is made, or if a special meeting be otherwise called, the place of meeting shall be at the principal office of the corporation.

Section 2.04 <u>Notice of Meetings</u>. The secretary or assistant secretary, if any, shall cause notice of the time, place, and purpose or purposes of all meetings of the shareholders (whether annual or special), to be mailed at least ten days, but not more than 60 days, prior to the meeting, to each shareholder of record entitled to vote.

Section 2.05 <u>Waiver of Notice</u>. Any shareholder may waive notice of any meeting of shareholders (however called or noticed, whether or not called or noticed and whether before, during, or after the meeting), by signing a written waiver of notice or a consent to the holding of such meeting, or an approval of the minutes thereof. Attendance at a meeting, in person or by proxy, shall constitute waiver of all defects of call or notice regardless of whether waiver, consent, or approval is signed or any objections are made. All such waivers, consents, or approvals shall be made a part of the minutes of the meeting.

Section 2.06 <u>Fixing Record Date</u>. For the purpose of determining shareholders entitled to notice of or to vote at any annual meeting of shareholders or any adjournment thereof, or shareholders entitled to receive payment of any dividend or in order to make a determination of shareholders for any other proper purpose, the Board of Directors of the corporation may provide that the share transfer books shall be closed, for the purpose of determining shareholders entitled to notice of or to vote at such meeting, but not for a period exceeding sixty (60) days. If the share transfer books are closed for the purpose of determining shareholders entitled to notice of or to vote at such meeting, such books shall be closed for at least ten (10) days immediately preceding such meeting.

In lieu of closing the share transfer books, the Board of Directors may fix in advance a date as the record date for any such determination of shareholders, such date in any case to be not more than sixty (60) and, in case of a meeting of shareholders, not less than ten (10) days prior to the date on which the particular action requiring such determination of shareholders is to be taken. If the share transfer books are not closed and no record date is fixed for the determination of shareholders entitled to notice of or to vote at a meeting or to receive payment of a dividend, the date on which notice of the meeting is mailed or the date on which the resolution of the Board of Directors declaring such dividend is adopted, as the case may be, shall be the record date for such determination of shareholders. When a determination of shareholders entitled to vote at any meeting of shareholders has been made as provided in this Section, such determination shall apply to any adjournment thereof. Failure to comply with this Section shall not affect the validity of any action taken at a meeting of shareholders.

Section 2.07 <u>Voting Lists</u>. The officer or agent of the corporation having charge of the share transfer books for shares of the corporation shall make, at least ten (10) days before each meeting of shareholders, a complete list of the shareholders entitled to vote at such meeting or any adjournment thereof, arranged in alphabetical order, with the address of, and the number of shares held by each, which list, for a period of ten (10) days prior to such meeting, shall be kept on file at the registered office of the corporation and shall be subject to inspection by any shareholder during the whole time of the meeting. The original share transfer book shall be prima facie evidence as to the shareholders who are entitled to examine such list or transfer books, or to vote at any meeting of shareholders.

Section 2.08 <u>Quorum</u>. A majority of the total voting power of the outstanding shares of the corporation entitled to vote, represented in person or by proxy, shall constitute a quorum at a meeting of the shareholders. If a quorum is present, the affirmative vote of the majority of the voting power represented by shares at the meeting and entitled to vote on the subject shall constitute action by the shareholders, unless the vote of a greater number or voting by classes is required by the laws of the state of incorporation of the corporation or the Articles of Incorporation. If less than a majority of the outstanding voting power is represented at a meeting, a majority of the voting power represented by shares so present may adjourn the meeting from time to time without further notice. At such adjourned meeting at which a quorum shall be present or represented, any business may be transacted which might have been transacted at the meeting as originally noticed.

Section 2.09 <u>Voting of Shares</u>. Each outstanding share of the corporation entitled to vote shall be entitled to one vote on each matter submitted to vote at a meeting of shareholders, except to the extent that the voting rights of the shares of any class or series of stock are determined and specified as greater or lesser than one vote per share in the manner provided by the Articles of Incorporation.

Section 2.10 <u>Proxies</u>. At each meeting of the shareholders, each shareholder entitled to vote shall be entitled to vote in person or by proxy; provided, however, that the right to vote by proxy shall exist only in case the instrument authorizing such proxy to act shall have been executed in writing by the registered holder or holders of such shares, as the case may be, as shown on the share transfer of the corporation or by his or her or her attorney thereunto duly authorized in writing. Such instrument authorizing a proxy to act shall be delivered at the beginning of such meeting to the secretary of the corporation or to such other officer or person who may, in the absence of the secretary, be acting as secretary of the meeting. In the event that any such instrument shall designate two or more persons to act as proxies, a majority of such persons present at the meeting, or if only one be present, that one shall (unless the instrument shall otherwise provide) have all of the powers conferred by the instrument on all persons so designated. Persons holding stock in a fiduciary capacity shall be entitled to vote the shares so held and the persons whose shares are pledged shall be entitled to vote, unless in the transfer by the pledge or on the books of the corporation he or she shall have expressly empowered the pledgee to vote thereon, in which case the pledgee, or his or her or her proxy, may represent such shares and vote thereon.

Section 2.11 <u>Written Consent to Action by Shareholders</u>. Any action required to be taken at a meeting of the shareholders, or any other action which may be taken at a meeting of the shareholders, may be taken without a meeting, if a consent in writing, setting forth the action so taken, shall be signed by a majority of the shareholders entitled to vote with respect to the subject matter thereof.

ARTICLE III

DIRECTORS

Section 3.01 <u>General Powers.</u> The property, affairs, and business of the corporation shall be managed by its Board of Directors. The Board of Directors may exercise all the powers of the corporation whether derived from law or the Articles of Incorporation, except such powers as are by statute, by the Articles of Incorporation or by these Bylaws, vested solely in the shareholders of the corporation.

Section 3.02 <u>Number, Term, and Qualifications</u>. The Board of Directors shall consist of one to nine persons. Increases or decreases to said number may be made, within the numbers authorized by the Articles of Incorporation, as the Board of Directors shall from time to time determine by amendment to these Bylaws. An increase or a decrease in the number of the members of the Board of Directors may also be had upon amendment to these Bylaws by a majority vote of all of the shareholders, and the number of directors to be so increased or decreased shall be fixed upon a majority vote of all of the shareholders of the corporation. Each director shall hold office until the next annual meeting of shareholders of the corporation and until his or her successor shall have been elected and shall have qualified. Directors need not be residents of the state of incorporation or shareholders of the corporation.

Section 3.03 <u>Classification of Directors</u>. In lieu of electing the entire number of directors annually, the Board of Directors may provide that the directors be divided into either two or three classes, each class to be as nearly equal in number as possible, the term of office of the directors of the first class to expire at the first annual meeting of shareholders after their election, that of the second class to expire at the second annual meeting after their election, and that of the third class, if any, to expire at the third annual meeting after their election. At each annual meeting after such classification, the number of directors equal to the number of the class whose term expires at the time of such meeting shall be elected to hold office until the second succeeding annual meeting, if there be two classes, or until the third succeeding annual meeting, if there be three classes.

Section 3.04 <u>Regular Meetings</u>. A regular meeting of the Board of Directors shall be held without other notice than this bylaw immediately following, and at the same place as, the annual meeting of shareholders. The Board of Directors may provide by resolution the time and place, either within or without the state of incorporation, for the holding of additional regular meetings without other notice than such resolution.

Section 3.05 <u>Special Meetings</u>. Special meetings of the Board of Directors may be called by or at the request of the president, vice president, or any two directors. The person or persons authorized to call special meetings of the Board of Directors may fix any place, either within or without the state of incorporation, as the place for holding any special meeting of the Board of Directors called by them.

Section 3.06 <u>Meetings by Telephone Conference Call</u>. Members of the Board of Directors may participate in a meeting of the Board of Directors or a committee of the Board of Directors by means of conference telephone or similar communication equipment by means of which all persons participating in the meeting can hear each other, and participation in a meeting pursuant to this Section shall constitute presence in person at such meeting.

Section 3.07 <u>Notice</u>. Notice of any special meeting shall be given at least ten (10) days prior thereto by written notice delivered personally or mailed to each director at his or her regular business address or residence, or by telegram. If mailed, such notice shall be deemed to be delivered when deposited in the United States mail so addressed, with postage thereon prepaid. If notice be given by telegram, such notice shall be deemed to be delivered when the telegram is delivered to the telegraph company. Any director may waive notice of any meeting. Attendance of a director at a meeting shall constitute a waiver of notice of such meeting, except where a director attends a meeting solely for the express purpose of objecting to the transaction of any business because the meeting is not lawfully called or convened.

Section 3.08 <u>Quorum</u>. A majority of the number of directors shall constitute a quorum for the transaction of business at any meeting of the Board of Directors, but if less than a majority is present at a meeting, a majority of the directors present may adjourn the meeting from time to time without further notice.

Section 3.09 <u>Manner of Acting</u>. The act of a majority of the directors present at a meeting at which a quorum is present shall be the act of the Board of Directors, and the individual directors shall have no power as such.

Section 3.10 <u>Vacancies and Newly Created Directorship</u>. If any vacancies shall occur in the Board of Directors by reason of death, resignation or otherwise, or if the number of directors shall be increased, the directors then in office shall continue to act and such vacancies or newly created directorships shall be filled by a vote of the directors then in office, though less than a quorum, in any way approved by the meeting. Any directorship to be filled by reason of removal of one or more directors by the shareholders may be filled by election by the shareholders at the meeting at which the director or directors are removed.

Section 3.11 <u>Compensation</u>. By resolution of the Board of Directors, the directors may be paid their expenses, if any, of attendance at each meeting of the Board of Directors, and may be paid a fixed sum for attendance at each meeting of the Board of Directors or a stated salary as director. No such payment shall preclude any director from serving the corporation in any other capacity and receiving compensation therefore.

Section 3.12 <u>Presumption of Assent</u>. A director of the corporation who is present at a meeting of the Board of Directors at which action on any corporate matter is taken shall be presumed to have assented to the action taken unless his or her or her dissent shall be entered in the minutes of the meeting, unless he or she shall file his or her or her written dissent to such action with the person acting as the secretary of the meeting before the adjournment thereof, or shall forward such dissent by registered or certified mail to the secretary of the corporation immediately after the adjournment of the meeting. Such right to dissent shall not apply to a director who voted in favor of such action.

Section 3.13 <u>Resignations</u>. A director may resign at any time by delivering a written resignation to either the president, a vice president, the secretary, or assistant secretary, if any. Unless the resignation provides otherwise, it shall become effective on its acceptance by the Board of Directors; provided, that if the board has not acted thereon within ten days from the date presented, the resignation shall be deemed accepted.

Section 3.14 <u>Written Consent to Action by Directors</u>. Any action required to be taken at a meeting of the directors of the corporation or any other action which may be taken at a meeting of the directors or of a committee, may be taken without a meeting, if a consent in writing, setting forth the action so taken, shall be signed by all of the directors, or all of the members of the committee, as the case may be. Such consent shall have the same legal effect as a unanimous vote of all the directors or members of the committee.

Section 3.15 <u>Removal.</u> At a meeting expressly called for that purpose, one or more directors may be removed by a vote of a majority of the shares of outstanding stock of the corporation entitled to vote at an election of directors.

ARTICLE IV

OFFICERS

Section 4.01 <u>Number.</u> The officers of the corporation shall be a president, one or more vice-presidents, as shall be determined by resolution of the Board of Directors, a secretary, a treasurer, and such other officers as may be appointed by the Board of Directors. The Board of Directors may elect, but shall not be required to elect, a chairman of the board and the Board of Directors may appoint a general manager.

Section 4.02 <u>Election, Term of Office, and Qualifications.</u> The officers shall be chosen by the Board of Directors annually at its annual meeting. In the event of failure to choose officers at an annual meeting of the Board of Directors, officers may be chosen at any regular or special meeting of the Board of Directors. Each such officer (whether chosen at an annual meeting of the Board of Directors to fill a vacancy or otherwise) shall hold his or her office until the next ensuing annual meeting of the Board of Directors and until his or her successor shall have been chosen and qualified, or until his or her death, or until his or her resignation or removal in the manner provided in these Bylaws. Any one person may hold any two or more of such offices. The chairman of the board, if any, shall be and remain a director of the corporation during the term of his or her office. No other officer need be a director.

Section 4.03 <u>Subordinate Officers, Etc</u>. The Board of Directors from time to time may appoint such other officers or agents as it may deem advisable, each of whom shall have such title, hold office for such period, have such authority, and perform such duties as the Board of Directors from time to time may determine. The Board of Directors from time to time may delegate to any officer or agent the power to appoint any such subordinate officer or agents and to prescribe their respective titles, terms of office, authorities, and duties. Subordinate officers need not be shareholders or directors.

Section 4.04 <u>Resignations</u>. Any officer may resign at any time by delivering a written resignation to the Board of Directors, the president, or the secretary. Unless otherwise specified therein, such resignation shall take effect on delivery.

Section 4.05 <u>Removal</u>. Any officer may be removed from office at any special meeting of the Board of Directors called for that purpose or at a regular meeting, by vote of a majority of the directors, with or without cause. Any officer or agent appointed in accordance with the provisions of Section 4.03 hereof may also be removed, either with or without cause, by any officer on whom such power of removal shall have been conferred by the Board of Directors.

Section 4.06 <u>Vacancies and Newly Created Offices.</u> If any vacancy shall occur in any office by reason of death, resignation, removal, disqualification, or any other cause, or if a new office shall be created, then such vacancies or new created offices may be filled by the Board of Directors at any regular or special meeting.

Section 4.07 <u>The Chairman of the Board</u>. The Chairman of the Board, if there be such an officer, shall have the following powers and duties.

(a) He or she shall preside at all shareholders' meetings;

(b) He or she shall preside at all meetings of the Board of Directors; and

(c) He or she shall be a member of the executive committee, if any.

Section 4.08 <u>The President</u>. The president shall have the following powers and duties:

(a) If no general manager has been appointed, he or she shall be the chief executive officer of the corporation, and, subject to the direction of the Board of Directors, shall have general charge of the business, affairs, and property of the corporation and general supervision over its officers, employees, and agents;

(b) If no chairman of the board has been chosen, or if such officer is absent or disabled, he or she shall preside at meetings of the shareholders and Board of Directors;

(c) He or she shall be a member of the executive committee, if any;

(d) He or she shall be empowered to sign certificates representing shares of the corporation, the issuance of which shall have been authorized by the Board of Directors; and

(e) He or she shall have all power and shall perform all duties normally incident to the office of a president of a corporation, and shall exercise such other powers and perform such other duties as from time to time may be assigned to him or her by the Board of Directors.

Section 4.09 <u>The Vice Presidents.</u> The Board of Directors may, from time to time, designate and elect one or more vice presidents, one of whom may be designated to serve as executive vice president. Each vice president shall have such powers and perform such duties as from time to time may be assigned to him or her by the Board of Directors or the president. At the request or in the absence or disability of the president, the executive vice president or, in the absence or disability of the executive vice president, the vice president designated by the Board of Directors or (in the absence of such designation by the Board of Directors) by the president, the senior vice president, may perform all the duties of the president, and when so acting, shall have all the powers of, and be subject to all the restrictions upon, the president.

Section 4.10 <u>The Secretary</u>. The secretary shall have the following powers and duties:

(a) He or she shall keep or cause to be kept a record of all of the proceedings of the meetings of the shareholders and of the board or directors in books provided for that purpose;

(b) He or she shall cause all notices to be duly given in accordance with the provisions of these Bylaws and as required by statute;

(c) He or she shall be the custodian of the records and of the seal of the corporation, and shall cause such seal (or a facsimile thereof) to be affixed to all certificates representing shares of the corporation prior to the issuance thereof and to all instruments, the execution of which on behalf of the corporation under its seal shall have been duly authorized in accordance with these Bylaws, and when so affixed, he or she may attest the same;

(d) He or she shall assume that the books, reports, statements, certificates, and other documents and records required by statute are properly kept and filed;

(e) He or she shall have charge of the share books of the corporation and cause the share transfer books to be kept in such manner as to show at any time the amount of the shares of the corporation of each class issued and outstanding, the manner in which and the time when such stock was paid for, the names alphabetically arranged and the addresses of the holders of record thereof, the number of shares held by each holder and time when each became such holder or record; and he or she shall exhibit at all reasonable times to any director, upon application, the original or duplicate share register. He or she shall cause the share book referred to in Section 6.04 hereof to be kept and exhibited at the principal office of the corporation, or at such other place as the Board of Directors shall determine, in the manner and for the purposes provided in such Section;

(f) He or she shall be empowered to sign certificates representing shares of the corporation, the issuance of which shall have been authorized by the Board of Directors; and

(g) He or she shall perform in general all duties incident to the office of secretary and such other duties as are given to him or her by these Bylaws or as from time to time may be assigned to him or her by the Board of Directors or the president.

Section 4.11 <u>The Treasurer</u>. The treasurer shall have the following powers and duties:

(a) He or she shall have charge and supervision over and be responsible for the monies, securities, receipts, and disbursements of the corporation;

(b) He or she shall cause the monies and other valuable effects of the corporation to be deposited in the name and to the credit of the corporation in such banks or trust companies or with such banks or other depositories as shall be selected in accordance with Section 5.03 hereof;

(c) He or she shall cause the monies of the corporation to be disbursed by checks or drafts (signed as provided in Section 5.04 hereof), electronic debits or wire transfers drawn on the authorized depositories of the corporation, and cause to be taken and preserved property vouchers for all monies disbursed;

(d) He or she shall render to the Board of Directors or the president, whenever requested, a statement of the financial condition of the corporation and of all of this transactions as treasurer, and render a full financial report at the annual meeting of the shareholders, if called upon to do so;

(e) He or she shall cause to be kept correct books of account of all the business and transactions of the corporation and exhibit such books to any director on request during business hours;

(f) He or she shall be empowered from time to time to require from all officers or agents of the corporation reports or statements given such information as he or she may desire with respect to any and all financial transactions of the corporation; and

(g) He or she shall perform in general all duties incident to the office of treasurer and such other duties as are given to him or her by these Bylaws or as from time to time may be assigned to him or her by the Board of Directors or the president.

Section 4.12 <u>General Manager</u>. The Board of Directors may employ and appoint a general manager who may, or may not, be one of the officers or directors of the corporation. The general manager, if any shall have the following powers and duties:

(a) He or she shall be the chief executive officer of the corporation and, subject to the directions of the Board of Directors, shall have general charge of the business affairs and property of the corporation and general supervision over its officers, employees, and agents:

(b) He or she shall be charged with the exclusive management of the business of the corporation and of all of its dealings, but at all times subject to the control of the Board of Directors;

(c) Subject to the approval of the Board of Directors or the executive committee, if any, he or she shall employ all employees of the corporation, or delegate such employment to subordinate officers, and shall have authority to discharge any person so employed; and

(d) He or she shall make a report to the president and directors as often as required, setting forth the results of the operations under his or her charge, together with suggestions looking toward improvement and betterment of the condition of the corporation, and shall perform such other duties as the Board of Directors may require.

Section 4.13 <u>Salaries</u>. The salaries and other compensation of the officers of the corporation shall be fixed from time to time by the Board of Directors, except that the Board of Directors may delegate to any person or group of persons the power to fix the salaries or other compensation of any subordinate officers or agents appointed in accordance with the provisions of Section 4.03 hereof. No officer shall be prevented from receiving any such salary or compensation by reason of the fact that he or she is also a director of the corporation.

Section 4.14 <u>Surety Bonds.</u> In case the Board of Directors shall so require, any officer or agent of the corporation shall execute to the corporation a bond in such sums and with such surety or sureties as the Board of Directors may direct, conditioned upon the faithful performance of his or her duties to the corporation, including responsibility for negligence and for the accounting of all property, monies, or securities of the corporation which may come into his or her hands.

ARTICLE V

EXECUTION OF INSTRUMENTS, BORROWING OF MONEY,

AND DEPOSIT OF CORPORATE FUNDS

Section 5.01 <u>Execution of Instruments</u>. Subject to any limitation contained in the Articles of Incorporation or these Bylaws, the president or any vice president or the general manager, if any, may, in the name and on behalf of the corporation, execute and deliver any contract or other instrument authorized in writing by the Board of Directors. The Board of Directors may, subject to any limitation contained in the Articles of Incorporation or in these Bylaws, authorize in writing any officer or agent to execute and deliver any contract or other instrument in the name and on behalf of the corporation; any such authorization may be general or confined to specific instances.

Section 5.02 <u>Loans.</u> No loans or advances shall be contracted on behalf of the corporation, no negotiable paper or other evidence of its obligation under any loan or advance shall be issued in its name, and no property of the corporation shall be mortgaged, pledged, hypothecated, transferred, or conveyed as security for the payment of any loan, advance, indebtedness, or liability of the corporation, unless and except as authorized by the Board of Directors. Any such authorization may be general or confined to specific instances.

Section 5.03 <u>Deposits</u>. All monies of the corporation not otherwise employed shall be deposited from time to time to its credit in such banks and or trust companies or with such bankers or other depositories as the Board of Directors may select, or as from time to time may be selected by any officer or agent authorized to do so by the Board of Directors.

Section 5.04 <u>Checks, Drafts, Etc</u>. All notes, drafts, acceptances, checks, endorsements, and, subject to the provisions of these Bylaws, evidences of indebtedness of the corporation, shall be signed by such officer or officers or such agent or agents of the corporation and in such manner as the Board of Directors from time to time may determine. Endorsements for deposit to the credit of the corporation in any of its duly authorized depositories shall be in such manner as the Board of Directors from time to time may determine.

Section 5.05 <u>Bonds and Debentures</u>. Every bond or debenture issued by the corporation shall be evidenced by an appropriate instrument which shall be signed by the president or a vice president and by the secretary and sealed with the seal of the corporation. The seal may be a facsimile, engraved or printed. Where such bond or debenture is authenticated with the manual signature of an authorized officer of the corporation or other trustee designated by the indenture of trust or other agreement under which such security is issued, the signature of any of the corporation's officers named thereon may be a facsimile. In case any officer who signed, or whose facsimile signature has been used on any such bond or debenture, should cease to be an officer of the corporation for any reason before the same has been delivered by the corporation, such bond or debenture may nevertheless be adopted by the corporation and issued and delivered as through the person who signed it or whose facsimile signature has been used thereon had not ceased to be such officer.

Section 5.06 <u>Sale, Transfer, Etc. of Securities</u>. Sales, transfers, endorsements, and assignments of stocks, bonds, and other securities owned by or standing in the name of the corporation, and the execution and delivery on behalf of the corporation of any and all instruments in writing incident to any such sale, transfer, endorsement, or assignment, shall be effected by the president, or by any vice president, together with the secretary, or by any officer or agent thereunto authorized by the Board of Directors.

Section 5.07 <u>Proxies</u>. Proxies to vote with respect to shares of other corporations owned by or standing in the name of the corporation shall be executed and delivered on behalf of the corporation by the president or any vice president and the secretary or assistant secretary of the corporation, or by any officer or agent thereunder authorized by the Board of Directors.

ARTICLE VI

CAPITAL SHARES

Section 6.01 <u>Share Certificates</u>. Every holder of shares in the corporation shall be entitled to have a certificate, signed by the president or any vice president and the secretary or assistant secretary, and sealed with the seal (which may be a facsimile, engraved or printed) of the corporation, certifying the number and kind, class or series of shares owned by him or her in the corporation; provided, however, that where such a certificate is countersigned by (a) a transfer agent or an assistant transfer agent, or (b) registered by a registrar, the signature of any such president, vice president, secretary, or assistant secretary may be a facsimile. In case any officer who shall have signed, or whose facsimile signature or signatures shall have been used on any such certificate, shall cease to be such officer of the corporation, for any reason, before the delivery of such certificate by the corporation, such certificate may nevertheless be adopted by the corporation and be issued and delivered as though the person who signed it, or whose facsimile signature or signatures shall have been used thereon, has not ceased to be such officer. Certificates representing shares of the corporation shall be in such form as provided by the statutes of the state of incorporation. There shall be entered on the share books of the corporation at the time of issuance of each share, the number of the certificate issued, the name and address of the person owning the shares represented thereby, the number and kind, class or series of such shares, and the date of issuance thereof. Every certificate exchanged or returned to the corporation shall be marked "Canceled" with the date of cancellation.

Section 6.02 <u>Transfer of Shares</u>. Transfers of shares of the corporation shall be made on the books of the corporation by the holder of record thereof, or by his or her attorney thereunto duly authorized by a power of attorney duly executed in writing and filed with the secretary of the corporation or any of its transfer agents, and on surrender of the certificate or certificates, properly endorsed or accompanied by proper instruments of transfer, representing such shares. Except as provided by law, the corporation and transfer agents and registrars, if any, shall be entitled to treat the holder of record of any stock as the absolute owner thereof for all purposes, and accordingly, shall not be bound to recognize any legal, equitable, or other claim to or interest in such shares on the part of any other person whether or not it or they shall have express or other notice thereof.

Section 6.03 <u>Regulations</u>. Subject to the provisions of this Article VI and of the Articles of Incorporation, the Board of Directors may make such rules and regulations as they may deem expedient concerning the issuance, transfer, redemption, and registration of certificates for shares of the corporation.

Section 6.04 <u>Maintenance of Stock Ledger at Principal Place of Business</u>. A share book (or books where more than one kind, class, or series of stock is outstanding) shall be kept at the principal place of business of the corporation, or at such other place as the Board of Directors shall determine, containing the names, alphabetically arranged, of original shareholders of the corporation, their addresses, their interest, the amount paid on their shares, and all transfers thereof and the number and class of shares held by each. Such share books shall at all reasonable hours be subject to inspection by persons entitled by law to inspect the same.

Section 6.05 <u>Transfer Agents and Registrars</u>. The Board of Directors may appoint one or more transfer agents and one or more registrars with respect to the certificates representing shares of the corporation, and may require all such certificates to bear the signature of either or both. The Board of Directors may from time to time define the respective duties of such transfer agents and registrars. No certificate for shares shall be valid until countersigned by a transfer agent, if at the date appearing thereon the corporation had a transfer agent for such shares, and until registered by a registrar, if at such date the corporation had a registrar for such shares.

Section 6.06 <u>Closing of Transfer Books and Fixing of Record Date</u>.

(a) The Board of Directors shall have power to close the share books of the corporation for a period of not to exceed sixty (60) days preceding the date of any meeting of shareholders, or the date for payment of any dividend, or the date for the allotment of rights, or capital shares shall go into effect, or a date in connection with obtaining the consent of shareholders for any purpose.

(b) In lieu of closing the share transfer books as aforesaid, the Board of Directors may fix in advance a date, not exceeding sixty (60) days preceding the date of any meeting of shareholders, or the date for the payment of any dividend, or the date for the allotment of rights, or the date when any change or conversion or exchange of capital shares shall go into effect, or a date in connection with obtaining any such consent, as a record date for the determination of the shareholders entitled to a notice of, and to vote at, any such meeting and any adjournment thereof, or entitled to receive payment of any such dividend, or to any such allotment of rights, or to exercise the rights in respect of any such change, conversion or exchange of capital stock, or to give such consent.

(c) If the share transfer books shall be closed or a record date set for the purpose of determining shareholders entitled to notice of or to vote at a meeting of shareholders, such books shall be closed for, or such record date shall be, at least ten (10) days immediately preceding such meeting.

Section 6.07 <u>Lost or Destroyed Certificates</u>. The corporation may issue a new certificate for shares of the corporation in place of any certificate theretofore issued by it, alleged to have been lost or destroyed, and the Board of Directors may, in its discretion, require the owner of the lost or destroyed certificate or his or her legal representatives, to give the corporation a bond in such form and amount as the Board of Directors may direct, and with such surety or sureties as may be satisfactory to the board, to indemnify the corporation and its transfer agents and registrars, if any, against any claims that may be made against it or any such transfer agent or registrar on account of the issuance of such new certificate. A new certificate may be issued without requiring any bond when, in the judgment of the Board of Directors, it is proper to do so.

Section 6.08 <u>No Limitation on Voting Rights; Limitation on Dissenter's Rights.</u> To the extent permissible under the applicable law of any jurisdiction to which the corporation may become subject by reason of the conduct of business, the ownership of assets, the residence of shareholders, the location of offices or facilities, or any other item, the corporation elects not to be governed by the provisions of any statute that (i) limits, restricts, modified, suspends, terminates, or otherwise affects the rights of any shareholder to cast one vote for each share of common stock registered in the name of such shareholder on the books of the corporation, without regard to whether such shares were acquired directly from the corporation or from any other person and without regard to whether such shareholder has the power to exercise or direct the exercise of voting power over any specific fraction of the shares of common stock of the corporation issued and outstanding or (ii) grants to any shareholder the right to have his or her stock redeemed or purchased by the corporation or any other shareholder on the acquisition by any person or group of persons of shares of the corporation. In particular, to the extent permitted under the laws of the state of incorporation, the corporation elects not to be governed by any such provision, including the provisions of the Nevada Control Share Acquisitions Act, Sections 78.378 to 78.3793, inclusive, of the Nevada Revised Statutes, or any statute of similar effect or tenor.

ARTICLE VII

EXECUTIVE COMMITTEE AND OTHER COMMITTEES

Section 7.01 <u>How Constituted</u>. The Board of Directors may designate an executive committee and such other committees as the Board of Directors may deem appropriate, each of which committees shall consist of two or more directors. Members of the executive committee and of any such other committees shall be designated annually at the annual meeting of the Board of Directors; provided, however, that at any time the Board of Directors may abolish or reconstitute the executive committee or any other committee. Each member of the executive committee and of any other committee shall hold office until his or her successor shall have been designated or until his or her resignation or removal in the manner provided in these Bylaws.

Section 7.02 <u>Powers</u>. During the intervals between meetings of the Board of Directors, the executive committee shall have and may exercise all powers of the Board of Directors in the management of the business and affairs of the corporation, except for the power to fill vacancies in the Board of Directors or to amend these Bylaws, and except for such powers as by law may not be delegated by the Board of Directors to an executive committee.

Section 7.03 <u>Proceedings</u>. The executive committee, and such other committees as may be designated hereunder by the Board of Directors, may fix its own presiding and recording officer or officers, and may meet at such place or places, at such time or times and on such notice (or without notice) as it shall determine from time to time. It will keep a record of its proceedings and shall report such proceedings to the Board of Directors at the meeting of the Board of Directors next following.

Section 7.04 <u>Quorum and Manner of Acting</u>. At all meeting of the executive committee, and of such other committees as may be designated hereunder by the Board of Directors, the presence of members constituting a majority of the total authorized membership of the committee shall be necessary and sufficient to constitute a quorum for the transaction of business, and the act of a majority of the members present at any meeting at which a quorum is present shall be the act of such committee. The members of the executive committee, and of such other committees as may be designated hereunder by the Board of Directors, shall act only as a committee and the individual members thereof shall have no powers as such.

Section 7.05 <u>Resignations</u>. Any member of the executive committee, and of such other committees as may be designated hereunder by the Board of Directors, may resign at any time by delivering a written resignation to either the president, the secretary, or assistant secretary, or to the presiding officer of the committee of which he or she is a member, if any shall have been appointed and shall be in office. Unless otherwise specified herein, such resignation shall take effect on delivery.

Section 7.06 <u>Removal.</u> The Board of Directors may at any time remove any member of the executive committee or of any other committee designated by it hereunder either for or without cause.

Section 7.07 <u>Vacancies</u>. If any vacancies shall occur in the executive committee or of any other committee designated by the Board of Directors hereunder, by reason of disqualification, death, resignation, removal, or otherwise, the remaining members shall, until the filling of such vacancy, constitute the then total authorized membership of the committee and, provided that two or more members are remaining, continue to act. Such vacancy may be filled at any meeting of the Board of Directors.

Section 7.08 <u>Compensation</u>. The Board of Directors may allow a fixed sum and expenses of attendance to any member of the executive committee, or of any other committee designated by it hereunder, who is not an active salaried employee of the corporation for attendance at each meeting of said committee.

ARTICLE VIII

INDEMNIFICATION, INSURANCE, AND

OFFICER AND DIRECTOR CONTRACTS

Section 8.01 <u>Indemnification: Third Party Actions</u>. The corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action, or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he or she is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees) judgments, fines, and amounts paid in settlement actually and reasonably incurred by him or her in connection with any such action, suit or proceeding, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. The termination of any action, suit, or proceeding by judgment, order, settlement, conviction, or upon a plea of nolo contendere or its equivalent, shall not, of itself, create a presumption that the person did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the corporation, and with respect to any criminal action or proceeding, he or she had reasonable cause to believe that his or her conduct was unlawful.

Section 8.02 <u>Indemnification: Corporate Actions</u>. The corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending, or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that he or she is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise, against expenses (including attorneys' fees) actually and reasonably incurred by him or her in connection with the defense or settlement of such action or suit, if he or she acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, except that no indemnification shall be made in respect of any claim, issue, or matter as to which such a person shall have been adjudged to be liable for negligence or misconduct in the performance of his or her duty to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine on application that, despite the adjudication of liability but in view of all circumstances of the case, the person is fairly and reasonably entitled to indemnity for such expenses as the court deems proper.

Section 8.03 <u>Determination.</u> To the extent that a director, officer, employee, or agent of the corporation has been successful on the merits or otherwise in defense of any action, suit, or proceeding referred to in Sections 8.01 and 8.02 hereof, or in defense of any claim, issue, or matter therein, he or she shall be indemnified against expenses (including attorneys' fees) actually and reasonably incurred by him or her in connection therewith. Any other indemnification under Sections 8.01 and 8.02 hereof, shall be made by the corporation upon a determination that indemnification of the officer, director, employee, or agent is proper in the circumstances because he or she has met the applicable standard of conduct set forth in Sections 8.01 and 8.02 hereof. Such determination shall be made either (i) by the Board of Directors by a majority vote of a quorum consisting of directors who were not parties to such action, suit, or proceeding; or (ii) by independent legal counsel on a written opinion; or (iii) by the shareholders by a majority vote of a quorum of shareholders at any meeting duly called for such purpose.

Section 8.04 <u>General Indemnification</u>. The indemnification provided by this Section shall not be deemed exclusive of any other indemnification granted under any provision of any statute, in the corporation's Articles of Incorporation, these Bylaws, agreement, vote of shareholders or disinterested directors, or otherwise, both as to action in his or her official capacity and as to action in another capacity while holding such office, and shall continue as to a person who has ceased to be a director, officer, employee, or agent, and shall inure to the benefit of the heirs and legal representatives of such a person.

Section 8.05 <u>Advances</u>. Expenses incurred in defending a civil or criminal action, suit, or proceeding as contemplated in this Section may be paid by the corporation in advance of the final disposition of such action, suit, or proceeding upon a majority vote of a quorum of the Board of Directors and upon receipt of an undertaking by or on behalf of the director, officers, employee, or agent to repay such amount or amounts unless if it is ultimately determined that he or she is to indemnified by the corporation as authorized by this Section.

Section 8.06 <u>Scope of Indemnification.</u> The indemnification authorized by this Section shall apply to all present and future directors, officers, employees, and agents of the corporation and shall continue as to such persons who ceases to be directors, officers, employees, or agents of the corporation, and shall inure to the benefit of the heirs, executors, and administrators of all such persons and shall be in addition to all other indemnification permitted by law.

8.07. <u>Insurance</u>. The corporation may purchase and maintain insurance on behalf of any person who is or was a director, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another corporation, partnership, joint venture, trust, or other enterprise against any liability asserted against him or her and incurred by him or her in any such capacity, or arising out of his or her status as such, whether or not the corporation would have the power to indemnify him or her against any such liability and under the laws of the state of incorporation, as the same may hereafter be amended or modified.

ARTICLE IX

FISCAL YEAR

The fiscal year of the corporation shall be fixed by resolution of the Board of Directors.

ARTICLE X

DIVIDENDS

The Board of Directors may from time to time declare, and the corporation may pay, dividends on its outstanding shares in the manner and on the terms and conditions provided by the Articles of Incorporation and these Bylaws.

ARTICLE XI

AMENDMENTS

All Bylaws of the corporation, whether adopted by the Board of Directors or the shareholders, shall be subject to amendment, alteration, or repeal, and new Bylaws may be made, except that:

(a) No Bylaws adopted or amended by the shareholders shall be altered or repealed by the Board of Directors.

(b) No Bylaws shall be adopted by the Board of Directors which shall require more than a majority of the voting shares for a quorum at a meeting of shareholders, or more than a majority of the votes cast to constitute action by the shareholders, except where higher percentages are required by law; provided, however that (i) if any Bylaw regulating an impending election of directors is adopted or amended or repealed by the Board of Directors, there shall be set forth in the notice of the next meeting of shareholders for the election of directors, the Bylaws so adopted or amended or repealed, together with a concise statement of the changes made; and (ii) no amendment, alteration or repeal of this Article XI shall be made except by the shareholders.

CERTIFICATE OF SECRETARY

The undersigned does hereby certify that he is the secretary of Liberated Syndication, a corporation duly organized and existing under and by virtue of the laws of the State of Nevada; that the above and foregoing Bylaws of said corporation were duly and regularly adopted as such by the Board of Directors of the corporation at a meeting of the Board of Directors, which was duly and regularly held on the 29th day of September, 2015, and that the above and foregoing Bylaws are now in full force and effect.

DATED THIS 22nd day of January, 2024.

<u>/s/ Larry Powalisz</u> 

Larry Powalisz, Secretary

## Ex-4

**Exhibit 4.2.1**

![](image_015.jpg)

1 \ 1(, : I \ IOF. H S IIIJ ' I NTERl - :ST r URC JI ASE AG R t , F,MJ. ,N T n,is Mcmb.:rSh1p ln1crc.s1 rurclmse Agrccmc11l (the "Ag r ume n t"} is nwdc nnd entered into effective as of July I l , 2024, by : ind hctwccn / \ din l', . utriuon, 1 f 1 c . , n Ncvado corporation (" l' u rch a su"), nnd Kevin Masson ("Masson") and Michael llnncocl : (• Uanc : or 1 ' ") (Ma . �� on and I hmcock being r eferred lo collectively as "Se ll e r "), the owners of niolctc, L r J n Florida hm 11 cd hability compnny (MAcquir ed CtJrporatio n ") . Uuyer, Masson and llnncock aro lhe only p : irties to thi s i \ grccmenl and a 11 ,·"uvc!y referred to herein as the "Parties", and each a " Pa rryr . Purchaser will acquire from Seller 311 of theissuedand outstandingmembership in t erests of Acquired Company, in exchangesolely forshores ofprcfcmxl s t ock of Purchaser (the " Pu rc h aser Pre ferre d Stock") having th e designations, rights and preferences set forth in fahibit A onachcd hereto and mudc a part hereof . Upon the consummation of this Agreement, Acquired Company will bocomca "t 1 olly -- 0 wncd subsidjory of Purchaser . In order to consummate th i s Agreemen t, Purc h aser an d Seller, in consideration of the mutual covenants and on the basis of lhe rcprcscnta 1 ions and warranties set forth, agree : is follows : t. E"changc o r Scc uril'i cs . t .01. Transfe r o f Acq uir e d C ompany 's Membe r.s hip I nt e r ests. Subject l o the tcnnsand conditionsof thisAgreement, each of Mas;,on and Ilnncock will transfer and deliver 10 Pureh:iser, on o r before tl1e C l osing Date, certificates. or other indicia of ownership, representing I00% of the membership interests (lbe " A cq u ired lnt acst.s") of Acquired Company. 1 . 02 . Co n sideration for Tran s f er . In exchangeforthe Acquired lntcrcslSofMasson and HancockpW'Suanllo paragrnph 1 . 01 , Purchaser will i ss ue nnd cause to be delivered to Mosson and Hancock, on the Closing Date, a 101 al of 1 , 750 , 000 shares or Purchaser Preferred Stock, as follows : Name # or Sbartt or Purcbiuu Prrfrrr

![](image_016.jpg)

'I 2.0.$, Finaocul Statcme.nts. Purchaser ac lmowlcd gcs 1 ccc1r 1 of Arqmrcd Company's unau,.htcd lin.inc1.&I ,tatcmc:r,1, w1cc inu.1'l1on (the "I inanriof S111fl!mt!nt Dolt'") l. OS. Opera ti ons !)Inc e f/i1111nrlol S t atement 0 11tc. S1nt,c the Financia l Statement l)atc, Acquired C'ompJJ'ly h.1, nut,Jlld prio r 10 the Uo � ing Date ,,,11 nn t ha � c, w,lllout wnllcn co n , or waived any rightsof s ubstmliol volue; (I) Sold, nssign< - '*. r I l' A<.t. !*

![](image_017.jpg)

I 2.08. lmkl>tcJoC' \ s. (a) Auiurrcd Company p!'t!,Cntly ha � no outstanding indcbtcdnc, ;. , other tlurn hRh 1 li 11 cq incurred in rhe o � unl and ordinal) conrsc of hu � inc,,s . Acquired Company i � not in default with rc � pccl ro nny lcrm � or cundrtion \ < f hl'IY 1 r J . ,tcdnch (b) Acquired Company ha:i not made any � s1gnrncn1 for the benefit or crcdllor;, nor ha, any anvolun 1:uy or \ ',,!unlJtY pc1irion in b:mkruptcy been filed by or agninst Acquired Company. 2.09. Litigatio n. (11) Acquired Company i � not party 10 , nor ha s it been threatened with, any litigati o n or govemmcnr . il proc«ding . Aci . 1 uirell Com 1 iany is not aware of any facts that might result in nny action, suit or o t her procccding that would rc � ull in any m . 11 cri,if advcrn : change in 1 J 1 c business or financial comlilion o f Acquired Company . (b) Acquired Company is not infringing on, or otherwise a cli n gadvcrsdyto, anycopyright �. trademark ngh �. p . ,tcnl righl �,lr licenses owne d by uny other person, and there is no pending claim or threatened acuon with respect to such nghl 'I . AC

![](image_018.jpg)

2.12. C h11ni::,..., in Co111penw1io n . Since the Fin:mciol Sl.itcmcnl Dale, Acquired Company ha � not granlcd any gcncr.il pay incn - ,a,c 1u cmployt:cs or chnngcd lhc rale of compcn.su1io11, commi �� ion or bonUJ pnyablc to any officer, employee, director . agcnl or ,h.m: h o ld l"!'. 2 . 1 J . � l'Conu . All oflhc account books,minute books, stock ccrt,fi � tc books and stock tran � fcr led ger � of Acq 1111 cd Company arc comp lete and accurate . 2 . 14 . Tuus . P'tccpl as described in Schedule 2 . 14 attached here t o and made a part hereof, Acquired Compaoy h , i_ � filed all required income twc returns as oftl 1 c dateof this Agreement . Acquired Company owes no income taxes . 2 . 1 S . Full Ui � clo � urc . As of the Closing Date, Seller will, and will have caused Acquired Company to, have disdo,ixl all cv 1 .. - nts , conditions and facts materially affecting the business and prospects of Acquired Company . Ne i ther Seller nor Acquired Company h : t � withheld knowledge of anyevents, co n ditions and facts that it has reasonable ground to know may materially afTcct the business and prospects of Acquired Comp any . None of the representationsand warranties made by Seller in this Agreement, or se t forth in any other instrument furnished to Purchaser, containany untrue statement of a mate ri al fact, fail 10 state materia l fuetsor fai l 10 state foe � llCCCMal)' to make the statements of foci made not misleading . 16. Ow n ershi p of A cqui red I nterests . C : lch of Masson and Hancock is, on the dote of this Agreement, and on theClosing Da 1 e will be, the lawful owner of the Acquired Interests lhot is sci forth opposite their respective names in par - . igraph . 0 I of this Agn . - cmcnt . f'ach of Masson and I lancock has the leglll right and power to sell, assign and transfer Uic Acquired Interests . T h e dehvery oftl 1 e Acquired Inter ests to Purehnsc : r pursuan 1 to the pro visions of this Agreement will transfer valid liUc 10 the shares free un d clear of all liens,encumbrances, claims and other restrictions of any kind . 17. Waivero f P reemptive Rights ; No Ri g h uofRefusa l . Each of Masson and Ilnncock haswa 1 vcd,and docshereby waive, any preemptive o r prescrip tiv e right 10 purchase any membership inlcrcsls of Acquired Company that each of Masson and I lanoock has or may hove bad in tl 1 e past Ncilhcr Mas s on nor Hancock i s subject to a right offirsl refusal as to h!S Acquired ln 1 cr csts 18. No Brokers o r F in d ers . All negotiations related to lhis Agreement on the part ofScUcr have been accumph � hcd solely by Seller without the assisl!lnec of any person employed as a broker or lindcr . Seller has done anything 10 give rise to any va lid claims against Purchaser or Acquired Company fora brokerage commission, finder's feeo r any similar charge . 3 . RcprC'scntnlions and \ \ ' an - natic . � of Purchaser . 3 . 0 I . Securities Act Di sclos u re - In formation Wi th Respect to Pur chaser . Purchaser filesannual and other periodic reports with OTC Madccis (www . olcnurkcts . com) . The periodic reports, as filed wiU, the OTC Markets by Purchaser, arc incorporotcd herein by this reference . Purchnser rcprcscnls und w : uranls thal tile information contained in the documents incorporated by reference acc urately rencc � its businc • s operations : ind current financial condition . 2. Organization nnd Standing or Purchaser . Purchaser is a corporation du l y organi 2 . Cd, validly existing and in good standing under !he law s oflhcState ofNevada, with corporate power to ownproperty andcarryon ils business as it is now being con ducted . 3. Subsidfarics . Purchaserhas no subsidiaries nor nny inlcrcst inanyotbercorporation, firm. p:i.rtocrship or other juridical entity. 4. Capilalimtion . Purchaser has nn authorized cnpitnlizalion of (a) 800 , 000 , 000 shares of commo n stock (nominally referred to in 1 hc Comp an y' s Articles oflncorporationas "Class, \ Common Stock," which the Company refers to as "Commo n S 1 ock"), S . 001 par value per share, (b) I 00 , 000 , 000 shares of Class B Common Stock, S . 001 par vnlue pcr share . and (3) 100 , 000 , 00 0 shares of pn : f crrcd s 10 ck, S . 00 · 1 par value per share, of which (I) one share is designated Spccinl 2022 Series A Preferred Stock, (2) I 0 , 000 , 000 sha re s arc designated Series A Preferred Stock and (3) 89 , 999 , 999 shares arc designated SeriesC Preferred Sto .: k . A . � oflhcdate of thi s Agreement, there were R 7 ,!! 99 , 8 6 I shares of common stock is � ucd and 0111 !,tnnding ; l'Cl"O share, ofCln � s B Common Ste - ck J � issued and outstanding : one sb : i . rc of Special 2022 Series A Preferred S 1 ock issued and ouistanding : 10 , 000 , 000 sh . arcs of Series, ? re ferred Stock i ssued and outstanding ; and zero shares of Series C Prefcm : d Stock issued and oulSt : mding, Ex . ccp t as set forth in Schedule 3 . 04 ana .: hcd hereto and made a part hereof . tl 1 cre arc no oulslandini, : option s . contracts, calls, commitments or d � mands rel ating 1 0 the aull,ori . rcd but unissucd capit . ,I stock of Purchaser . 3 . 05 . Financial Stateme n ts . Acopy of Purchaser's urn 1 udiced financial � tatemcnts for theperiod ended March JI . 202 4 , nrc a, , nilablc al www . otcmarkcts . com and : ire made a part hereof . The linnneinl smlcmcnlS listed in Ibis paragr - . iph 3 . 05 prc scn 1 t : mly the financial condition of Purchaser as oflhe date thereof .

![](image_019.jpg)

6. Hoaocl : 11 Co ndition Since Muth JI, 1014 . Smee Ma . rcb 3 1 , 2024 , Purchnscr has not made dn)' lr . lll 5 f< • of an y of us o p, . ·rn u 11 g asscLs other than in the ordin : iry cour .; c ofbusmcs • . 7. Tille In Assets . All book ,J . ssets of rurclm � cr arc in cxi � t cncc nnd in its pos 5 c_ssion, arc in g ood rn nd 1 t 1 on ur cl repa ir nnd c onform 10 nll npplicnblclaw s , rcgulo 1 ions ondordinances . Purchaser ha ..• good und marketable ti Ile to ullof i ts n • , ; et< nn d ho l , J � suc h n,w thedateof this A1,'Tcemcnt unt il consummation hereof , full n ecessd uringn orrnal business hours 10 all pro penics. books, ae ee> l11tli<. co n 1.r.1c is , commitments andany other records of any kind of A e quircd Co mpany . Sufficient access sha ll be allowed t o provide l'un,hascr w1t h ful l opponunily 10 m:ikc nny invcs1ig:uion it de s ire s to make of Acq uired Company and to keep itself lillly infonned of it,, a ffa i n. . w S H AR}; P URClf, \ J,F \ GR.[nn :. ,"T I Pi \ Cl : s I I I

![](image_020.jpg)

(b) In nddtlion, Se ll cr s hall. ond shall cause Acquired Company to, ,x;rm11 l'ur � h �,c.:r tu m a l<.e c:xlJ.icts u u r , pu • of , 1 11 �11 . - h � wi.,. :ic:c<>unts c , u nuact �.com1111lmcn1, and rcoord,. lllld 10 fomi � h lo f>urcho.sc r , on demand, ony furthcr lirta11c1al andopcraung d . iLI of Ac< 11 un : d Comp 3 ny ns l'urcha . _ - ,cr reasonably IUJUC! . l, . (c) l'urch 3 Sa - \ \ 111 useanyinfol'llUl l 1 on oblamcd unJcr lh 1 s paragraph only for it , o wn � i n t onn(tt 11 , n wit h th e l·o 11 �111 nn 1 Jtionof the tran,action conh :. ·mplotcd by this Agreemen t, and will noldivulge the mfonT 1 Jt 1011 tuany o thn pc r,on Inth e ' " cn t th e rmns . 1 ct 1 nn contcmplntcd by this Agreemen t is n o t co n . ,ummntcd wi tl 11 n ninety(90)doys ol thedote of mutua c l x c u· t 1 u n . JIIdo c um e n t . or mfomuuon g . 1 l 11 crcd by l'u . rch= hcrcunda - will be returned to i \ cqu 1 rcd Company forthwith, unle 5 S ,uch pcno,d , II be ext . ended by mu tu a l cons . ent 4.04. Nc1tati \ 'CCov enaotJ . Except wi th the prior writtc11 consent of Purchu.,er, Seller shall cause A _ cqu1r �, l< .:t, mp an y notto : (a) Incur any l i3b1litics, otl1CT than curre nt li ab il ities incurred in the usual and ordinary cour..cofbu. \ 1ne �; (b) Incur any mo rt gage, l i en, pledge, hypothccation,charge, cncu.mbrancc or n:su,ctJoo of anykind . (c) Occo 111 c o p arty t o MY co ntract, or renew, exte n d or m odi f y any exis t i n g controcl, exce p t m th e usual and onlin : iry coul"IC of business : (d) Mnkc any capital e x penditures, except forordin.uy repairs, maintenance and rcpl:lCCtncnt: (c) Declnrc or pay:mydividend, o r make an y other distribution, to shareho l ders; (f) l'urch3SC, retire or rcdccm nny sbartl> of its capital stoclc: (g) l \ � ue or sell :iny warrants, righbor options t o acquire any shares of its capital stock; (h) Amend its Articles of locori><>ration o r B ylaw �; (i) Pa) or agn : c top . iy anybonus, increase in comJlC 11 salion,pensio n o r severance p .; y to any d r,cctor, � harcholdcr, officer , consult . "lnt, agc : nt or employee ; (j) Di, ; ehargc o r satisfy nny l ienorencumbrance, nor payanyobligation or liability, c)(ccptcurrent liabi l ities shown on the Fil 13 Jlc 1 al Statement dntcd March 3 1 . 2024 , or incurred in the usua l and ordinary course of business since that d a te, (k) Merge or con.'iOlidatc with w1y ulhcr entity: (I) Unta - into any transactions or tal< . c anyacts tllilt would constit \ Jte a breach oftl 1 e representations Md w : irmntics conl 3 incd in thl! . \ grccmcnt ; and (m) ln \ titutc. settle,or agree lO settle, any nction or proceeding before any court or governmenta l body . 4 . 0 5. Cons ull n ti o n. Acq u ired Company will consult with Purchaser at a .II time,; until the Closing Date wit11 r espec t to the operation and conduct of Acquired Company's business. 5 . Conduct o f B u siness o f P urc h :i � cr P cn itin g C l osing D a t e. 5.0 I. Co nd uct o f Bu s ine ss in I ts O rdin ary Co ur se. Purchase r wi ll carry on its business in subst.10ti:illy tlic some manner ns before the dntc of execution oflhi � AgrccmcnL 2. Satis f y Con d i t io n s Pr e c e d e n t . Purcbnscr will use it:. best efforts 10 satisfy aU conditions precedent contamcd m tlu � Agn:cmenl. 3. Access t o I nfo rm a ti o n on d D oc um e nt �. (a) Pu . rchascr : will provide Seller, from thed ; itcofth � Agreement until theco � ummatioo m . TCOI , lull acc � s dunni ; normal business hours to all properties . books . accounts, contraets, comm 1 lmcnts and records of Purchaser . Sufficient ac,c ss shall b .: allowed to provide Selle r \ vi lh fiJ II oppo rtu ni t y to make any invcstigotion t hey desi r e 10 m : ikc of Purch . iscr and t o keep th c m - . c vcs full \ informed oflhe affairs of Purchnscr . SJlAR f. PU R C'U \ $t: . \ CRft , 1r,, I P \ Lf I>

![](image_021.jpg)

(h) l'urdw,, .; r wrll l"TI 11 Jl Sclh . "T to m .• kc c � lm is or c . op 1 cJ of all hook,, account!<, tontnllS, comrr :• 'mcnL, and r« : onl , s \ , . khtJ<>n � lly, l' � ha Seller . , � ilhm lhn : c (3)d, 1 ys utter dcn � m11contcmph1lcu by this 1 \ 11n. - c111cnt.01111 will 1101 divulge the 111fnmu1ior, Inm,, oth � r �• .,,n In11,cc:vcnl thc lrJn,.1c11on rnntcmplJtcu hcrchy is not wn. � u1111n.1h,:d wuhrn ntncty (\ 10) day5 ol the date of rnut � JI e,etut,,,n, ,11 dr 11r11c1th w infom1.1hon plhct �- d hy Seller hereunder will he retumc:d to l 'urchuscr lorlhw1U1, unlt:!1 � such 11eriod shall l1e �'llltnd• ,I hy m111u.1I \ ing Oate . f>urch �- r � hoJI ha,e pcrfonncd all obligations and complied with all covenants required by this Agrccmcnt to be pcrformcd or tQmpl 1 c : d " 1 th by 1 t pnor 10 the Clo 5 ing 0 Jte . Purehol!>er sh 311 deliver to Seller : , ccrtifi � te . , in the fonn of P .. xhibit 6 . 02 auachcd hereto and made a pa . rt ha, :: nf . datoo : isoflhc Closing Date : ind signed by the C h ief Executive O ffi ce r of Purcha . - er, certifying the truth of the rcprcscntnuons 11 nd "arr : 1 nt 1 cs . 3. o R � trl ctinn, . No action or proceeding by nny governmental body or agency shall have been thrca1cncd ..._,scru:d or instituted to prohibit the conswnmat . ion of the trnnsaetion � contcmpl21cd herein. 6. Conditions P rc«dc nt toObligalions or Purc b ,uu. 7.0 I. Conditioni P r rccdc n t to C l oQnJ:. ·1 he obhcruions of Purch:iscrto consununatc this Agreement ureh:t,cr a cet111ic:itc, in the form ofP � hibi t 7.02 :itt:u:hcd hcn:10 and made :i part hereof.d3tcu the Clos mg Date and signed by each ofMa � n and I l oncoclc.cc11ifying the truth of the n:p � n1:1tion.s :ind \ \ '3l'T:IO Ii C$, 3. Retention o r M11n11:emcnl. Thcpn:.,cnt management pcrsoMclof Acquired Company shall �'Dl:lin irtofficc,ubscqucnt to the Closing and w11il their c:irlicr n:.sign.11ion or rcmo \ 'al. 7.04. No Restriction<. No :iclionor procecdioi; by anygovcmmcnl:11 bodyor ngency sJiall be thrc.itc:ncd, :i:;scrtoo or iiutitutcd th:tt prolubtts the con � w:nrnation of the trnns:iction• contcmplnlcd herein. 7.05. No Con t ract, Tc rm i nGt c d . Acquired Company shall not hJvc1,nninatcd any contracts pnor to ll1c Closing 0Jtc lhat. m lhc Jg.l,'ni, - Ic, "ould nutcn:illy nnd ad,"t:=ly "ffcct its bw.,ncs �. 7.0b. ' \ o l)am,11:e lo M,sct•. At tlteClosing Date.the machinery,equipment, invcn1oryor other tangible property of Acquired Company ,h311 not bc

![](image_022.jpg)

!1.02. lml c mnlficatlon hy Scllrr.Seller ,grcc!I IU 1111k111r11ly tmd huh.J Purcl wwr, 1Ls ufliur �.•r. � nl, And auon,n, l1J1mli:s., onn th � date of thi \ Arr, - cmcnt m respect 1 0 any darn Jgcs QS defined 111 1111 � r:irnr,raph 11.02 D:un ai;.,;a, .is ustd m Ill• r �1 - 1 ;:raph, wit indu,lc nny claim. a1.hon, Jcn1.111d, fo!,.", w,t. expense, liab1ltly. p.:n rhy nnd other d:irnae,c. rncluJm,•. but not hm,tcd lo, nu,imcy's fees ,nd other cosh rmd cxpcn,cs1111.uncd nuc n,plm g to ovoid d,rn ugc., or m enfore mll th ! \ mdcrnmty, rc,uh.11tl lo Purchil er lrom· (a) An) m .1 leri11lly 1r=urn1e rcprescnU&11 o n mode by Seller 111, or pwsuant to, th• � Ay,,ccr ,c:r,1. (h) Ma1crial breach ofany of thewumrntics by Seller in, or pursuant t o, !hi � Agnxmen l, or (c) Mn t criJI bn:ach or defaul t of any of the obhgations to be performed by Seller under thu A&rtcncnL Seller , as u . cd in 1111 s paragraph, � hall include Jny cl ;: urn . a � l 1 on, 1 kmand, lo :. !>,cost, c : xpcn,c, li ab 1 hty . penalty and otherdam : lge, including . bul not limited to , attorney's fees and othercosts and expenses in curred n 11 cmp 1 ing t o ovoid damages or in enforcing this indcn,nity, r esu lt ing lO Seller from : (a) Any m.i1erially1n:ICC'Ur.llc rcprcscnta11on mndc by. o r on behalf of. Purchaser in, or pursuant to, t his \ grccmcn l; (b) M a terial brea c h of nny¼':lrrnnty by Purchaser in, or pursu:int to, this Agrc,cm cnt, or (c) Material hrc:ich or default of any of the obligations to be performed by P urchaser under lhi, AgrcemaiL Purch= shnll be l \ !quircd 10 reimburseSeller fo r ony payment madeor l o - tSs uffered by Selle r, at any umc nncr theClo, in g Date, b.t. � cd ,,n the Judgment of any arbitrator or :ury court of competen tJuri - .di etio n or pursuant to a bon:i fide compromise or • 1 1lcmen1of cl:um, dcmmJs or ac11ons with respect 10 any damages d C$CTlbcd in 1h1 1 p:iragr.i ph. 8.0 - 1. l::J:ptn \ <'S. Seller , in cluJmg Acq uired Comp:my, shall paya ll ofthci ro wn c:xpcn,;cs incurred hy them an· ,ng ou1 ofthrs Ai;11. - cm �,il an d the lr1ln."3C t ions con1cm pla1 ed in this Agreement, inc ludmg, but not limited to, all fee, andnpcn..cs,,f 1hc1r co1m - cl and .1ccoun1an ts . W hether or 001 lllis Agreement 1s1crmin a 1 cd, c.,ch oflhc p.lll1cs sha ll bear all of their rcspcciJ � e exp=, incurred by them m C< : ddl \ \ . 'fcJ to Seller p u . r .. o : 1 n 1 to this 1 \ grccmcn 1 hJve not been rcg"lcn : d under 1 h c Securities Act of 1 933 , a, . micntkd (the " 1 933 , \ ct'") . and th . it , therefore, the shores of Purch a � cr Preferred Stock ru - c not tr . msferable, except as pcrrui 1 tcd unde r \ annus cxcmptron � conr . , : ncJ in th �1933 Acl and the Rules of the Sccuri 1 ics and Exchange Commi - . sion under the 1933 AcL The provisions cont . lim : d m lhil . p . imi ;: r . iph 9 . 0 I arc in!A : nd � d t o e nsure compliance \ \ 1 th the I IJ 33 Act . 2. , • o Di \ lribu l ion of Stock t o Public . Seller represent< an d warrants to Purch 35 Cr that Seller 1 < acquinng the � hare< ; of Ille run : ha .. ucd to Selle r pur..uanl o th i � Agreement "'ill be ulT1:rcd, so ld, a,, - ,igncJ. plcJ :. - l.1r.1n,fcrr.. - J or othm.,1 � d1sro• - c:J oi: c � ccrt .i/1cr full cornph311CC w ith all of the npp!icable provision, oftl1c 1933 Act an d lhc rules and regula1., n, ol the Securuics Jnd I � change Cornmi \ ,ion under 1hc 1 933 AcL ' I herefore, Seller ai;rcc � no t 10 se ll o r otl,cnvi,c dispose of any of the \ h.1n: � of the l'ul"l:hJscr Preferred Stock r i:cc1vcJ pur,;uant lo llus A greemen t. unlcs· Setler: (a) I las d chvercd to Pur c; h a - .c ra wrill,n l ega l ori ni o n m form JOd ,ub,tancc ,.;i1i - ,f.1c1ory 10 coun \ Cl for Pun:ha.,cr. lo 1hc effect t hJt lhc dJspos1 1 1on i � permissible under the t erms of the IIJU Act and regula11oru. under the 1933 Act; �

![](image_023.jpg)

(b) J Jaq comphcJ with the n:g � lnlllon onfR ntf. SiC:L'RITll - .:>ACTOF 19)) . AS AMENDPD . AND IIAVB DCEN TAKl!N fOR JNVESlMENT . nm SF . CURmtS MAY NOT Rf SOI O (JR OAT . RED FOR SAUHJJ \ 11 . ! : SS A Rr . GISTKA 110 N S TATF . M I NT UNDr R TIIE FE'l)FRAL srCURITTES ACT OF I 93), AS AMf . Nl)l : D, · � IN Ef"'FfC"'T ASTO TIIFSEC 1 JRITIF . S . O R AN l : XrMl'TION F'RO \ I nrr RCC - JSTRATION R[QUIREMENTS 01 !>LC"II AC T IS IN FA< ; f APPUC \ Oil?TOSUC H OFFCR OR SAU �" 9 . 05 In de mnifi c ati o n b y Sdlcr . If, nt nny time in the future . Seller sells or otherwise disposes of nny of the shares of Purchru,cr Preferred Stock in violation of the provisions of the 1933 Act or the Rules and Regulations oflhe Securities Md Exchange Commission promulgated lhcreumlcr, or nny similnr fcdcm l ur st . lite haw, rule or rc 1 ,,ulation that may th �- n be in effect, Scllt . r agrees lO indemnify and hold h : irmlcss Purcl 1 o . scngo 1 nstony cl : iirru . habihlics . penalties,costsande • pcnscs that may be ns � cd ogoin � t or � uffcred by Purch= 3 S a R'Sllh ofsuch disposition . 10. Termination. 1. U cfaul L Purchaser or Seller, acting 3 S a group, may, by wriuen notice, on or al ony time prior lo t . 1 , CIO'iing Date, 1 cnnina 1 c this 1 \ gn : cmcnt by notice to !be other p : irty in the event : (a) One party hns determined th.it any material fl.j)rcscnblion of the other pany is untrue; (b) The other party 113s defaulted under the Agrocmcnt byfailing to perform any of il.5CO \ cnnnl.5 and a � ments coniamcd in thu, Agn:cmc:n t . ; and (c) Each default has not been fully cured "ilhin tJm:c(3) days afterreceipt of the notice specifying parucularly the nature of the dc1aulL 2. D cllly . If consurnrn . uion of the tr : ins . iction specified in this Agreement bas not occum : d by 11 : 59 p . m .. Eastern Time, on July 31 . 2024 , : my p : irty that is not in default 10 the timely performance of any of its covcnants and conditions may terrrunale this Agreement subsequent to that time by giving wriucn notice oflcrminarion 10 the other party . The Wlincn notice oftcrmmalion shall be effective upon rhc delivery of the notice in pen . on to an officerof the partyor, if served by mail o r overnight courier, upon the receipt of lhc notice by such party . 3. Dama :: c or Loss - Ac quired Com p ouy . Purchascrmny, al its option, tcnninntcIbis Agreement priorlO tJicClosing Date, if Acquin . - d Comp .: iny has � uffcrcd : my damage, destruction or loss (\ \ hCthcr or not CO \ - crcd by in . rur . incc) rhat 11 l 31 Crially and acherscly affec 1 s the property, business or financial condition of Acquired Comp ; llly . Daamgc, destruction or lo :; s � hall be considered materially and Jdvcr . ely lo affect tJ 1 c propcnics, bu � incss or financial condition of Acquin : d Company if 1 hc book or market value (whichever is lower) of the as � clS damaged, d 1 . - < ; troycd or lo � t exceeds ten percent (I 0 %) io book or market value (whichever is lo"cr)ofallo � sels of Acquired Comrany . I 0.04. Oam:i J!c o r L on - Purcho sc r. Seller,:it ib opuon, term mate tl1isAgreement prior 10 the Closmi; Date, 11' Purchaser has ,ulTcrcJ .inydmn:igc, destruction or los,. (\ \ hcther or not covered by insurance)1hn t nuterfally and :idvcrscly affects 1he propcn}. busin= or fin,mcial condition uf Purchaser. Damage, destruc t ion or l<1ss shall be considered rnatcriully and adversely t o aJTcct the prupcnics. businc � s o r financial condition of Purchaser i f the book or marke t value (whichever is lower) of th e OSSCIS dnn1ag � d � troyeJ or loM c � cccd � ten percent (10%) m book or market value (\ \ - hicbcvcr is lower) of all a � scb of Purchaser. S II AltE P URC!IA.'> • . \ GREt " \ tt:." \ "T PALF 9

![](image_024.jpg)

11. ;'lfaccllancous. 1. l'ublic Anno un cement,. l'urchnser,hall have theexclusive right to 1ssueoneore more prl:.'I � release.. 1 thcrv. - uc 1mlce :mypubhcstate mcnts wil11rcs �- ct 1 0 l11eexis1.:nceof1his i \ grccmcntor1hclrnnsuc11onseon1cmplotedherein. provided, how � that Seller � lull ha,c the right to prc - opprovc any such press release or public statements, w h ich approva l shall not be unrcaw11.1bly ....ihhcld l 1.0 2. Amendm e nts. Tiiis i \ grcemcnt m.1y be amended or modified at any time and in any manner only by an mstrumeot m \ \ Tilin& C" t · \ C,Rn \ It, T I l" \ GI 10

![](image_025.jpg)

(n) l fto r urc h a � cr. 4421 Gabriell., Lane, Winter Park, I l ondo 32792. lfto M.1S50n. Kenn \ .1nsson, 1520 T win Oaks t1rclc.Oviedo, rlorida 32765. (b) (c) tr to ll ruicock: Mi c h 3c l ll ancock, 43 IJ WyndcliffCirclc,Orlando, florid �32817. I 1.07. l'arni:rnp h Il eadings . l'lll'Ogmph nud othe r hcndmgs conlnmcd in tlu s Agreem e nt arc for reference pur pv,Q only and ,lull not .iffcx.'1 in :my w.iy the m.:aning o r interpretation of this Agn: emcnL l I . 08 . Entire Ag r ccmc nL This i nstrument and thecx hi biL \ to this i nstrument contain theentire o grc : cmcnt hl . 1 wccn th e pJrtic, " ,th respect to the trans . ictio n contemplated by this Agreement . It may be execu t ed in MY number of counterparts, but th, : aggregate of thecountcrpans together constitute only one and tl 1 c s : imc instrumenL I I .09. E ff ect o f P a rti a l l n v a l id i t y . In theevent tha t any one or more of the provisions conl:lincd in this A gn:c:rncnt � hall for any reaso n be held 10 be i nvalid , illegal or unenforceable in any respect, s uch invalidiry, illeg11lity or uncnforccability shall r "t affect any other provisions of tl1is Agreement, but this Agreement shall be constructed :u if it never contained any such inval

## Ex-4

**Exhibit 4.2.2**

**MEMBERSHIP INTEREST PURCHASE AGREEMENT**

This Membership Interest Purchase Agreement ("Agreement") is made as of the 24th day of September, 2024, by and between Cement Factory, LLC, a Florida limited liability company (the ***"Company"),*** and Adia Nutrition, Inc., a Nevada corporation ***("Investor").***

 ****

<u>RECITALS</u>

**WHEREAS,** Investor is a publicly-traded company (trading symbol: ADIA); and

**WHEREAS,** The Company is an established purveyor of nutritional supplements; and

**WHEREAS,** Investor wishes to purchase from the Company, and the Company wishes to sell and issue to Investor, a eighteen percent (18%) membership interest in the Company (the ***"Subject Interest"),*** for certain securities of Investor, upon the terms and conditions set forth in the Agreement.

**NOW, THEREFORE,** in consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1. Definitions.** In addition to those terms defined above and elsewhere in this Agreement, for the purposes of this Agreement, the following terms shall have the meanings set forth below:

***"1933 Act"*** means the Securities Act of 1933, as amended, or any successor statute, and the rules and regulations promulgated thereunder.

***"Affiliate"*** means, with respect to any Person, any other Person which directly or indirectly through one or more intermediaries Controls, is controlled by, or is under common control with, such Person.

***"Business Day"*** means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general transaction of business.

***"Closing"*** has the meaning set forth in Section 3.

***"Closing Date"*** has the meaning set forth in Section 3.

***"Company's Knowledge"*** means the actual knowledge of the managers of the Company.

***"Control"*** (including the terms "controlling", "controlled by" or "under common control with") means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the ownership of voting securities, by contract or otherwise.

***"Investor's Knowledge"*** means the actual knowledge of Larry Powalisz, the current Chief Executive Officer of the Company.

***"Investor Securities"*** means 1,875,000 shares of preferred stock having the designations, rights and preferences set forth in <u>Exhibit A</u> attached hereto and made a part hereof.

***"LLC Agreement"*** means the Operating Agreement of the Company, a copy of which is attached hereto as <u>Exhibit B.</u>

***"Material Adverse Effect"*** means a material adverse effect on (i) the assets, liabilities, results of operations, condition (financial or otherwise), business, or prospects of the Company or Investor, as the case may be, or (ii) the ability of the Company or Investor, as the case may be, to perform its obligations under the Transaction Documents.

***"Person"*** means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein.

***"Purchase Price"*** means the Investor Securities.

***"Referral Agreement"*** means the Sales Referral Agreement between the Company and Investor, in the form of <u>Exhibit C</u> attached hereto.

***"Subject Interest"*** has the meaning set forth in the Recitals of this Agreement.

***"Transaction Documents"*** means this Agreement and any document executed in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2. Purchase and Issuance of the Subject Interest.** Subject to the terms and conditions of this Agreement, on the Closing Date, Investor shall purchase, and the Company shall sell and issue to Investor, the Subject Interest, in exchange for the Purchase Price.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3. Closing.** Within three (3) Business Days of the date of mutual execution of this Agreement, Investor shall deliver evidence of the Company's ownership of the Investor Securities, the Purchase Price, and the Company shall deliver evidence of investor's ownership of the Subject Interest ***("Closing"*** or ***"Closing Date").*** The Closing shall occur upon confirmation that the conditions to Closing in Section 7 hereof have been satisfied. The Closing of the purchase and sale of the Subject Interest shall be deemed to have occurred upon completion of the deliveries required of the Company and Investor in the foregoing sentence.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4. Further Agreements.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.01. LLC Agreement.** As further consideration for the Company's entering into this Agreement, the LLC Agreement shall have been duly executed by Investor at or prior to Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.02. Referral Agreement.** As further consideration for Investor's entering into this Agreement, the Referral Agreement shall have been duly executed by the Company at or prior to Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5. Representations and Warranties of the Company.** The Company hereby represents and warrants to Investor that, except as set forth in the schedules and exhibits delivered herewith:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.01 Organization, Good Standing and Qualification.** The Company is a limited liability company organized, validly existing and in good standing under the laws of the State of Florida and has all requisite power and authority to carry on its business as now conducted and to own its properties. The Company is duly qualified to do business as a foreign entity and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary, unless the failure to so qualify has not had and could not reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.02 Authorization.** The Company has full power and authority and has taken all requisite action on the part of the Company, its officers, managers and directors necessary for (a) the authorization, execution and delivery of the Transaction Documents, (b) the authorization of the performance of all obligations of the Company hereunder or thereunder and (c) the authorization, issuance and delivery of the Subject Interest. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors' rights generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.03 Capitalization.** <u>Schedule 5.03</u> sets forth the capitalization of the Company immediately following the consummation of this Agreement. There are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the Company is or may be obligated to issue any equity securities of any kind and, except as contemplated by this Agreement, the Company is not currently in negotiations for the issuance of any equity securities of any kind. Except as described in <u>Schedule 5.03</u>, there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among the Company and any of the security holders of the Company relating to securities of the Company held by them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.04 Valid Issuance.** Upon the Closing, the Subject Interest shall have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and non-assessable, and shall be free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.05 Consents.** The execution, delivery and performance by the Company require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to relevant state and federal securities laws which the Company undertakes to file within the applicable time periods. Subject to the accuracy of the representations and warranties of Investor set forth in Section 6 hereof, the Company has taken all action necessary to exempt the issuance and sale of the Subject Interest from registration under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.06 Delivery of Information.** Included in <u>Schedule 5.06</u> hereto is all pertinent information regarding the Company, including its properties and its financial condition, as well as all information regarding the Building currently in the possession of the Company and its managers.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.07 No Conflict, Breach, Violation or Default.** The execution, delivery and performance of the Transaction Documents by the Company will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (a) the Company's Articles of Organization or the Company's Operating Agreement, both as in effect on the date hereof (true and complete copies of which have been made available to Investor), or (b)(i) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over the Company or any of its assets or properties, or (ii) any agreement or instrument to which the Company is a party or by which the Company is bound or to which any of its assets or properties is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.08 Tax Matters.** The Company has timely prepared and filed all tax returns required to have been filed by the Company with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of the Company in respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against the Company nor, to the Company's Know ledge, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material to the Company, taken as a whole. All taxes and other assessments and levies that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due. There are no tax liens or claims pending or, to the Company's Knowledge, threatened against the Company or any of its assets or property. There are no outstanding tax sharing agreements or other such arrangements between the Company or any other corporations or entities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.09 Title to Properties.** Except as disclosed in <u>Schedule 5.09</u>, the Company has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof by it; and, except as disclosed in <u>Schedule 5.09,</u> the Company holds any leased real or personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently planned to be made thereof by it.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.10 Certificates, Authorities and Permits.** The Company possesses adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, and the Company has not received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to the Company, could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.11 Labor Matters.** The Company is not (a) a party to any collective bargaining agreement or (b) delinquent in payments to any of its employees or consultants for wages, salaries, commissions, bonuses or other direct compensation for any services performed by them to the date of this Agreement and as of the Closing or amounts required to be reimbursed to such employees. To the Company's Knowledge, the Company is and has heretofore been in compliance in all respects with all laws, rules and regulations respecting employment and employment practices, terms and conditions of employment and wages and hours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.12 Litigation.** There are no pending actions, suits or proceedings against or affecting the Company and, to the Company's Knowledge, no such actions, suits or proceedings are threatened or contemplated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.13 Brokers and Finders.** No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon the Company for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.14 No Integrated Offering.** Neither the Company nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Company security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by the Company on Section 4(a)(2) and Regulation D for the exemption from registration for the transactions contemplated hereby or would require registration of the Subject Interest under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.15 Private Placement.** The offer and sale of the Subject Interest to Investor as contemplated hereby are exempt from the registration requirements of the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.16 Disclosures.** The written materials delivered to Investor in connection with the transactions contemplated by the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.17 Investment Purpose.** The Company is acquiring the Investor Securities for the Company's own account for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act. The Company agrees not to sell, hypothecate or otherwise transfer Investor's securities, unless such securities are registered under the federal and applicable state

securities laws or unless, in the opinion of counsel satisfactory to Investor, an exemption from such law is available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.18 No Other Representations or Information.** In evaluating the suitability of an investment in the Investor Securities, the Company has not relied upon any representation or information (oral or written) other than as stated in the Transaction Documents. No oral or written representations have been made, or oral or written information furnished, to the Company in connection with the offering of the Investor Securities which are in any way inconsistent with the information contained in the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.19 Restrictions on Transfer or Resale.** The Company understands that there will not be any trading market for the Investor Securities, although there does exist a public trading market for the common stock of lnvestor. The Company further understands and agrees that it may never realize any economic benefit from its investment in the Investor Securities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.** **Representations and Warranties of lnvestor.** Investor represents and warrants that:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.01 Organization, Good Standing and Qualification.** Investor is a corporation organized, validly existing and in good standing under the laws of the State of Nevada and has all requisite power and authority to carry on its business as now conducted and to own its properties. Investor is duly qualified to do business as a foreign entity and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary, unless the failure to so qualify has not had and could not reasonably be expected to have a Material Adverse Effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.02 Authorization.** Investor has full power and authority and has taken all requisite action on the part of Investor, its officers, managers and directors necessary for (a) the authorization, execution and delivery of the Transaction Documents, (b) the authorization of the performance of all obligations of Investor hereunder or thereunder and (c) the authorization, issuance and delivery of the Investor Securities. The Transaction Documents constitute the legal, valid and binding obligations of Investor, enforceable against Investor in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors' rights generally.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.03 Capitalization.** <u>Schedule 6.03</u> sets forth the capitalization of Investor immediately following the consummation of this Agreement. There are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which Investor is or may be obligated to issue any equity securities of any kind and, except as contemplated by this Agreement, Investor is not currently in negotiations for the issuance of any equity securities of any kind. Except as described in <u>Schedule 6.03,</u> there are no voting agreements, buy-sell agreements, option or right of first purchase agreements or other agreements of any kind among Investor and any of the security holders of Investor relating to securities of Investor held by them.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.04** The Investor Securities have been duly and validly authorized and, when issued and paid for pursuant to this Agreement, will be validly issued, fully paid and non-assessable, and shall be free and clear of all encumbrances and restrictions, except for restrictions on transfer set forth in the Transaction Documents or imposed by applicable securities laws.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.05 Consents.** The execution, delivery and performance by Investor require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than filings that have been made pursuant to applicable state securities laws and post-sale filings pursuant to relevant state and federal securities laws which Investor undertakes to file within the applicable time periods. Subject to the accuracy of the representations and warranties of the Company set forth in Section 5 hereof, Investor has taken all action necessary to exempt the issuance and sale of the Investor Securities from registration under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.06 Delivery of Information.** Included in Schedule 6.06 hereto is all pertinent information regarding Investor, including its properties and its financial condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.07 No Conflict, Breach, Violation or Default.** The execution, delivery and performance of the Transaction Documents by Investor will not conflict with or result in a breach or violation of any of the terms and provisions of, or constitute a default under (a) Investor's Articles of Incorporation or Investor's Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to Investor), or (b)(i) any statute, rule, regulation or order of any governmental agency or body or any court, domestic or foreign, having jurisdiction over Investor or any of its assets or properties, or (ii) any agreement or instrument to which Investor is a party or by which Investor is bound or to which any of its assets or properties is subject.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.08 Tax Matters.** Investor has timely prepared and filed all tax returns required to have been filed by Investor with all appropriate governmental agencies and timely paid all taxes shown thereon or otherwise owed by it. The charges, accruals and reserves on the books of Investor in respect of taxes for all fiscal periods are adequate in all material respects, and there are no material unpaid assessments against Investor nor, to Investor's Knowledge, any basis for the assessment of any additional taxes, penalties or interest for any fiscal period or audits by any federal, state or local taxing authority except for any assessment which is not material to Investor, taken as a whole. All taxes and other assessments and levies that Investor is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper governmental entity or third party when due.

There are no tax liens or claims pending or, to Investor's Knowledge, threatened against Investor or any of its assets or property. There are no outstanding tax sharing agreements or other such arrangements between Investor or any other corporations or entities.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.09 Title to Properties.** Except as disclosed in <u>Schedule 6.09</u>, Investor has good and marketable title to all real properties and all other properties and assets owned by it, in each case free from liens, encumbrances and defects that would materially affect the value thereof or materially interfere with the use made or currently planned to be made thereof by it; and, except as disclosed in <u>Schedule 6.09,</u> Investor holds any leased real or personal property under valid and enforceable leases with no exceptions that would materially interfere with the use made or currently plam1ed to be made thereof by it.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.10 Certificates, Authorities and Permits.** Investor possesses adequate certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, and Investor has not received any notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that, if determined adversely to Investor, could reasonably be expected to have a Material Adverse Effect, individually or in the aggregate.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.11 Labor Matters.** Investor is not (a) a party to any collective bargaining agreement or (b) delinquent in payments to any of its employees or consultants for wages, salaries, commissions, bonuses or other direct compensation for any services performed by them to the date of this Agreement and as of the Closing or amounts required to be reimbursed to such employees. To Investor's Know ledge, the Company is and has heretofore been in compliance in all respects with all laws, rules and regulations respecting employment and employment practices, terms and conditions of employment and wages and hours.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.12 Litigation.** There are no pending actions, suits or proceedings against or affecting Investor and, to Investor's Knowledge, no such actions, suits or proceedings are threatened or contemplated.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.13 Brokers and Finders.** No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid right, interest or claim against or upon Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of Investor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.14 No Integrated Offering.** Neither Investor nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any Investor security or solicited any offers to buy any security, under circumstances that would adversely affect reliance by Investor on Section 4(a)(2) and Regulation D for the exemption from registration for the transactions contemplated hereby or would require registration of the Investor Securities under the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.15 Private Placement.** The offer and sale of the Investor Securities to the Company as contemplated hereby are exempt from the registration requirements of the 1933 Act.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.16 Disclosures.** The written materials delivered to the Company in connection with the transactions contemplated by the Transaction Documents do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not misleading.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.17 Investment Purpose.** Investor is acquiring the Subject Interest for Investor's own account for investment only and not with a view towards, or for resale in connection with, the public sale or distribution thereof, except pursuant to sales registered or exempted under the 1933 Act. Investor agrees not to sell, hypothecate or otherwise transfer the Company's securities, unless such securities are registered under the federal and applicable state securities laws or unless, in the opinion of counsel satisfactory to the Company, an exemption from such law is available.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.18 No Other Representations or Information.** In evaluating the suitability of an investment in the Subject Interest, Investor has not relied upon any representation or information (oral or written) other than as stated in the Transaction Documents. No oral or written representations have been made, or oral or written information furnished, to Investor in connection with the offering of the Subject Interest which are in any way inconsistent with the information contained in the Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**6.19 Restrictions on Transfer or Resale.** Investor understands that there will not be any trading market for the Subject Interest. Investor understands further that the Subject Interest are subject to the restrictions on transfer contained in the LLC Agreement. Additionally, Investor acknowledges that it may never realize any economic benefit from its investment in the Subject Interest.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Conditions
 to Closing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.01 Conditions to Obligations of Investor.** The obligation of Investor to purchase the Subject Interest at the Closing is subject to the fulfillment to Investor's satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by Investor:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** The representations and warranties made by the Company in Section 5 hereof qualified as to materiality shall be true and correct at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct as of such earlier date, and, the representations and warranties made by the Company in Section 5 not qualified as to materiality shall be true and correct in all material respects at all times prior to and on the Closing Date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and correct in all material respects as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b)** The Company shall have duly executed and delivered this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c)** The Company shall have duly executed and delivered the Referral Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(d)** The Company shall have delivered the Subject Interest to Investor.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** and waivers necessary or appropriate for consummation of the purchase and sale of the Subject Interest and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(t)** No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.02 Conditions to Obligations of the Company.** The Company's obligations to sell and issue the Subject Interest at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a)** The representations and warranties made by Investor in Section 6 hereof shall be true and correct in all material respects when made, and shall be true and correct in all material respects on the Closing Date with the same force and effect as if they had been made on and as of said date. Investor shall have performed in all material respects all obligations and covenants herein required to be performed prior to the Closing Date.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **(b)** Investor shall have duly executed and delivered this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **(c)** Investor shall have duly executed and delivered the LLC Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; **(d)** Investor shall have delivered the Purchase Price to the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(e)** The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary or appropriate for consummation of the purchase and sale of the Subject Interest and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(t)** No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated hereby or in the other Transaction Documents.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**7.03 Termination by Either the Company or Investor.** Either the Company or Investor shall have the right to terminate this Agreement, if the Closing fails to occur prior to September 30, 2024.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Miscellaneous.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.01 Legal Representation.** Each of the Company and Investor acknowledges that each has utilized separate legal counsel with respect to this Agreement and the transactions contemplated hereby.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.02 Survival.** The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of the transactions contemplated by this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.03 Counterparts.** This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.04 Titles and Subtitles.** The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.05 Notices.** Unless otherwise provided, any notice required or permitted under this Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (a) if given by personal delivery, then such notice shall be deemed given upon such delivery, (b) if given by e-mail, then such notice shall be deemed given upon completion of transmittal, (c) if given by mail, then such notice shall be deemed given upon the earlier of (i) receipt of such notice by the recipient or (ii) three days after such notice is deposited in first class mail, postage prepaid, and (d) if given by an internationally recognized overnight air courier, then such notice shall be deemed given one Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or at such other address as such party may designate by ten days' advance written notice to the other party:

---

| | |
|:---|:---|
| If to the Company: | Cement Factory, LLC<br> 4455 Old Bear Run, Winter Park, Florida 32792 |
| If to Investor: | Adia Nutrition, Inc.<br> 4421 Gabriella Lane, Winter Park, Florida 32792 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.06 Expenses.** The parties hereto shall pay their own costs and expenses in connection herewith.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.07 Amendments and Waivers.** Any term of this Agreement may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and Investor. Any amendment or waiver effected in accordance with this paragraph shall be binding upon each holder of any Subject Interest purchased under this Agreement at the time outstanding, each future holder of all such Subject Interest and the Company.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.08 Severability.** Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.09 Entire Agreement.** This Agreement, including the Schedules, and the other Transaction Documents constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect to the subject matter hereof and thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.10 Further Assurances.** The parties shall execute and deliver all such further instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.11 Governing Law.** This Agreement shall be governed by, and construed in accordance with, the laws of the State of Florida without regard to the choice of law principles thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**8.12 Arbitration.** In the event of a dispute between the parties hereto that arises out of this Agreement, the parties hereby agree to submit such dispute to arbitration before the American Arbitration Association (the "Association") at its Dallas, Texas, offices, in accordance with the then-current rules of the Association; the award given by the arbitrators shall be binding and a judgment may be obtained on any such award in any court of competent jurisdiction. It is expressly agreed that the arbitrators, as part of their award, may award attorneys fees to the prevailing party.

IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized officers to execute this Agreement as of the date first above written.

---

| | | | |
|:---|:---|:---|:---|
| **INVESTOR:** | **INVESTOR:** | **THE COMPANY:** | **THE COMPANY:** |
| ADIA NUTRITION, INC. | ADIA NUTRITION, INC. | CEMENT FACTORY, LLC | CEMENT FACTORY, LLC |
| By: | /s/ Larry Powalisz | By: | /s/ Jeff Sciullo |
|  | Larry Powalisz |  | Jeff Sciullo |
|  | Chief Executive Officer |  | Manager |

---

<u>**EXHIBIT A**</u>

**Certificate of Designation of Preferred Stock of Investor**

**ADIA NUTRITION, INC.**

**CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS**

**OF**

**SERIES C PREFERRED STOCK**

PURSUANT TO SECTION 78.1955

OF THE NEV ADA REVISED STATUTES

Pursuant to Section 78.1955 of the Nevada Revised Statutes, the undersigned does hereby certify, on behalf of Adia Nutrition, lnc., a Nevada corporation (the ***"Company"),*** that the following resolution was duly adopted by the Board of Directors of the Company.

**WHEREAS,** the Articles of Incorporation of the Company, as amended (the ***"Articles of l11corporation***''), authorize the issuance of up to I 00,000,000 shares of preferred stock, par value $0.001 per share, of the Company (the ***"Preferred Stock'')*** in one or more series, which Preferred Stock shall have such distinctive designation or title, voting powers or no voting powers, and such preferences, rights, qualifications, limitations or restrictions, as shall be stated in such resolution or resolutions providing for the issuance of such class or series of Preferred Stock as may be adopted from time to time by the Board prior to the issuance of any shares thereof; and

**WHEREAS,** it is the desire of the Board of Directors to establish and fix the number of shares to be included in a new series of Preferred Stock and the designation, rights, preferences, powers, restrictions and limitations of the shares of such new series.

**NOW, THEREFORE, IT IS RESOLVED,** that the Board of Directors does hereby provide for the issue of a series of Preferred Stock and does hereby in this Certificate ofDesignation (this ***"Certificate of Designation'')***establish and fix and herein state and express the designation, rights, preferences, powers, restrictions, and limitations of such series of Preferred Stock as follows:

**TERMS OF SERIES C PREFERRED STOCK**

**Section 1. Designation, Amount and Par Value.** The series of Preferred Stock shall be designated as Series C Preferred Stock (the ***"Series CPreferred Stock'')*** and the number of shares so designated shall be Eighty-Nine Million Nine Hundred Ninety-Nine Thousand Nine-Hundred Ninety Nine (89,999,999). Each share of the Series C Preferred Stock shall have a par value of $0.00 I.

**Section 2. Fractional Shares.** The Series C Preferred Stock may be issued in fractional shares.

**Section 3. Voting Rights.** Each share the Series C Preferred Stock shall have one (I) vote in all matters requiring shareholder approval.

**Section 4. Dividends.** The Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the dividend on each share of Series C Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 5. Liquidation.** Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of Series C Preferred Stock shall be equal to the amount of the payment on each share of the Company's common stock multiplied by the Conversion Rate, as tbat term is defined in Section 6(a).

**Section 6. Conversion and Adjustments.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Conversion Rate.** Each shares of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock (the ***"Conversion Rate").***

 ****

The Conversion Rate shall not be subject to adjustment by a combination of the outstanding shares of the Company's common stock into a smaller number of shares of common stock.

The Conversion Rate shall be subject to adjustment by a subdivision of the outstanding shares of the Company's common stock into a greater number of shares of common stock (the "Common Stock Event") by multiplying the Conversion Rate then in effect by a fraction: (l) the numerator of which shall be the number of shares of Company common stock issued and outstanding immediately prior to such Common Stock Event and (2) the denominator of which shall be the number of shares of Company common stock issued and outstanding immediately after such Common Stock Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Partial Conversion.** A holder of shares of Series C Preferred Stock shall have the right to convert, from time to time, some or all of such holder's shares of Series C Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Adjustment for Merger and Reorganization, etc.** If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger (a ***"Reorganization Event")*** involving the Company in which the Company's common stock (but not the Series C Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Series C Preferred Stock shall be deemed to have been converted into shares of the Company's common stock at the Conversion Rate.

**Section** 7. **Protection Provisions.** So long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without first obtaining the written consent of the holders of a majority the Series C Preferred Stock, alter or change the rights, preferences or privileges of the Series C Preferred Stock.

**Section 8. Waiver.** Any of the rights, powers or preferences of the holders of the Series C Preferred Stock may be waived by the affirmative consent or vote of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.

**Section 9. No Other Rights or Privileges.** Except as specifically set forth herein, the holder(s) of the shares of Series C Preferred Stock shall have no other rights, privileges or preferences with respect to the Series C Preferred Stock.

<u>**EXHIBIT B**</u>

**Operating Agreement of the Company**

To be delivered separately.

<u>**EXHIBIT C**</u>

**Referral Agreement**

To be delivered separately.

## Ex-4

**Exhibit 4.2.3**

**Biolete LLC Purchase Agreement**

This Purchase Agreement ("Agreement") is entered into as of Sept. 22, 2025, by and between Cement Factory LLC, a limited liability company organized under the laws of Florida, with its principal place of business at 4455 OLD BEAR RUN WINTER PARK, FL 32792 ("Buyer"), represented by Jeff Sciullo and Austin J. Sims, and Adia Nutrition Inc., a corporation organized under the laws of Nevada, operating under the laws of Florida, with its principal place of

business at 1561 W FAIRBANKS AVE WINTER PARK, FL 32789 and mailing address 4421 GABRIELLA LN WINTER PARK, FL 32792 ("Seller"). Buyer and Seller are collectively referred to as the "Parties" and individually as a "Party."

WHEREAS, Seller owns Biolete LLC, including all associated rights, the Biolete Coffee trademark, the Biolete website, the Shopify account associated with Biolete Coffee, the Amazon account associated with Biolete Coffee, and an

inventory of 6,550 units (bags) of Biolete Coffee; and

WHEREAS, Buyer desires to purchase Biolete LLC and all its rights, including the Biolete Coffee trademark, website, Shopify account, Amazon account, and the entire inventory of 6,550 units from Seller, and Seller agrees to

transfer such assets to Buyer under the terms set forth herein; and WHEREAS, Buyer agrees to reimburse Seller $11.05 for each unit of Biolete Coffee sold, with a total reimbursement obligation of $72,362.31, to be paid monthly based on sales from the prior month; and

WHEREAS, Buyer, with Seller's assistance, will take necessary steps to transfer or integrate Biolete's Shopify account and link their bank account; and

WHEREAS, Buyer agrees to update the bank account associated with the Amazon account on or by September 30, 2025, upon receiving access to the account.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1. Transfer
 of Assets

Seller hereby agrees to sell, assign, transfer, and deliver to Buyer, and Buyer agrees to purchase and accept from Seller, the following assets (collectively, the "Assets"):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. All ownership interest in Biolete LLC, a limited liability company, including all associated rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The Biolete Coffee trademark, including all associated intellectual property rights;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. The Biolete website, including all domain names, content, and associated digital assets;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. The Shopify account associated with Biolete Coffee, including all account rights and data;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. The Amazon account associated with Biolete Coffee, including all listings and account rights; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;f. The entire inventory of 6,550 units (bags) of Biolete Coffee.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;2. Purchase
 Price and Reimbursement Terms

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. The total purchase price for the Assets shall be $72,362.31 (the "Purchase Price").

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Buyer shall reimburse Seller $11.05 for each unit of Biolete Coffee sold by Buyer.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Payments shall be made monthly to Seller based on the number of units sold during the preceding month. Buyer shall provide Seller with a monthly report detailing the number of units sold and the corresponding payment amount.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Payments shall be made via check delivered on the 5th day of each month or via ACH scheduled the day before for delivery on the 5th to an account designated by Seller for sales made in the prior month.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;e. The obligation to pay the Purchase Price shall continue until the full amount of $72,362.31 is paid to Seller, or until all 6,550 units are sold, whichever occurs first.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;3. Transfer
 of Ownership and Digital Accounts

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Seller shall deliver to Buyer all necessary documents to effect thet ransfer of Biolete LLC, the Biolete Coffee trademark, the Biolete website, the Shopify account, and the Amazon account, including but not limited to assignment agreements, trademark transfer documents, website domain transfer agreements, Shopify account transfer documentation, Amazon account transfer documentation, and any related certificates.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. The inventory of 6,550 units of Biolete Coffee shall be delivered to Buyer's warehouse on or by September 30, 2025, with delivery costs to be borne by Seller.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c. Shopify Account Transfer or Integration: Buyer, with Seller's reasonable assistance, shall take all necessary steps to transfer the Biolete Shopify account to Buyer or integrate the Biolete Shopify account into Buyer's existing Shopify account. Buyer shall link a bank account designated by Buyer to the Shopify account to facilitate payments. Seller shall provide necessary access and support to complete the transfer or integration by September 30, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d. Amazon Account Bank Update: Upon receiving access to the Amazon account associated with Biolete Coffee, Buyer shall update the bank account information linked to the Amazon account to a bank account designated by Buyer on or before September 30, 2025. Buyer shall notify Seller in writing upon completion of the bank account update.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4. Representations
 and Warranties

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a. Seller's Representations: Seller represents and warrants that it has full authority to sell the Assets, that Biolete LLC, the Biolete Coffee trademark, the Biolete website, the Shopify account, and the Amazon account are free of any liens, encumbrances, or claims, and that the inventory consists of 6,550 units of Biolete Coffee in good and marketable condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b. Buyer's Representations: Buyer represents and warrants that it has the authority to enter into this Agreement and fulfill its obligations hereunder, including the transfer or integration of the Shopify account and the update of the Amazon account bank information.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5. Indemnification

Each Party shall indemnify and hold harmless the other Party from any claims, damages, or liabilities arising from a breach of their respective representations and warranties under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6. Governing
 Law

This Agreement shall be governed by and construed in accordance with the laws of the State of Florida, without regard to its conflict of law principles.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7. Dispute
 Resolution

Any disputes arising under this Agreement shall be resolved through mediation in Florida.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8. Entire
 Agreement

This Agreement constitutes the entire understanding between the Parties with respect to the subject matter hereof and supersedes all prior agreements, whether written or oral.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9. Amendments

This Agreement may only be amended in writing signed by both Parties.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;10. Notices

Any notices required under this Agreement shall be sent to the addresses listed above via email or as otherwise designated by the Parties.

IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first written above.

Cement Factory LLC

By: <u>/s/ Jeff Sciullo</u> 

Name: Jeff Sciullo

Title: Partner

By: <u>/s/ Austin J. Sims</u> 

Name: Austin J. Sims

Title: Partner

Adia Nutrition Inc.

By: <u>/s/ Larry Powalisz</u> 

Name: Larry Powalisz

Title: CEO

## Ex-5

**Exhibit 5.1.1**

**DIRECTOR AGREEMENT**

This Director Agreement (the *"**Agreement**"*) is made and entered into as of August **<u>19</u>** , 2024, by and between Adia Nutrition, Inc., a Nevada corporation (the *"**Company**"*), and Monica Sher, MD, an individual (*"**Director**"*).

**RECITALS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The common stock of the Company is a traded in the public markets of the United States (symbol: ADIA); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Company desires to appoint Director to serve on the Company's board of directors (the *"**Board**"*) and Director desires to accept such appointment to serve on the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Director may be appointed as a member of one or more committees of the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Director may also be appointed to serve as Chairman of one or more committees of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;I. SERVICES

&nbsp;&nbsp;&nbsp;&nbsp;1.1 <u>Board of Directors</u>. Director agrees to perform such tasks as may be necessary to fulfill Director's obligations as a member of the Board and its committees and serve as a director so long as she is duly appointed or elected and qualified in accordance with the applicable provisions of the Company's Articles of Incorporation and Bylaws (collectively, the *"**Charter**"*) and any necessary approval by the Company's stockholders and/or Board, and until such time as Director resigns, fails to stand for election, fails to be elected by the stockholders of the Company or is removed from Director's position. Director may at any time and for any reason resign or be removed from such position consistent with the Charter (subject to any other contractual obligation or other obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement with respect to Director.

&nbsp;&nbsp;&nbsp;&nbsp;1.2 <u>Director Services</u>. Director shall provide the following Services (*"**Director Services**"*):

&nbsp;&nbsp;&nbsp;&nbsp;(a) During the term of services as a director of the Company (*"**Directorship Term**"*), Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make herself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

&nbsp;&nbsp;&nbsp;&nbsp;(b) Director will use her best efforts to promote the interests of the Company. The Company recognizes that Director (i) is or may become a full-time employee of another entity and that her responsibilities to such entity must have priority and (ii) sits or may sit on the board of directors of other entities, subject to any limitations set forth by the Sarbanes-Oxley Act of 2002 and limitations provided by any exchange or quotation service on which the Company's common stock is listed or traded, if and when applicable to the Company. Notwithstanding the same, Director will provide the Company with prior written notice of any future commitments to such entities and use reasonable business efforts to coordinate her respective commitments so as to fulfill her obligations to the Company and, in any event, will fulfill her legal obligations as a director. Other than as set forth above, Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of her duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that the foregoing shall in no way limit her activities on behalf of (i) any current employer and its affiliates or (ii) the board of directors of any entities on which she currently sits. At such time as the Board receives such notification, the Board may require the resignation of Director if it determines that such business activity does in fact materially interfere with the performance of Director's duties, services and responsibilities hereunder.

&nbsp;&nbsp;&nbsp;&nbsp;1.3 <u>Term</u>. This Agreement shall terminate upon the *"**Expiration Date**"* which shall be the earlier of the date on which Director ceases to be a member of the Board for any reason, including death, resignation, removal, or failure to be elected by the stockholders of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;II. COMPENSATION

&nbsp;&nbsp;&nbsp;&nbsp; 2.1 <u>Expense Reimbursement</u>. The Company shall reimburse Director for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of Director's duties for the Company. Such reimbursement shall be made by the Company upon submission by Director of a signed statement itemizing the expenses incurred, which shall be accompanied by sufficient documentation to support the expenditures.

&nbsp;&nbsp;&nbsp;&nbsp;2.2 <u>Bonus</u>. Upon Director's execution of this Agreement, the Company shall issue to Director, as a bonus, 250,000 shares of the Company's Series C Preferred Stock (***"Bonus Shares"***). The Bonus Shares have the designations, rights and preferences set forth in <u>Annex 1</u> attached hereto and made a part hereof.

&nbsp;&nbsp;&nbsp;&nbsp;2.3 <u>Director and Officer Liability Insurance</u>. The Company will use its best efforts to maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

&nbsp;&nbsp;&nbsp;&nbsp;2.4 <u>Independent Contractor</u>. Director's status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to Director under this Section 2 shall be made or provided without withholding or deduction of any kind, and Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

&nbsp;&nbsp;&nbsp;&nbsp;III. CONFIDENTIALITY AND NONDISCLOSURE

&nbsp;&nbsp;&nbsp;&nbsp;3.1 <u>Confidentiality</u>. During the term of this Agreement, and for a period of three (3) years after the Expiration Date, Director shall maintain in strict confidence all information she has obtained or shall obtain from the Company, which the Company has designated as "confidential" or which is by its nature confidential, relating to the Company's business, operations, properties, assets, services, condition (financial or otherwise), liabilities, employee relations, customers, suppliers, prospects, technology, or trade secrets, except to the extent such information (i) is in the public domain through no act or omission of the Company, (ii) is required to be disclosed by law or a valid order by a court or other governmental body, or (iii) is independently learned by Director outside of this relationship (the *"**Confidential Information**"*).

&nbsp;&nbsp;&nbsp;&nbsp;3.2 <u>Nondisclosure and Nonuse Obligations</u>. Director will use the Confidential Information solely to perform her obligations for the benefit of the Company hereunder. Director will treat all Confidential Information of the Company with the same degree of care as Director treats her own Confidential Information, and Director will use her best efforts to protect the Confidential Information. Director will not use the Confidential Information for her own benefit or the benefit of any other person or entity, except as may be specifically permitted in this Agreement. Director will immediately give notice to the Company of any unauthorized use or disclosure by or through her, or of which she becomes aware, of the Confidential Information.

&nbsp;&nbsp;&nbsp;&nbsp;3.3 <u>Return of Company Property</u>. All materials furnished to Director by the Company, whether delivered to Director by the Company or made by Director in the performance of Director Services under this Agreement (the "Company Property"), are the sole and exclusive property of the Company. Director agrees to promptly deliver the original and any copies of the Company Property to the Company at any time upon the Company's request. Upon termination of this Agreement by either party for any reason, Director agrees to promptly deliver to the Company or destroy, at the Company's option, the original and any copies of the Company Property. Director agrees to certify in writing that Director has so returned or destroyed all such Company Property.

&nbsp;&nbsp;&nbsp;&nbsp;3.4 Insider Trading Guidelines. Director acknowledges and agrees that Director may have access to "material non-public information" for purposes of the federal securities laws ("Insider Information") and that Director will abide by all securities laws relating to the handling of and acting upon such Insider Information. Upon request by the Company, Director will be asked to execute the Company's Insider Trading and Section 16 Compliance Policy upon adoption by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;IV. COVENANTS OF DIRECTOR

&nbsp;&nbsp;&nbsp;&nbsp;4.1 <u>No Conflict of Interest.</u> During the term of this Agreement, Director shall not be employed by, own, manage, control or participate in the ownership, management, operation or control of any person, firm, partnership, corporation or unincorporated association or entity of any kind that is competitive with the Company or otherwise undertake any obligation inconsistent with the terms hereof, provided that Director may continue Director's current affiliation or other current relationships with the entity or entities described on Exhibit A (all of which entities are referred to collectively as "Current Affiliations"). This Agreement is subject to the current terms and agreements governing Director's relationship with Current Affiliations, and nothing in this Agreement is intended to be or will be construed to inhibit or limit any of Director's obligations to Current Affiliations. Director represents that nothing in this Agreement conflicts with Director's obligations to Current Affiliations. A business shall be deemed to be "competitive with the Company" for purpose of this Article IV only if and to the extent it engages in a business substantially similar to the Company's business.

&nbsp;&nbsp;&nbsp;&nbsp;4.2 <u>Disparaging Statements</u>. At all times during and after the period in which Director is a member of the Board and at all times thereafter, the Company, its employees, affiliates, or assignees, and Director, one and for the other, shall not either verbally, in writing, electronically or otherwise: (i) make any derogatory or disparaging statements about the Company, any of its affiliates, any of their respective officers, directors, shareholders, employees and agents, or any of the Company's current or past customers or employees, or (ii) make any public statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of the Company or any of its affiliates or otherwise interfere with the business of the Company or any of its affiliates; provided, however, that nothing in this paragraph shall preclude Director from complying with all obligations imposed by law or legal compulsion, and provided, further, however, that nothing in this paragraph shall be deemed applicable to any testimony given by Director, or the Company, its employees, affiliates, or assignees, in any legal or administrative proceedings.

&nbsp;&nbsp;&nbsp;&nbsp;4.3 <u>Market Stand-Off Agreement</u>. In the event of a public or private offering of the Company's securities, and upon request of the Company, the underwriters or placement agents placing the offering of the Company's securities, Director agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company that Director may own, other than those included in the registration, without the prior written consent of the Company or such underwriters, as the case may be, for such period of time from the effective date of such registration as may be requested by the Company or such placement agent or underwriter.

&nbsp;&nbsp;&nbsp;&nbsp;V. TERM AND TERMINATION

&nbsp;&nbsp;&nbsp;&nbsp;5.1 <u>Term</u>. This Agreement is effective as of the date of this Agreement and will continue until the Expiration Date.

&nbsp;&nbsp;&nbsp;&nbsp;5.2 <u>Survival</u>. The rights and obligations contained in Articles III and IV will survive any termination or expiration of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;VI. MISCELLANEOUS

&nbsp;&nbsp;&nbsp;&nbsp;6.1 <u>Assignment.</u> Except as expressly permitted by this Agreement, neither party shall assign, delegate, or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the other party. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

&nbsp;&nbsp;&nbsp;&nbsp;6.2 <u>Remedies</u>. Director agrees that any breach of the terms of this Articles III and IV would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by Director and/or any and all entities acting for and/or with Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from Director. Director acknowledges that the Company would not have entered into this Agreement had Director not agreed to the provisions of this Section 6.2.

&nbsp;&nbsp;&nbsp;&nbsp;6.3 <u>No Waiver</u>. The failure of any party to insist upon the strict observance and performance of the terms of this Agreement shall not be deemed a waiver of other obligations hereunder, nor shall it be considered a future or continuing waiver of the same terms.

&nbsp;&nbsp;&nbsp;&nbsp;6.4 <u>Notice</u>s. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by e-mail or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth on the signature page of this Agreement or such other address as either party may specify in writing.

&nbsp;&nbsp;&nbsp;&nbsp;6.5 <u>Governing Law; Jurisdiction</u>. This Agreement shall be governed in all respects by the laws of the State of Nevada, without regard to conflicts of law principles thereof. Any action brought to enforce, or otherwise arising out of, this Agreement shall be heard and determined in either a Federal or state court sitting in the County of Orange, State of Florida, and the parties consent to jurisdiction in the State of Florida.

&nbsp;&nbsp;&nbsp;&nbsp;6.6 <u>Severability</u>. Should any provisions of this Agreement be held by a court to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

&nbsp;&nbsp;&nbsp;&nbsp;6.7 <u>Entire Agreement</u>. This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all Director Services undertaken by Director for the Company.

&nbsp;&nbsp;&nbsp;&nbsp;6.8 <u>Amendments</u>. This Agreement may only be amended, modified or changed by an agreement signed by he the Company and Director. The terms contained herein may not be altered, supplemented or interpreted by any course of dealing or practices.

&nbsp;&nbsp;&nbsp;&nbsp;6.9 <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **COMPANY:** |  | **ADIA NUTRITION, INC.** |
|  | By: | /s/ Larry Powalisz |
|  | Name: | Larry Powalisz |
|  | Title: | Chief Executive Officer |
|  | Address: | 4421 Gabriella Lane |
|  |  | Winter Park, Florida 32792 |
| **DIRECTOR** |  |  |
|  | By: | /s/ Monica Sher |
|  | Name: | Monica Sher, MD |
|  | Address: | 1122 Azalea Lane |
|  |  | Winter Park, Florida 32789 |

---

<u>**EXHIBIT A**</u>

**Director's Current Affiliations**

None.

<u>**ANNEX I**</u>

**TERMS OF SERIES C PREFERRED STOCK**

**Section 1. Designation, Amount and Par Value.** The series of Preferred Stock shall be designated as Series C Preferred Stock (the ***"Series C Preferred Stock"***) and the number of shares so designated shall be Eighty-Nine Million Nine Hundred Ninety-Nine Thousand Nine- Hundred Ninety Nine (89,999,999). Each share of the Series C Preferred Stock shall have a par value of $0.001.

**Section 2. Fractional Shares.** The Series C Preferred Stock may be issued in fractional

shares.

**Section 3. Voting Rights.** Each share the Series C Preferred Stock shall have one (1) vote in all matters requiring shareholder approval.

**Section 4. Dividends.** The Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the dividend on each share of Series C Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 5. Liquidation.** Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of Series C Preferred Stock shall be equal to the amount of the payment on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 6. Conversion and Adjustments.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Conversion Rate.** Each shares of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock (the ***"Conversion Rate"***).

The Conversion Rate shall not be subject to adjustment by a combination of the outstanding shares of the Company's common stock into a smaller number of shares of common stock.

The Conversion Rate shall be subject to adjustment by a subdivision of the outstanding shares of the Company's common stock into a greater number of shares of common stock (the "Common Stock Event") by multiplying the Conversion Rate then in effect by a fraction: (1) the numerator of which shall be the number of shares of Company common stock issued and outstanding immediately prior to such Common Stock Event and (2) the denominator of which shall be the number of shares of Company common stock issued and outstanding immediately after such Common Stock Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Partial Conversion.** A holder of shares of Series C Preferred Stock shall have the right to convert, from time to time, some or all of such holder's shares of Series C Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Adjustment for Merger and Reorganization, etc.** If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger (a ***"Reorganization Event"***) involving the Company in which the Company's common stock (but not the Series C Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Series C Preferred Stock shall be deemed to have been converted into shares of the Company's common stock at the Conversion Rate.

**Section 7. Protection Provisions.** So long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without first obtaining the written consent of the holders of a majority the Series C Preferred Stock, alter or change the rights, preferences or privileges of the Series C Preferred Stock.

**Section 8. Waiver.** Any of the rights, powers or preferences of the holders of the Series C Preferred Stock may be waived by the affirmative consent or vote of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.

**Section 9. No Other Rights or Privileges.** Except as specifically set forth herein, the holder(s) of the shares of Series C Preferred Stock shall have no other rights, privileges or preferences with respect to the Series C Preferred Stock.

## Ex-5

**Exhibit 5.1.2**

**DIRECTOR AGREEMENT**

This Director Agreement (the *"**Agreement**"*) is made and entered into as of September 10, 2024, by and between Adia Nutrition, Inc., a Nevada corporation (the *"**Company**"*), and Richard Edwards, DO, an individual (*"**Director**"*).

**RECITALS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The common stock of the Company is a traded in the public markets of the United States (symbol: ADIA); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Company desires to appoint Director to serve on the Company's board of directors (the *"**Board**"*) and Director desires to accept such appointment to serve on the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Director may be appointed as a member of one or more committees of the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Director may also be appointed to serve as Chairman of one or more committees of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;I. SERVICES

1.1 <u>Board of Directors</u>. Director agrees to perform such tasks as may be necessary to fulfill Director's obligations as a member of the Board and its committees and serve as a director so long as he is duly appointed or elected and qualified in accordance with the applicable provisions of the Company's Articles of Incorporation and Bylaws (collectively, the *"**Charter**"*) and any necessary approval by the Company's stockholders and/or Board, and until such time as Director resigns, fails to stand for election, fails to be elected by the stockholders of the Company or is removed from Director's position. Director may at any time and for any reason resign or be removed from such position consistent with the Charter (subject to any other contractual obligation or other obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement with respect to Director.

1.2 <u>Director Services</u>. Director shall provide the following Services (*"**Director Services**"*):

(a) During the term of services as a director of the Company (*"**Directorship Term**"*), Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

(b) Director will use his best efforts to promote the interests of the Company. The Company recognizes that Director (i) is or may become a full-time employee of another entity and that his responsibilities to such entity must have priority and (ii) sits or may sit on the board of directors of other entities, subject to any limitations set forth by the Sarbanes-Oxley Act of 2002 and limitations provided by any exchange or quotation service on which the Company's common stock is listed or traded, if and when applicable to the Company. Notwithstanding the same, Director will provide the Company with prior written notice of any future commitments to such entities and use reasonable business efforts to coordinate his respective commitments so as to fulfill his obligations to the Company and, in any event, will fulfill his legal obligations as a director. Other than as set forth above, Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that the foregoing shall in no way limit his activities on behalf of (i) any current employer and its affiliates or (ii) the board of directors of any entities on which he currently sits. At such time as the Board receives such notification, the Board may require the resignation of Director if it determines that such business activity does in fact materially interfere with the performance of Director's duties, services and responsibilities hereunder.

1.3 <u>Term</u>. This Agreement shall terminate upon the *"**Expiration Date**"* which shall be the earlier of the date on which Director ceases to be a member of the Board for any reason, including death, resignation, removal, or failure to be elected by the stockholders of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;II. COMPENSATION

2.1 <u>Expense Reimbursement</u>. The Company shall reimburse Director for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of Director's duties for the Company. Such reimbursement shall be made by the Company upon submission by Director of a signed statement itemizing the expenses incurred, which shall be accompanied by sufficient documentation to support the expenditures.

2.2 <u>Bonus</u>. Upon Director's execution of this Agreement, the Company shall issue to Director, as a bonus, 250,000 shares of the Company's Series C Preferred Stock (***"Bonus Shares"***). The Bonus Shares have the designations, rights and preferences set forth in <u>Annex 1</u> attached hereto and made a part hereof.

2.3 <u>Director and Officer Liability Insurance</u>. The Company will use its best efforts to maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

2.4 <u>Independent Contractor</u>. Director's status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to Director under this Section 2 shall be made or provided without withholding or deduction of any kind, and Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

&nbsp;&nbsp;&nbsp;&nbsp;III. CONFIDENTIALITY AND NONDISCLOSURE

3.1 <u>Confidentiality</u>. During the term of this Agreement, and for a period of three (3) years after the Expiration Date, Director shall maintain in strict confidence all information he has obtained or shall obtain from the Company, which the Company has designated as "confidential" or which is by its nature confidential, relating to the Company's business, operations, properties, assets, services, condition (financial or otherwise), liabilities, employee relations, customers, suppliers, prospects, technology, or trade secrets, except to the extent such information (i) is in the public domain through no act or omission of the Company, (ii) is required to be disclosed by law or a valid order by a court or other governmental body, or (iii) is independently learned by Director outside of this relationship (the *"**Confidential Information**"*).

3.2 <u>Nondisclosure and Nonuse Obligations</u>. Director will use the Confidential Information solely to perform his obligations for the benefit of the Company hereunder. Director will treat all Confidential Information of the Company with the same degree of care as Director treats his own Confidential Information, and Director will use his best efforts to protect the Confidential Information. Director will not use the Confidential Information for his own benefit or the benefit of any other person or entity, except as may be specifically permitted in this Agreement. Director will immediately give notice to the Company of any unauthorized use or disclosure by or through him, or of which he becomes aware, of the Confidential Information.

3.3 <u>Return of Company Property</u>. All materials furnished to Director by the Company, whether delivered to Director by the Company or made by Director in the performance of Director Services under this Agreement (the *"**Company Property**"*), are the sole and exclusive property of the Company. Director agrees to promptly deliver the original and any copies of the Company Property to the Company at any time upon the Company's request. Upon termination of this Agreement by either party for any reason, Director agrees to promptly deliver to the Company or destroy, at the Company's option, the original and any copies of the Company Property. Director agrees to certify in writing that Director has so returned or destroyed all such Company Property.

3.4 <u>Insider Trading Guidelines</u>. Director acknowledges and agrees that Director may have access to "material non-public information" for purposes of the federal securities laws (*"**Insider Information**"*) and that Director will abide by all securities laws relating to the handling of and acting upon such Insider Information. Upon request by the Company, Director will be asked to execute the Company's Insider Trading and Section 16 Compliance Policy upon adoption by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;IV. COVENANTS OF DIRECTOR

4.1 <u>No Conflict of Interest</u>. During the term of this Agreement, Director shall not be employed by, own, manage, control or participate in the ownership, management, operation or control of any person, firm, partnership, corporation or unincorporated association or entity of any kind that is competitive with the Company or otherwise undertake any obligation inconsistent with the terms hereof, provided that Director may continue Director's current affiliation or other current relationships with the entity or entities described on <u>Exhibit A</u> (all of which entities are referred to collectively as *"**Current Affiliations**"*). This Agreement is subject to the current terms and agreements governing Director's relationship with Current Affiliations, and nothing in this Agreement is intended to be or will be construed to inhibit or limit any of Director's obligations to Current Affiliations. Director represents that nothing in this Agreement conflicts with Director's obligations to Current Affiliations. A business shall be deemed to be "competitive with the Company" for purpose of this Article IV only if and to the extent it engages in a business substantially similar to the Company's business.

4.2 <u>Disparaging Statements</u>. At all times during and after the period in which Director is a member of the Board and at all times thereafter, the Company, its employees, affiliates, or assignees, and Director, one and for the other, shall not either verbally, in writing, electronically or otherwise: (i) make any derogatory or disparaging statements about the Company, any of its affiliates, any of their respective officers, directors, shareholders, employees and agents, or any of the Company's current or past customers or employees, or (ii) make any public statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of the Company or any of its affiliates or otherwise interfere with the business of the Company or any of its affiliates; provided, however, that nothing in this paragraph shall preclude Director from complying with all obligations imposed by law or legal compulsion, and provided, further, however, that nothing in this paragraph shall be deemed applicable to any testimony given by Director, or the Company, its employees, affiliates, or assignees, in any legal or administrative proceedings.

4.3 <u>Market Stand-Off Agreement</u>. In the event of a public or private offering of the Company's securities, and upon request of the Company, the underwriters or placement agents placing the offering of the Company's securities, Director agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company that Director may own, other than those included in the registration, without the prior written consent of the Company or such underwriters, as the case may be, for such period of time from the effective date of such registration as may be requested by the Company or such placement agent or underwriter.

&nbsp;&nbsp;&nbsp;&nbsp;V. TERM AND TERMINATION

5.1 <u>Term</u>. This Agreement is effective as of the date of this Agreement and will continue until the Expiration Date.

5.2 <u>Survival</u>. The rights and obligations contained in Articles III and IV will survive any termination or expiration of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;VI. MISCELLANEOUS

6.1 <u>Assignment</u>. Except as expressly permitted by this Agreement, neither party shall assign, delegate, or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the other party. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

6.2 <u>Remedies</u>. Director agrees that any breach of the terms of this Articles III and IV would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by Director and/or any and all entities acting for and/or with Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from Director. Director acknowledges that the Company would not have entered into this Agreement had Director not agreed to the provisions of this Section 6.2.

6.3 <u>No Waiver</u>. The failure of any party to insist upon the strict observance and performance of the terms of this Agreement shall not be deemed a waiver of other obligations hereunder, nor shall it be considered a future or continuing waiver of the same terms.

6.4 <u>Notices</u>. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by e-mail or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth on the signature page of this Agreement or such other address as either party may specify in writing.

6.5 <u>Governing Law; Jurisdiction</u>. This Agreement shall be governed in all respects by the laws of the State of Nevada, without regard to conflicts of law principles thereof. Any action brought to enforce, or otherwise arising out of, this Agreement shall be heard and determined in either a Federal or state court sitting in the County of Orange, State of Florida, and the parties consent to jurisdiction in the State of Florida.

6.6 <u>Severability</u>. Should any provisions of this Agreement be held by a court to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of

this Agreement shall not be affected or impaired thereby.

6.7 <u>Entire Agreement</u>. This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all Director Services undertaken by Director for the Company.

6.8 <u>Amendments</u>. This Agreement may only be amended, modified or changed by an agreement signed by the Company and Director. The terms contained herein may not be altered, supplemented or interpreted by any course of dealing or practices.

6.9 <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**IN WITNESS WHEREOF**, the parties have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **COMPANY:** |  | **ADIA NUTRITION, INC.** |
|  | By: | /s/ Larry Powalisz |
|  | Name: | Larry Powalisz |
|  | Title: | Chief Executive Officer |
|  | Address: | 4421 Gabriella Lane |
|  |  | Winter Park, Florida 32792 |
| **DIRECTOR** |  |  |
|  | By: | /s/ Richard Edwards, DO |
|  | Name: | Richard Edwards, DO |
|  | Address: | 1122 Azalea Lane |
|  |  | Winter Park, Florida 32789 |

---

<u>**EXHIBIT A**</u>

**Director's Current Affiliations**

None.

<u>**ANNEX I**</u>

**TERMS OF SERIES C PREFERRED STOCK**

**Section 1. Designation, Amount and Par Value.** The series of Preferred Stock shall be designated as Series C Preferred Stock (the ***"Series C Preferred Stock"***) and the number of shares so designated shall be Eighty-Nine Million Nine Hundred Ninety-Nine Thousand Nine- Hundred Ninety Nine (89,999,999). Each share of the Series C Preferred Stock shall have a par value of $0.001.

**Section 2. Fractional Shares.** The Series C Preferred Stock may be issued in fractional shares.

**Section 3. Voting Rights.** Each share the Series C Preferred Stock shall have one (1) vote in all matters requiring shareholder approval.

**Section 4. Dividends.** The Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the dividend on each share of Series C Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 5. Liquidation.** Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of Series C Preferred Stock shall be equal to the amount of the payment on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 6. Conversion and Adjustments.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Conversion Rate.** Each shares of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock (the ***"Conversion Rate"***).

The Conversion Rate shall not be subject to adjustment by a combination of the outstanding shares of the Company's common stock into a smaller number of shares of common stock.

The Conversion Rate shall be subject to adjustment by a subdivision of the outstanding shares of the Company's common stock into a greater number of shares of common stock (the "Common Stock Event") by multiplying the Conversion Rate then in effect by a fraction: (1) the numerator of which shall be the number of shares of Company common stock issued and outstanding immediately prior to such Common Stock Event and (2) the denominator of which shall be the number of shares of Company common stock issued and outstanding immediately after such Common Stock Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Partial Conversion.** A holder of shares of Series C Preferred Stock shall have the right to convert, from time to time, some or all of such holder's shares of Series C Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Adjustment for Merger and Reorganization, etc.** If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger (a ***"Reorganization Event"***) involving the Company in which the Company's common stock (but not the Series C Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Series C Preferred Stock shall be deemed to have been converted into shares of the Company's common stock at the Conversion Rate.

**Section 7. Protection Provisions.** So long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without first obtaining the written consent of the holders of a majority the Series C Preferred Stock, alter or change the rights, preferences or privileges of the Series C Preferred Stock.

**Section 8. Waiver.** Any of the rights, powers or preferences of the holders of the Series C Preferred Stock may be waived by the affirmative consent or vote of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.

**Section 9. No Other Rights or Privileges.** Except as specifically set forth herein, the holder(s) of the shares of Series C Preferred Stock shall have no other rights, privileges or preferences with respect to the Series C Preferred Stock.

## Ex-5

**Exhibit 5.1.3**

**DIRECTOR AGREEMENT**

This Director Agreement (the ***"Agreement')*** is made and entered into as of September **22**, 2024, by and between Adia Nutrition, Inc., a Nevada corporation (the ***"Company*** '), and Dr. Kalpesh Barot, an individual ***("Director'').***

 ****

**RECITALS**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A. The common stock of the Company is a traded in the public markets of the United States (symbol: ADIA); and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B. The Company desires to appoint Director to serve on the Company's board of directors (the ***"Board')*** and Director desires to accept such appointment to serve on the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C. Director may be appointed as a member of one or more committees of the Board; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D. Director may also be appointed to serve as Chairman of one or more committees of the Board.

**I. SERVICES**

1.1 <u>Board of Directors</u>. Director agrees to perform such tasks as may be necessary to fulfill Director's obligations as a member of the Board and its committees and serve as a director so long as he is duly appointed or elected and qualified in accordance with the applicable provisions of the Company's Articles of Incorporation and Bylaws (collectively, the ***"Charter')*** and any necessary approval by the Company's stockholders and/or Board, and until such time as Director resigns, fails to stand for election, fails to be elected by the stockholders of the Company or is removed from Director's position. Director may at any time and for any reason resign or be removed from such position consistent with the Charter (subject to any other contractual obligation or other obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement with respect to Director.

1.2 <u>Director Services</u>. Director shall provide the following Services (***"Director Services'):***

(a) During the term of services as a director of the Company (***"Directorship Term"),*** Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make herself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position.

(b) Director will use his best efforts to promote the interests of the Company. The Company recognizes that Director (i) is or may become a full-time employee of another entity and that his responsibilities to such entity must have priority and (ii) sits or may sit on the board of directors of other entities, subject to any limitations set forth by the Sarbanes-Oxley Act of 2002 and limitations provided by any exchange or quotation service on which the Company's common stock is listed or traded, if and when applicable to the Company. Notwithstanding the same, Director will provide the Company with prior written notice of any future commitments to such entities and use reasonable business efforts to coordinate his respective commitments so as to fulfill his obligations to the Company and, in any event, will fulfill his legal obligations as a director. Other than as set forth above, Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that the foregoing shall in no way limit his activities on behalf of (i) any current employer and its affiliates or (ii) the board of directors of any entities on which he currently sits. At such time as the Board receives such notification, the Board may require the resignation of Director if it determines that such business activity does in fact materially interfere with the performance of Director's duties, services and responsibilities hereunder.

1.3 <u>Term</u>. This Agreement shall terminate upon the ***"Expiration Date"*** which shall be the earlier of the date on which Director ceases to be a member of the Board for any reason, including death, resignation, removal, or failure to be elected by the stockholders of the Company.

II. COMPENSATION

2.1 <u>Expense Reimbursement</u>. The Company shall reimburse Director for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of Director's duties for the Company. Such reimbursement shall be made by the Company upon submission by Director of a signed statement itemizing the expenses incurred, which shall be accompanied by sufficient documentation to support the expenditures.

2.2 <u>Bonus</u>. Upon Director's execution of this Agreement, the Company shall issue to Director, as a bonus, 250,000 shares of the Company's Series C Preferred Stock ***("Bonus Shares").*** The Bonus Shares have the designations, rights and preferences set forth in <u>Annex</u> I attached hereto and made a part hereof.

2.3 <u>Director and Officer Liability Insurance</u>. The Company will use its best efforts to maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

2.4 <u>Independent Contractor</u>. Director's status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to Director under this Section 2 shall be made or provided without withholding or deduction of any kind, and Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

**III.** **CONFIDENTIALITY AND NONDISCLOSURE**

3.1 ****<u>Confidentiality</u>. During the term of this Agreement, and for a period of three (3) years after the Expiration Date, Director shall maintain in strict confidence all information he has obtained or shall obtain from the Company, which the Company has designated as "confidential" or which is by its nature confidential, relating to the Company's business, operations, properties, assets, services, condition (financial or otherwise), liabilities, employee relations, customers, suppliers, prospects, technology, or trade secrets, except to the extent such information (i) is in the public domain through no act or omission of the Company, (ii) is required to be disclosed by law or a valid order by a court or other governmental body, or (iii) is independently learned by Director outside of this relationship (the ***"Confidential Information").***

 ****

3.2 <u>Nondisclosure and Nonuse Obligations</u>. Director will use the Confidential Information solely to perform his obligations for the benefit of the Company hereunder. Director will treat all Confidential Information of the Company with the same degree of care as Director treats his own Confidential Information, and Director will use his best efforts to protect the Confidential Information. Director will not use the Confidential Information for his own benefit or the benefit of any other person or entity, except as may be specifically permitted in this Agreement. Director will immediately give notice to the Company of any unauthorized use or disclosure by or through his, or of which he becomes aware, of the Confidential Information.

3.3 <u>Return of Company Property</u>. All materials furnished to Director by the Company, whether delivered to Director by the Company or made by Director in the performance of Director Services under this Agreement (the ***"Company Prope rty'),*** are the sole and exclusive property of the Company. Director agrees to promptly deliver the original and any copies of the Company Property to the Company at any time upon the Company's request. Upon termination of this Agreement by either party for any reason, Director agrees to promptly deliver to the Company or destroy, at the Company's option, the original and any copies of the Company Property. Director agrees to certify in writing that Director has so returned or destroyed all such Company Property.

3.4 <u>Insider Trading Guidelines</u>. Director acknowledges and agrees that Director may have access to "material non-public information" for purposes of the federal securities laws (***"Insider Information")*** and that Director will abide by all securities laws relating to the handling of and acting upon such Insider Information. Upon request by the Company, Director will be asked to execute the Company's Insider Trading and Section 16 Compliance Policy upon adoption by the Company.

IV. COVENANTS OF DIRECTOR

4.1 <u>No Conflict of Interest</u>. During the term of this Agreement, Director shall not be employed by, own, manage, control or participate in the ownership, management, operation or control of any person, firm, partnership, corporation or unincorporated association or entity of any kind that is competitive with the Company or otherwise undertake any obligation inconsistent with the terms hereof, provided that Director may continue Director's current affiliation or other current relationships with the entity or entities described on <u>Exhibit A</u> (all of which entities are referred to collectively as ***"Current Affiliations').*** This Agreement is subject to the current terms and agreements governing Director's relationship with Current Affiliations, and nothing in this Agreement is intended to be or will be construed to inhibit or limit any of Director's obligations to Current Affiliations. Director represents that nothing in this Agreement conflicts with Director's obligations to Current Affiliations . A business shall be deemed to be "competitive with the Company" for purpose of this Article IV only if and to the extent it engages in a business substantially similar to the Company's business.

4.2 <u>Disparaging Statements</u>. At all times during and after the period in which Director is a member of the Board and at all times thereafter, the Company, its employees, affiliates, or assignees, and Director, one and for the other, shall not either verbally, in writing, electronically or otherwise: (i) make any derogatory or disparaging statements about the Company, any of its affiliates, any of their respective officers , directors, shareholders, employees and agents, or any of the Company's current or past customers or employees, or (ii) make any public statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of the Company or any of its affiliates or otherwise interfere with the business of the Company or any of its affiliates; provided, however, that nothing in this paragraph shall preclude Director from complying with all obligations imposed by Jaw or legal compulsion , and provided, further, however, that nothing in this paragraph shall be deemed applicable to any testimony given by Director, or the Company, its employees, affiliates, or assignees, in any legal or administrative proceedings.

4.3 <u>Market Stand-Off Agreement</u>. In the event of a public or private offering of the Company's securities, and upon request of the Company, the underwriters or placement agents placing the offering of the Company's securities, Director agrees not to sell, make any short sale of, lo an, grant any option for the purchase of, or otherwise dispose of any securities of the Company that Director may own, other than those included in the registration, without the prior written consent of the Company or such underwriters, as the case may be, for such period of time from the effective date of such registration as may be requested by the Company or such placement agent or underwriter.

V. TERM AND TERMINATION

5.1 <u>Term</u>. This Agreement is effective as of the date of this Agreement and will continue until the Expiration Date.

5.2 <u>Survival</u>. The rights and obligations contained in Articles Ill and IV will survive any termination or expiration of this Agreement.

VI. MISCELLANEOUS

6.1 <u>Assignment</u>. Except as expressly permitted by this Agreement, neither party shall assign, delegate, or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the other party. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

6.2 <u>Remedies</u>. Director agrees that any breach of the terms of this Articles III and IV would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by Director and/or any and all entities acting for and/or with Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from Director. Director acknowledges that the Company would not have entered into this Agreement had Director not agreed to the provisions of this Section 6.2.

6.3 <u>No Waiver</u>. The failure of any party to insist upon the strict observance and performance of the terms of this Agreement shall not be deemed a waiver of other obligations hereunder, nor shall it be considered a future or continuing waiver of the same terms.

6.4 <u>Notices</u>. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by e-mail or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth on the signature page of this Agreement or such other address as either party may specify in writing.

6.5 <u>Governing Law: Jurisdiction</u>. This Agreement shall be governed in all respects by the laws of the State of Nevada, without regard to conflicts of law principles thereof. Any action brought to enforce, or otherwise arising out of, this Agreement shall be heard and determined in either a Federal or state court sitting in the County of Orange, State of Florida, and the parties consent to jurisdiction in the State of Florida.

6.6 <u>Severability</u>. Should any provisions of this Agreement be held by a court to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby .

6.7 <u>Entire Agreement</u>. This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all Director Services undertaken by Director for the Company.

6.8 <u>Amendments</u>. This Agreement may only be amended, modified or changed by an agreement signed by he the Company and Director. The terms contained herein may not be altered, supplemented or interpreted by any course of dealing or practices.

6.9 <u>Counterparts</u>. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

**IN WITNESS WHEREOF,** the parties have executed this Agreement as of the date first written above.

---

| | | |
|:---|:---|:---|
| **COMPANY:** |  | **ADIA NUTRITION, INC.** |
|  | By: | /s/ Larry Powalisz |
|  | Name: | Larry Powalisz |
|  | Title: | Chief Executive Officer |
|  | Address: | 4421 Gabriella Lane |
|  |  | Winter Park, Florida 32792 |
| **DIRECTOR** |  |  |
|  | By: | /s/ Kalpesh Barot, MD |
|  | Name: | Dr. Kalpesh Barot |
|  | Address: | 4814 Kensington Park Blvd. |
|  |  | Orlando, FL 32819 |
|  |  | 9/12/24 |

---

<u>**EXHIBIT A**</u>

**Director's Current Affiliations**

None.

<u>**ANNEX I**</u>

**TERMS OF SERIES C PREFERRED STOCK**

**Section 1. Designation, Amount and Par Value.** The series of Preferred Stock shall be designated as Series C Preferred Stock (the *"Series C Preferred Stock")* and the number of shares so designated shall be Eighty-Nine Million Nine Hundred Ninety-Nine Thousand Nine-Hundred Ninety Nine (89,999,999). Each share of the Series C Preferred Stock shall have a par value of $0.001.

**Section 2. Fractional Shares.** The Series C Preferred Stock may be issued in fractional shares.

**Section 3. Voting Rights.** Each share the Series C Preferred Stock shall have one (1) vote in all matters requiring shareholder approval.

**Section 4. Dividends.** The Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the dividend on each share of Series C Preferred Stock shall be equal to the amount of the dividend declared and paid on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 5. Liquidation.** Upon any liquidation, dissolution or winding up of the Company, whether voluntary or involuntary, payments to the holders of Series C Preferred Stock shall be treated *pari passu* with the Company's common stock, except that the payment on each share of Series C Preferred Stock shall be equal to the amount of the payment on each share of the Company's common stock multiplied by the Conversion Rate, as that term is defined in Section 6(a).

**Section 6. Conversion and Adjustments.**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(a) Conversion Rate.** Each shares of Series C Preferred Stock shall be convertible into four (4) shares of the Company's common stock (the ***"Conversion Rate").***

 ****

The Conversion Rate shall not be subject to adjustment by a combination of the outstanding shares of the Company's common stock into a smaller number of shares of common stock.

The Conversion Rate shall be subject to adjustment by a subdivision of the outstanding shares of the Company's common stock into a greater number of shares of common stock (the "Common Stock Event") by multiplying the Conversion Rate then in effect by a fraction: (1) the numerator of which shall be the number of shares of Company common stock issued and outstanding immediately prior to such Common Stock Event and (2) the denominator of which shall be the number of shares of Company common stock issued and outstanding immediately after such Common Stock Event.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(b) Partial Conversion.** A holder of shares of Series C Preferred Stock shall have the right to convert, from time to time, some or all of such holder's shares of Series C Preferred Stock.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**(c) Adjustment for Merger and Reorganization, etc.** If there shall occur any reorganization, recapitalization, reclassification, consolidation or merger (a ***"Reorganization Event")*** involving the Company in which the Company's common stock (but not the Series C Preferred Stock) is converted into or exchanged for securities, cash or other property, then each share of Series C Preferred Stock shall be deemed to have been converted into shares of the Company's common stock at the Conversion Rate.

**Section 7. Protection Provisions.** So long as any shares of Series C Preferred Stock are outstanding, the Company shall not, without first obtaining the written consent of the holders of a majority the Series C Preferred Stock, alter or change the rights, preferences or privileges of the Series C Preferred Stock.

**Section 8. Waiver.** Any of the rights, powers or preferences of the holders of the Series C Preferred Stock may be waived by the affirmative consent or vote of the holders of at least a majority of the shares of Series C Preferred Stock then outstanding.

**Section 9. No Other Rights or Privileges.** Except as specifically set forth herein, the holder(s) of the shares of Series C Preferred Stock shall have no other rights, privileges or preferences with respect to the Series C Preferred Stock.-

## Ex-5

**Exhibit 5.1.4**

**DIRECTOR AND ACTING MEDICAL DIRECTOR AGREEMENT**

This Director and Acting Medical Director Agreement (the "Agreement") is made and entered into as of October 7th, 2025, by and between Adia Nutrition, Inc., a Nevada corporation (the "Company"), and Dr. Evan Thomas, an individual ("Director").

RECITALS

A. The common stock of the Company is traded in the public markets of the United States (symbol: ADIA); and

B. The Company desires to appoint Director to serve on the Company's board of directors (the "Board") as the Acting Medical Director and Director desires to accept such appointment to serve on the Board; and

C. Director may be appointed as a member of one or more committees of the Board; and

D. Director may also be appointed to serve as Chairman of one or more committees of the Board.

&nbsp;&nbsp;&nbsp;&nbsp;I. SERVICES

1.1 Board of Directors and Acting Medical Director. Director agrees to perform such tasks as may be necessary to fulfill Director's obligations as a member of the Board and its committees, serve as a director, and act as the Acting Medical Director so long as he is duly appointed or elected and qualified in accordance with the applicable provisions of the Company's Articles of Incorporation and Bylaws (collectively, the "Charter") and any necessary approval by the Company's stockholders and/or Board, and until such time as Director resigns, fails to stand for election, fails to be elected by the stockholders of the Company or is removed from Director's position. As Acting Medical Director and active director, Director will be listed on all relevant Company documents and will sign such documents, including but not limited to those related to the Agency for Health Care Administration (ACHA), health insurance companies, and vendors. Director may at any time and for any reason resign or be removed from such position consistent with the Charter (subject to any other contractual obligation or other obligation imposed by operation of law), in which event the Company shall have no obligation under this Agreement with respect to Director.

1.2 Director Services. Director shall provide the following Services ("Director Services"):

(a) During the term of services as a director and Acting Medical Director of the Company ("Directorship Term"), Director shall make reasonable business efforts to attend all Board meetings, serve on appropriate subcommittees as reasonably requested by the Board, make himself available to the Company at mutually convenient times and places, attend external meetings and presentations, as appropriate and convenient, and perform such duties, services and responsibilities, and have the authority commensurate to such position, including oversight of medical operations, compliance with healthcare regulations, and signing authority on medical-related documents as specified in Section 1.1.

(b) Director will use his best efforts to promote the interests of the Company. The Company recognizes that Director (i) is or may become a full-time employee of another entity and that his responsibilities to such entity must have priority and (ii) sits or may sit on the board of directors of other entities, subject to any limitations set forth by the Sarbanes-Oxley Act of 2002 and limitations provided by any exchange or quotation service on which the Company's common stock is listed or traded, if and when applicable to the Company. Notwithstanding the same, Director will provide the Company with prior written notice of any future commitments to such entities. and use reasonable business efforts to coordinate his respective commitments so as to fulfill his obligations to the Company and, in any event, will fulfill his legal obligations as a director and Acting Medical Director. Other than as set forth above, Director will not, without the prior notification to the Board, engage in any other business activity which could materially interfere with the performance of his duties, services and responsibilities hereunder or which is in violation of the reasonable policies established from time to time by the Company, provided that the foregoing shall in no way limit his activities on behalf of (i) any current employer and its affiliates or (ii) the board of directors of any entities on which he currently sits. Should the Board determine, in good faith, that such new business activity creates a direct and material conflict of interest that substantially interferes with the performance of Director's duties hereunder, the Company shall provide Director with written notice detailing the specific nature of the conflict. Director shall have a period of thirty (30) days from the receipt of such notice to cure the conflict. Should the Board determine, in good faith, that the conflict has not been remedied within the specified period, the Board may request Director's resignation.

1.3 Term. This Agreement shall terminate upon the "Expiration Date" which shall be the earlier of the date on which Director ceases to be a member of the Board for any reason, including death, resignation, removal, or failure to be elected by the stockholders of the Company.

1.4 **Transition of Title.** The parties acknowledge that the title "Acting Medical Director" is an interim designation. Provided that Director is in good standing and has not materially breached this Agreement, the "Acting" designation shall be automatically removed from Director's title upon the earlier of: (a) six (6) months from the effective date of this Agreement, or (b) a formal resolution by the Board of Directors confirming the appointment. Upon such date, Director's title shall be "Medical Director," and all references to "Acting Medical Director" in this Agreement shall be deemed to refer to "Medical Director."

&nbsp;&nbsp;&nbsp;&nbsp;II. COMPENSATION

2.1 Expense Reimbursement. The Company shall reimburse Director for pre-approved reasonable business-related expenses incurred in good faith in connection with the performance of Director's duties for the Company. Such reimbursement shall be made by the Company upon submission by Director of a signed statement itemizing the expenses incurred, which shall be accompanied by sufficient documentation to support the expenditures.

2.2 Bonus. Upon Director's execution of this Agreement, the Company shall issue to Director, as a bonus, 250,000 shares of the Company's Series C Preferred Stock (Convertible at 1:4, which would be 1,000,000 shares of Common Stock) ("Bonus Shares"). The Bonus Shares have the designations, rights and preferences set forth in Annex 1 attached hereto and made a part hereof.

2.3 Additional Compensation. In addition to the Bonus Shares, Director shall receive compensation equal to 1% of the gross revenue of Adia Med of Winter Park or $5,000 per month, whichever is greater. Compensation for Hematopoietic Stem Cell Transplantation (HSCT) services shall be determined after insurance review.

2.4 Referral Incentive. Director shall receive 10% of all revenue generated from patients referred by Director to Adia Med, payable on a quarterly basis following verification of patient referrals and associated revenue, provided that this incentive does not apply to Hematopoietic Stem Cell Transplantation (HSCT).

2.5 Director and Officer Liability Insurance. The Company will use its best efforts to maintain a customary director and officer liability insurance policy for all Board members and such policy will cover Director to the same extent as other directors and officers covered under the policy.

2.6 Independent Contractor. Director's status during the Directorship Term shall be that of an independent contractor and not, for any purpose, that of an employee or agent with authority to bind the Company in any respect. All payments and other consideration made or provided to Director under this Section 2 shall be made or provided without withholding or deduction of any kind, and Director shall assume sole responsibility for discharging all tax or other obligations associated therewith.

2.7 Clinic Expenses. Director shall not be responsible for any clinic expenses incurred by the Company or its affiliates, including but not limited to Adia Med.

2.8 **Medical Malpractice Insurance.** During the term of this Agreement, should a separate medical malpractice policy be required for the scope of work performed or overseen by Director, the Company shall procure and maintain, at its sole expense, a professional liability (medical malpractice) insurance policy naming Director as an insured. Such policy shall provide coverage in amounts no less than $1,000,000 per occurrence and $3,000,000 in the aggregate, or such higher amounts as are customary for a medical director in a similar position. The Company shall provide Director with a certificate of insurance evidencing such coverage upon request. Upon termination of this Agreement for any reason, the Company shall, at its sole expense, procure and maintain an extended reporting period endorsement or "tail coverage" for a period of not less than three (3) years, providing continued coverage for any claims arising from Director's performance of services under this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;III. CONFIDENTIALITY AND NONDISCLOSURE

3.1 Confidentiality. During the term of this Agreement, and for a period of three (3) years after the Expiration Date, Director shall maintain in strict confidence all information he has obtained or shall obtain from the Company, which the Company has designated as "confidential" or which is by its nature confidential, relating to the Company's business, operations, properties, assets, services, condition (financial or otherwise), liabilities, employee relations, customers, suppliers, prospects, technology, or trade secrets, except to the extent such information (i) is in the public domain through no act or omission of the Company, (ii) is required to be disclosed by law or a valid order by a court or other governmental body, or (iii) is independently learned by Director outside of this relationship (the "Confidential Information").

3.2 Nondisclosure and Nonuse Obligations. Director will use the Confidential Information solely to perform his obligations for the benefit of the Company hereunder. Director will treat all Confidential Information of the Company with the same degree of care as Director treats his own Confidential Information, and Director will use his best efforts to protect the Confidential Information. Director will not use the Confidential Information for his own benefit or the benefit of any other person or entity, except as may be specifically permitted in this Agreement. Director will immediately give notice to the Company of any unauthorized use or disclosure by or through him, or of which he becomes aware, of the Confidential Information.

3.3 Return of Company Property. All materials furnished to Director by the Company, whether delivered to Director by the Company or made by Director in the performance of Director Services under this Agreement (the "Company Property"), are the sole and exclusive property of the Company. Director agrees to promptly deliver the original and any copies of the Company Property to the Company at any time upon the Company's request. Upon termination of this Agreement by either party for any reason, Director agrees to promptly deliver to the Company or destroy, at the Company's option, the original and any copies of the Company Property. Director agrees to certify in writing that Director has so returned or destroyed all such Company Property.

3.4 Insider Trading Guidelines. Director acknowledges and agrees that Director may have access to "material non-public information" for purposes of the federal securities laws ("Insider Information") and that Director will abide by all securities laws relating to the handling of and acting upon such Insider Information. Upon request by the Company, Director will be asked to execute the Company's Insider Trading and Section 16 Compliance Policy upon adoption by the Company.

&nbsp;&nbsp;&nbsp;&nbsp;IV. COVENANTS OF DIRECTOR

4.1 No Conflict of Interest. During the term of this Agreement, Director shall not be employed by, own, manage, control or participate in the ownership, management, operation or control of any person, firm, partnership, corporation or unincorporated association or entity of any kind that is competitive with the Company or otherwise undertake any obligation inconsistent with the terms hereof, provided that Director may continue Director's current affiliation or other current relationships with the entity or entities described on Exhibit A (all of which entities are referred to collectively as "Current Affiliations"). This Agreement is subject to the current terms and agreements governing Director's relationship with Current Affiliations, and nothing in this Agreement is intended to be or will be construed to inhibit or limit any of Director's obligations to Current Affiliations. Director represents that nothing in this Agreement conflicts with Director's obligations to Current Affiliations. A business shall be deemed to be "competitive with the Company" for purpose of this Article IV only if and to the extent it engages in a business substantially similar to the Company's business.

4.2 Disparaging Statements. At all times during and after the period in which Director is a member of the Board and at all times thereafter, the Company, its employees, affiliates, or assignees, and Director, one and for the other, shall not either verbally, in writing, electronically or otherwise: (i) make any derogatory or disparaging statements about the Company, any of its affiliates, any of their respective officers, directors, shareholders, employees and agents, or any of the Company's current or past customers or employees, or (ii) make any public statement or perform or do any other act prejudicial or injurious to the reputation or goodwill of the Company or any of its affiliates or otherwise interfere with the business of the Company or any of its affiliates; provided, however, that nothing in this paragraph shall preclude Director from complying with all obligations imposed by law or legal compulsion, and provided, further, however, that nothing in this paragraph shall be deemed applicable to any testimony given by Director, or the Company, its employees, affiliates, or assignees, in any legal or administrative proceedings.

4.3 Market Stand-Off Agreement. In the event of a public or private offering of the Company's securities, and upon request of the Company, the underwriters or placement agents placing the offering of the Company's securities, Director agrees not to sell, make any short sale of, loan, grant any option for the purchase of, or otherwise dispose of any securities of the Company that Director may own, other than those included in the registration, without the prior written consent of the Company or such underwriters, as the case may be, for such period of time from the effective date of such registration as may be requested by the Company or such placement agent or underwriter.

&nbsp;&nbsp;&nbsp;&nbsp;V. TERM AND TERMINATION

5.1 Term. This Agreement is effective as of the date of this Agreement and will continue until the Expiration Date.

5.2 Survival. The rights and obligations contained in Articles III and IV will survive any termination or expiration of this Agreement.

&nbsp;&nbsp;&nbsp;&nbsp;VI. MISCELLANEOUS

6.1 Assignment. Except as expressly permitted by this Agreement, neither party shall assign, delegate, or otherwise transfer any of its rights or obligations under this Agreement without the prior written consent of the other party. Subject to the foregoing, this Agreement will be binding upon and inure to the benefit of the parties hereto and their respective heirs, legal representatives, successors and assigns.

6.2 Remedies. Director agrees that any breach of the terms of this Articles III and IV would result in irreparable injury and damage to the Company for which the Company would have no adequate remedy at law; Director therefore also agrees that in the event of said breach or any threat of breach, the Company shall be entitled to an immediate injunction and restraining order to prevent such breach and/or threatened breach and/or continued breach by Director and/or any and all entities acting for and/or with Director, without having to prove damages or paying a bond, in addition to any other remedies to which the Company may be entitled at law or in equity. The terms of this Section shall not prevent the Company from pursuing any other available remedies for any breach or threatened breach hereof, including, but not limited to, the recovery of damages from Director. Director acknowledges that the Company would not have entered into this Agreement had Director not agreed to the provisions of this Section 6.2.

6.3 No Waiver. The failure of any party to insist upon the strict observance and performance of the terms of this Agreement shall not be deemed a waiver of other obligations hereunder, nor shall it be considered a future or continuing waiver of the same terms.

6.4 Notices. Any notice required or permitted by this Agreement shall be in writing and shall be delivered as follows with notice deemed given as indicated: (i) by personal delivery when delivered personally; (ii) by overnight courier upon written verification of receipt; (iii) by e-mail or facsimile transmission upon acknowledgment of receipt of electronic transmission; or (iv) by certified or registered mail, return receipt requested, upon verification of receipt. Notice shall be sent to the addresses set forth on the signature page of this Agreement or such other address as either party may specify in writing.

6.5 Governing Law; Jurisdiction. This Agreement shall be governed in all respects by the laws of the State of Nevada, without regard to conflicts of law principles thereof. Any action brought to enforce, or otherwise arising out of, this Agreement shall be heard and determined in either a Federal or state court sitting in the County of Orange, State of Florida, and the parties consent to jurisdiction in the State of Florida.

6.6 Severability. Should any provisions of this Agreement be held by a court to be illegal, invalid or unenforceable, the legality, validity and enforceability of the remaining provisions of this Agreement shall not be affected or impaired thereby.

6.7 Entire Agreement. This Agreement constitutes the entire agreement between the parties relating to this subject matter and supersedes all prior or contemporaneous oral or written agreements concerning such subject matter. The terms of this Agreement will govern all Director Services undertaken by Director for the Company.

6.8 Amendments. This Agreement may only be amended, modified or changed by an agreement signed by the Company and Director. The terms contained herein may not be altered, supplemented or interpreted by any course of dealing or practices.

6.9 Counterparts. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.

IN WITNESS WHEREOF, the parties have executed this Agreement as of the date first written above.

COMPANY: ADIA NUTRITION, INC.

By: <u>/s/ Larry Powalisz</u> 

Name: Larry Powalisz

Title: Chief Executive Officer

Address: 4421 Gabriella Lane

Winter Park, FL 32792

DIRECTOR:

By: <u>/s/ Dr. Evan Thomas</u> 

Name: Dr. Evan Thomas

Address: 1561 Fairbanks RD Suite 100

Winter Park, FL 32789

Exhibit A

**TO THE DIRECTOR AND ACTING MEDICAL DIRECTOR AGREEMENT**

**This Exhibit A ("Exhibit") is attached to and made a part of that certain Director and Acting Medical Director Agreement dated October 7th, 2025 (the "Agreement"), by and between Adia Nutrition, Inc. (the "Company") and Dr. Evan Thomas ("Director").**

**Pursuant to Section 4.1 of the Agreement, "No Conflict of Interest," the following entities and roles are hereby defined as Director's "Current Affiliations". Nothing in the Agreement shall be construed to inhibit or limit any of Director's obligations to these Current Affiliations.**

**Director's Current Affiliations include, but are not limited to:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Renaissance Institute of Precision Oncology & Radiosurgery: Chief Medical Officer, Medical Director, and Co-Founder.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.** **JointGlow: Chief Technology Officer.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.** **United States Army: Major, Medical Corps.** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.** **American College of Radiation Oncology (ACRO): Co-Chair, Payer Relations Sub-Committee, Government Relations and Economics Committee (GREC).** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**5.** **American Society for Radiation Oncology (ASTRO): Member of the following:** 

o**Government Affairs / Government Relations Council**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.** **Congressional Relations Subcommittee** 

o**Non-Oncologic Disease Task Force**